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1 Chapter I : Introduction 
1.1 Polymeric Biomaterials 
Over the past few decades polymeric biomaterials have revolutionized the medical field 
and have been used in a wide variety of applications such as controlled drug delivery 
systems, cell culture supports, scaffolds for tissue engineering, biosensor, actuators, 
bioseparation devices, reactive coatings, medical imaging and devices. 
Biomaterials science is highly interdisciplinary in nature, involving materials science, 
physical, engineering, biological and clinical sciences principles. 
The definition for the term “biomaterial” has been widely accepted as the following: 
 
 A biomaterial is any material, natural or synthetic, that comprises a whole or 
part of a living structure or biomedical device that performs , augments, or 
replaces a natural function. 
 A biomaterial is a nonviable material used in medical device intended to interact 
with a biological system without harming it. 
The most important requirements for biomaterials are biocompatibility and controlled 
degradability. Biocompatibility prevents toxic effects of materials on the physiological 
system. Synthetic biomaterials are not typically rejected by the body, although solid 
scaffolds or devices may be encapsulated in a fibrous capsule after implantation, and 
soluble polymers or small particles undergo various routes of elimination, sometimes 
including chemical breakdown. While the biocompatibility is an intrinsic property of the 
polymer (related to chemical structure), degradation can be directly engineered, 
chemically tuned, and controlled by various stimuli. Indeed, degradation of polymeric 
biomaterials can be initiated by an environmental, internal or external stimulus. For 
example, hydrolysis is a commonly used controlled degradation mechanism, and the 
stimulus for degradation is environmental (water). Enzymolysis is another popular 
method that relies on an internal stimulus (enzyme production) to control degradation 
[Deshayes 2013]. 
Stimulus-responsive polymers, as ‘intelligent’, ‘smart’ or ‘environmentally sensitive’ 
polymers, are biomaterials systems that exhibit large, sharp changes in response to 
physical stimuli (such as temperature, solvents, or light) or to chemical stimuli (such as 
reactants, pH, ions in solution, or chemical recognition). Responses differ depending on 
the stimulus applied and may include changes in shape, volume, mechanical properties, 
or permeation rates, among other things. These systems possess a variety of interesting 
applications for encapsulation, controlled delivery, or as intelligent switches to mention 
just a few [York, 2008]. Engineering polymeric nanostructures such as hyperbranched 
polymers, dendrimers and polymeric nanoparticles (NPs) [Xu 2012; Gong 2012] are a 
growing area of contemporary biomaterials science, due to their unique properties and 
large potential in drug delivery [Kim 2012; Lim 2012; Bielawski et al., 2011]. For using 
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polymers in drug delivery, a polymer must be biocompatible. Biocompatibility was 
defined as the ability of a material to act with an appropriate host response in a specific 
application [Williams 1999]. Moreover, biocompatible polymers used in drug delivery 
are often biodegradable with the formation of non-harmful byproducts, such as non-toxic 
alcohols, acids and other easily eliminated low molecular weight products. They can 
indeed contribute to the drug release as a result of their erosion/degradation, in addition 
to drug diffusion through the polymeric material. Biodegradable polymer, in the 
development of drug delivery systems, must meet very specific requirements such as: a) 
Biocompatibility of the polymer backbone and its degradation products; b) Mechanical 
strength sufficient to meet the needs of specific applications, c) Degradability with 
degradation kinetics matching a biological process such as wound healing, d) 
Processibility using available equipment. e) Solubility in various solvents. f) Chemical, 
structural and application versatility d)Economically acceptable shelf life and obviously, 
the agreement of the European Medicine Evaluation Agency (EMEA) or Food and Drug 
Administration (FDA), USA.  
Polymers remain the most versatile class of biomaterials, being extensively applied in 
medicine and biotechnology, as well as in the food and cosmetics industries. 
Applications include surgical devices, implants and supporting materials (e.g. artificial 
organs, prostheses and sutures), drug-delivery systems with different routes of 
administration and design, carriers of immobilized enzymes and cells, biosensors, 
components of diagnostic assays, bioadhesives, ocular devices, and materials for 
orthopaedic applications. Polymers used as biomaterials can be synthesized to have 
appropriate chemical, physical, interfacial and biomimetic characteristics, which permit 
various specific applications [Chiellini 2008; Williams 2009; Kohane 2010]. Compared 
with other types of biomaterials, such as metals and ceramics, polymers offer the 
advantage that they can be prepared in different compositions with a wide variety of 
structures and properties.  
Polymers are mainly divided into two groups, natural polymers, such as proteins, 
cellulose, silk and synthetic polymers, such as full carbon backbone polymers: 
polystyrene, polyethylene, polypropylene, poly(vinyl chloride) and heteropolymers: 
polyamides, polyesters, polyurethanes.  
1.1.1 Natural Polymeric Biomaterials  
Natural polymers  are produced by several living organisms. Their synthesis is due to the 
presence of enzymatic catalysts through reactions of chain growth polymerization of 
activated monomers, formed within cells as a result of complex metabolic processes. Use 
of biopolymers for diversified applications in life sciences has several advantages, such 
as availability from replenishable agricultural or marine food resources, 
biocompatibility, biodegradability, therefore leading to ecological safety and the 
possibility of preparing a variety of chemically or enzymatically modified derivatives for 
specific end uses. 
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Human serum albumin (HSA), a protein polymer, is one of the most frequently used 
biopolymers in medicine. HSA is known to be used for treating shock, burns, 
hypoalbuminemia, after surgery trauma, cardiopulmonary bypass, acute respiratory 
distress and hemodialysis. Albumin-conjugates are also used in treatment of arthritic 
diseases, for liver targeting, and others. Albumin is known to be accumulated in 
malignant and inflamed tissues and nanoparticles made of HSA were found to be non-
toxic and well-tolerated by human organism. Owing to its capability to transport low 
molecular weight compounds it is a unique carrier for drugs. Binding drugs with albumin 
provided prolonged effect of such proteins and peptides as Albuferon and Levemir. 
Functional groups (carboxylic and amine groups) which are present in the structure of 
albumin allow to modify the surface of the particles by attaching the molecules for 
targeting purposes [Langer 2007; Elzoghby 2012]. Collagen is the most abundant protein 
of connective tissues in all animals, it is a nonantigenic, biocompatible, biodegradable 
and bioreabsorbable biopolymer and it can be easly purified from living organism. 
Gelatin is a natural polymer  is obtained by controlling the hydrolysis of collagen, and it 
is used widely for pharmaceutical (as a plasma expander, wound dressing, adhesive, and 
absorbent pad for surgical use) and cosmetics applications. 
Silks have been investigated as biomaterials due to the successful use of silk fibers 
from B. mori as suture material for centuries. The silk bio-polymer is used in tissue 
regeneration for treating burn victims and as matrix of wound healing. The silk fibroin 
peptides are used in cosmetics due to their glossy, flexible, elastic coating power, easy 
spreading and adhesion characters. The silk is used to fight edema, adenosine 
augmentation therapy and cancer [Vepari 2007]. 
Alginate is a polysaccharide that offers an attractive alternative for sustained-release 
systems. It offers advantages over synthetic polymers as it forms hydrogels under 
relatively mild pH and temperature and is generally regarded as non-toxic, 
biocompatible, biodegradable, less expensive and abundantly available in nature; in 
addition, alginate meets the important requirement of being amenable to sterilization and 
storage. All these advantages make alginates very useful materials for biomedical 
applications, especially for controlled delivery of drugs and other biologically active 
compounds and for the encapsulation of cells [Chiellini 2008; Ha 2013]. 
Dextran is a polysaccharide composed of branched glucan and synthesized by bacteria 
and yeast. Due to dextran’s biocompatibility, dextran-based hydrogels have been widely 
used as a blood plasma substitute, as delivery systems of various drugs and for tissue 
engineering scaffolds [Sun 2012]. 
 
1.1.1.1 Chitosan 
Chitosan (CS) is a linear, randomcopolymer of β-(1–4)-linked D-glucosamine and N-
acetyl-D-glucosamine whos emolecular structure comprises a linear backbone linked 
through glycosidic bonds (Figure 1). 
 





Figure 1: Chemical structure of chitosan. 
 
The basic amine groups of this polysaccharide are protonated and, thus positively 
charged in most physiological fluids. Chitosan is a product derived from alkaline N-
deacetylation of chitin. Chitin, being the second most abundant natural biopolymer 
mainly derived from exoskeletons of crustaceans and also from cell walls of fungi and 
insects, is a linear cationic  heteropolymer of randomly distributed GlcNAc and GlcN 
residues with β-1, 4 linkage. In general, the degree of deacetylation (DD) of chitosan 
ranges from 40 to 98% and the molecular weight ranges in between 50 kD and 2000 kD. 
CS can be considered mostly hydrophilic, but the percentage of acetylated units and their 
distribution in the chains has a critical effect on its solubility and conformation in 
aqueous media. Because of these molecular features, CS exhibits in solution a pH-
dependent behavior and interesting biopharmaceutical properties such as muco-
adhesiveness and ability to open epithelial tight junctions. These characteristics have 
attracted the attention of many scientists working in biomedical fields, and particularly in 
drug delivery. CS is biodegradaded by a number of enzymes, such as lysozyme, di-N-
acetylchitobiase, N-acetyl-beta-D-glucosaminidase and chitiotriosidase, which are 
present in human mucosas and other physiological fluids [Garcia-Fuentes 2012]. 
This renewable polysaccharide is currently being explored extensively for its 
applications in various fields such as pharmaceutical, cosmetics, biomedical, 
biotechnological, agriculture, and both food and non-food industries. It has emerged as a 
new class of biomaterial with highly sophisticated functions due to their versatile 
biological activity, excellent biocompatibility, and complete biodegradability, in addition 
to low toxicity [Jain 2013]. 
The degree of deacetylation and the degree of polymerization (DP) controls the 
molecular weight of a polymer and these two are important parameters deciding the use 
of chitosan and its modifications for various applications. Chitosan possesses reactive 
hydroxyl and amino groups but is usually less crystalline than chitin, which presumably 
makes chitosan more accessible to reagents. After heating, it decomposes prior to 
melting; thus, it has no melting point. The solubility profile of chitosan well depicts that 
it is soluble in dilute aqueous organic or mineral acids below pH 6.5, p-Toulene sulfonic 
acid, DMSO, and 10-Camphorsulfonic acid. Almost all aqueous acids dissolve chitosan, 
out of which the most commonly used are formic acid and acetic acid. The increase in its 
solubility by increasing both the polarity and the degree of electrostatic repulsion is due 
to generation of an enormous number of cationic sites formed due to protonation of 
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aminogroups by acids along the chitosan backbone. Water-soluble salts of chitosan 
include formate, acetate, lactate, maleate, citrate, tartarate, glyoxylate, pyruvate, 
glycolate, malonate, and ascorbate. 
Chitosan is widely regarded as being a nontoxic, biologically compatible polymer. It has 
been approved for dietary applications in Japan, Italy, and Finland, and additionally, it 
has been approved by the FDA for wound dressings [Jain 2013]. 
This interesting biopharmaceutical and toxicological profile of CS has encouraged its use 
as a biomaterial for drug delivery applications, it has been presented in several 
pharmaceutical forms including polymer solutions, micro/nanoparticles, and hydrogels [ 
Dash 2011, Nagpa 2010].  
The potential of CS nanocarrier technology has been reported for a variety of 
applications that include immunization, topical ocular/dermal drug delivery, 
transmucosal oral/nasal peptide absorption, anti-cancer drug delivery, brain delivery and 
gene delivery [Garcia Fuentes 2012]. 
Many preparation methods for chitosan-based nanocarriers have already been developed. 
Among them, ionic cross-linking methods based on the electrostatic interactions between 
positively charged chitosan and negatively charged polyanions, demonstrated advantages 
for bioactive molecular and hydrophilic drug encapsulation owing to their simple and 
mild processes.  In the ionic gelation method, chitosan nanoparticles are constructed by 
dropping CS droplets into a solution of a polyanion such as tripolyphosphate 
(TPP)[Lopez-leon 2005] . The coacervation/precipitation method is based on the 
insolubility of CS in an alkaline solution, therefore when it is put into a solution with an 
alkaline pH such as sodium hydroxide or ethane diamine, precipitate/coacervate particles 
are produced [Amidi 2010]. In the emulsion cross-linking method, due to the reactive 
amine group, CS can easily be cross-linked with the aldehyde groups of cross-linking 
agents such as glutaraldehyde [Karnchanajindanun 2011]. Recently, amphiphilic 
chitosan-based polymers were synthesized for self-assembled nanocarriers, which 
exhibit significant potential for the delivery of both hydrophobic and hydrophilic drugs.  
Due to the fairly abundant primary amine groups of chitosan, they are easily conjugated 
to hydrophobic polymers such as polylactide, polycaprolactone and polymers containing 
acid moieties [ Huo 2010; Jain 2013; Hu 2013]. 
 
1.1.1.2 Hyaluronic Acid 
Hyaluronic acid (HA), also named hyaluronan, is a high molecular weight (10
5–107 Da), 
naturally occurring biodegradable polymer. HA is an unbranched non-sulfated 
glycosaminoglycan (GAG) composed of repeating disaccharides (β-1,4-D-glucuronic 
acid (known as uronic acid) and β-1,3-N-acetyl-D-glucosamide) (Figure 2).  
 




Figure 2: Chemical structure of hyaluronic acid. 
 
HA is produced and secreted by cells including fibroblasts, keratinocytes or 
chondrocytes; it is naturally synthesized by hyaluronan synthases (HAS1, HAS2 and 
HAS3), a class of integral membrane proteins [Hunt 2013].The mechanism of HA 
synthesis involves chain extension by addition of a monosaccharide (alternating addition 
of glucuronic acid and N-acetyl glucosamine) to the reducing end of the chain. The 
number of repeat  disaccharides units in a completed HA molecule can reach a value as 
high as 10,000 or more, and a molecular weight of 4 million Da.  
HA is a polyanion that can self-associate and can also bind to water molecules (when not 
bound to other molecules), giving it a stiff, viscous quality similar to gelatin. HA is one 
of the major elements in the extracellular matrix (ECM) of vertebrate tissues. It is 
available in almost all body fluids and tissues, such as the synovial fluid, the vitreous 
humor of the eye, and hyaline cartilage. This biopolymer functions as a scaffold, binding 
other matrix molecules, including aggrecan [Garg 2004]. HA is also involved in several 
important biological functions, such as regulation of cell adhesion and cell motility, 
manipulation of cell differentiation and proliferation, and providing mechanical 
properties to tissues. Several cell surface receptors, such as CD44, RHAMM and ICAM-
1, have been shown to interact with HA, influencing cellular processes, including 
morphogenesis, wound repair, inflammation and metastasis [Eng 2010]. Moreover, HA 
is responsible for providing the viscoelasticity of some biological fluids (synovial fluid 
and vitreous humor of the eye) and controlling tissue hydration and water transport. In 
addition, HA has been found during embryonic development in the umbilical cord, 
suggesting that materials composed of HA may persuade favorable conditions for tissue 
regeneration and growth. HA’s characteristics, including its consistency, 
biocompatibility and hydrophilicity have made it an excellent moisturizing component in 
cosmetic dermatology and skin-care products [Falcone 2006]. Its unique viscoelasticity 
and limited immunogenicity have led to its use in several biomedical applications, such 
as viscosupplementation in osteoarthritis treatment, as an aid in eye surgery and for 
wound regeneration. Hyaluronan has been widely studied for drug delivery, for dermal, 
nasal, pulmonary, topical, parenteral, liposome-modified, implantable delivery devices 
and for gene delivery [Liao 2005, Fakhari 2013, Burdick 2011, Yadav 2008]. 
Hyaluronan for tissue engineering has been focused on cartilage, bone and osteochondral 
applications, most likely due to the fact that it is a major macromolecular component of 
the extracellular matrix [Malafaya 2007] . 
Commercially available hyaluronan is obtained from different sources, mainly by 
extraction from umbilical cord, rooster comb, synovial fluid, or vitreous humour. In 
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addition, hyaluronic acid can be easily and controllably produced in large scales through 
microbial fermentation, from strains of bacteria such as Streptococci, enabling the scale-
up of derived products and avoiding the risk of animal-derived pathogens. Hyaluronan is 
available for several applications, for lubrication and mechanical support for the joints in 
osteoarthritis (Hyalgan® and Hyalubrix® from Fidia in Italy; Artz® from Seikagaku 
Corporation in Japan) as a viscoelastic gel for surgery and wound healing (Bionect® 
from CSC Pharmaceutical in USA; Jossalind® from Hexal in Germany), for 
implantation of artificial intraocular lens (Healon® from OVD from Advanced Medical 
Optics in USA, Opegan R® from Seikagaku in Japan, Opelead® from Shiseido in Japan, 
Orthovisc® from Anika in USA) and as culture media for use in in vitro fertilization 
(EmbryoGlue® from Vitrolife, USA)[Liao 2005, Malafaya 2007]. Hyaff® 
commercialized by Fidia in Italy has been widely used as a biomaterial for biomedical 
applications. 
 
1.1.1.3 Poly(γ-glutamic acid) 
Poly-γ-glutamic acid (γ-PGA) in an anionic naturally occurring homo-polyamide that is 
made of D- and L-glutamic acid units coonected by amide linkages between α-amino and 
γ-carboxylic acid groups (Figure 3).  
 
Figure 3: Chemical structure of γ-PGA. 
γ-PGA is produced predominantly by bacteria belonging to Bacillus sp., such as B. 
licheniformis, B. subtilis, B. megaterium, B. pumilis, B. mojavensis and B. 
amyloliquefaciens. γ-PGA has diverse physiological functions that vary according to the 
species synthesizing it and its environment. Soil bacteria (mostly from the genus 
Bacillus, but excluding B. anthracis) use the released γ-PGA for sequestration of toxic 
metal ions, thereby increasing their resistance to adverse environments. γ-PGA may also 
be a source of glutamate for bacteria during starvation in the late stationary phase. Two 
highly pathogenic bacteria viz., B. anthracis and Staphylococcus epidermidis synthesizes 
surface-associated γ-PGA, which enables them to escape phagocytosis, and enables them 
to act as virulence factor. Furthermore, B. anthracis capsule is composed exclusively of 
the D-enantiomer, making it particularly non-immunogenic. This capsule also prevents 
antibodies from gaining access to the bacterium. It protects B. anthracis against phage 
infections and S. epidermidis against antimicrobial peptides, probably by acting as a 
passive barrier. Thus, anchored γ-PGA is a bacterial virulence factor that protects the 
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pathogen from the immune system, whereas released PGA may be a persistence factor 
that protects the bacterium from its environment. 
Multienzyme system mostly operates on the basis of the thiotemplate mechanism which 
generally offers high sterioselectivity for amino acid precursors and productivity of 
comparatively small peptides in which amino acid arrangements are strictly regulated. 
Synthesis of highly elongated γ-PGA involves extremely unique mechanism [Ashiuchi 
2005]. Biosynthesis of γ-PGA in bacteria is carried out in two steps: in the first step, 
synthesis of L- and D-glutamic acid takes place; where as in second step, these D and L-
glutamic acid units are joined together to form γ-PGA. 
γ- PGA is water soluble, biodegradable, edible and non toxic towards human and the 
environment. Therefore potential applications of γ-PGA and its derivatives have been of 
interest in a broad range of industrial field such as food, water treatment and biomedical 
field as cosmetics and medicine being used as thickener, humectants, cryoprotectant, 
sustained release materials, drug carrier, adhesive, fibers, hydrogels, biopolymer 
flocculants. 
Its multifunctionality, biodegradability, nontoxicity, compatibility, and edibility have 
made it a promising biopolymer for use as a health food, a thickener, an osteoporosis-
preventing factor, and a stabilizer in the food industry; as a moisturizing agent in 
cosmetics; as a chelating agent in waste-water treatment; as a hydrogel (especially super 
absorbent polymer, SAP) for environmental, agricultural, and biomedical product 
applications; as a biodegradable packing material, and in many other possible 
applications including Liquid Crystal Displays (LCDs) and conductive display material, 
drug deliverer, gene vector, curative biological adhesive, dispersant, and enzyme-
immobilizing material [Bajaj 2011]. 
Carboxyl groups of the side chains of γ-PGA offer attachment points for the conjugation 
of chemotherapeutic agents, thereby rendering the drug more soluble and easier to 
administer. Its breakdown product, glutamic acid, can enter normal cellular metabolism 
and is not excreted by the kidney [Singer 2005]. A wide variety of anticancer agents 
have been conjugated to γ-PGA and the resultant conjugates have been tested. Chemical 
crosslinking of gelatin and γ-PGA has been shown to be promising as a surgical adhesive 
and hemostatic agent that may be a potential replacement for the blood-originated fibrin 
glue [Bajaj 2011]. Self-assembled particulate carriers γ-PGA based materials have been 
produced by self-assembly of oppositely charged biopolymers. Utility of γ-PGA NPs as 
an efficient antigen delivery carriers in dendritic cell-based cancer immunotherapy has 
been demonstrated by Matsuo et al, 2010. Lin et al (2007) showed chitosan/poly-γ-
glutamic acid-based self-assembling nanoparticulate system as a drug delivery platform 
for insulin oral delivery.  
Moreover biodegradable nanoparticles, composed of chitosan (CS) and poly-g-glutamic 
acid (γ-PGA), were prepared by an ionic-gelation method for transdermal DNA delivery 
[Lee 2008]. 
 
1.1.1.4 Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)  
Giulia Ciampi PhD Thesis 
14 
 
Polyhydroxyalkanoates (PHAs) are a group of naturally occurring biodegradable and 
biocompatible polymers that belong to the aliphatic polyester family (Figure 4). PHAs 
act as storage compounds of carbon and energy stored in inclusion bodies within the 
cytoplasm that accumulate during imbalanced growth by various microorganisms in the 
presence of an excess of a carbon source and nutrient  (Figure 4) limiting conditions 
(e.g., nitrogen, phosphorus). PHAs occur naturally in a variety of organisms, but 
microorganisms can be employed to tailor their production in cells
1.The simplest PHAs, 
polyhydroxybutyrate (PHB), was discovered in 1926 by Maurice Lemoigne as a 
constituent of the bacterium Bacillus megaterium. Since that time, many discoveries 
have generated excitement over the potential of utilizing PHA in household, industrial, 




Figure 4: Schematic structures of representative poly(hydroxyalkanoate)s. 
 
Members of the PHA family can exist as homopolymers or copolymers of two or more 
hydroxyalkanoic acids. The monomer composition of PHAs is variable and can be 
manipulated by means of the carbon source used and by changing the growth conditions. 
Due to their natural origin and enhanced biocompatibility, PHAs are widely used as 
biomedical implant materials including wound management (sutures, skin substitutes, 
nerve cuffs, surgical meshes, staples, swabs), vascular system devices (heart valves, 
cardiovascular fabrics, pericardial patches, vascular grafts), orthopedics (scaffolds for 
cartilage engineering, spinal cages, bone graft substitutes, meniscus regeneration, 
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internal fixation devices), and drug delivery systems [Chen 2009, Park 2012, Babu 2013, 
Puppi 2010].  
Poly(R-3-hydroxybutyrate-co-R-3-hydroxyhexanoate) (PHBHHx) is a newly developed 
member of the PHA family, with improved physical and chemical properties compared 
with other PHAs as PHB and PHBV.  
PHBHHx had improved hemocompatibility and cytocompatibility; it holds promise as a 
blood-contact material with less platelet adhesion, reduced erythrocyte contact and 
hemolysis reactivity compared with PHB and PHBV films [Qu 2006]. PHBHHx had 
better performances on attachment, proliferation, and differentiation of osteoblasts [Li 
2005, Wang 2004 ] compared with PHB. In vitro chondrocytes proliferated better and 
preserved their phenotype on the PHBHHx/PHB scaffolds than on PHB ones. Scaffolds 
made of PHBHHx/PHB consisting of 60 wt% PHBHHx showed strong growth and 
proliferation of chondrocytes on the blending materials . PHBHHx had a positive effect 
on ECM production of chondrocytes in the composite PHB/PHBHHx scaffolds.  
Recently, PHBHHx was successfully used as an osteosynthetic material for stimulating 
bone growth owing to its piezoelectric properties ,and for effectively repairing damaged 
nerves [Wang 2009]. PHBHHx was found to be totally biodegradable, and its degraded 
products are nontoxic and nonimmunogenic. The main degraded product, 3-
hydroxybutyrate, is a kind of ketone body, which can even been metabolized by 
extrahepatic tissues to supply energy.  
PHBHHx/collagen scaffolds have been successfully used to culture hMSC and SDhESC 
over an extended period supporting the potential of this scaffold combination in future 
tissue engineering applications [Lomas 2013]. 
PHBHHx scaffolds with or without seeded chondrocytes were evaluated in a rabbit 
articular cartilage defect model and the defects were found to be filled with white 
cartilaginous tissue throughout 16 weeks of implantation in vivo [Wang 2008].
 
PHBHHx based 3D scaffold has a great potential for sustained delivery of proteins, 
especially growth factors. When growth factors are incorporated, it can serve as a 
bifunctional system that provides a porous skeleton for cells attachment and 
proliferation, as well as a matrix for long term release of the loaded growth factors [Peng 
2013]. PHBHHx based NPs, loaded with Etoposide and attached folic acid as a ligand on 
the nanoparticles,  were produced for targeted cancer therapy [Kilicai 2011] 
PHBHHx is a promising kind of biomaterial and is expected to have special applications, 
such as scaffolding for tissue engineering and drug-delivery carriers. Because of its ester 
backbone and alkane side chain, PHBHHx is a promising carrier candidate, specifically 
the delivery of hydrophobic therapeutic agents. 
 
1.1.2 Synthetic Polymeric Biomaterials 
Synthetic polymers are available in a wide variety of compositions with readily adjusted 
properties. Processing, copolymerization and blending provide simultaneous means of 
optimizing a polymer’s mechanical characteristics and its diffusive and biological 
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properties. The types of synthetic polymers used in biomaterials include hydrophilic and 
nonhydrolytically degradable materials such as poly(ethylene glycol) (PEG), poly(vinyl 
alcohol) (PVA), and poly(acrylamide) (PAAm). Hydrophobic polymers, such as poly(n-
butyl acrylate), as well as hydrophobic and hydrolytically susceptible materials such as 
poly-(α-esters),PGA, PLA, PLGA, are also widely employed. Amphiphilic block 
polymers such as (PEG-b-PPO-b-PEG) and thermally sensitive polymers such as poly(N-
isopropylacrylamide) (pNIPAAM) have also been widely employed owing to their lower 
critical solution temperatures, which afford thermal sensitivity to control microstructure 
formation, drug delivery, and cell adhesion. The nonhydrolytically degradable polymers 
are often employed at lower molecular weights (<30-50 kDa) to allow for renal clearance 
from the body, or are engineered via conjugation techniques to impart points of local 
hydrolytic or enzymatic degradation [Duncan 2011]. Of these polymers, PEG in 
particular has enjoyed tremendous use as a biomaterial because of its solubility in a 
range of organic solvents, ease of end-functionalization, low PDI, and reasonable cost. 
Consequently, functionalization with PEG of small molecule drugs, peptides, and 
proteins has been widely employed, with such benefits as increased circulation lifespan, 
reduced elimination pathways, and improved efficacy [Hamidi 2006]. 
 
Table 1: Overview of synthetic polymer and relative pharmaceutical applications 
Polymer Main applications 
Poly (glycolic acid); 
Poly (lactic acid) and 
their copolymers 
Used in sutures, drug delivery systems and tissue engineering. 
Copolymerized to regulate degradation time. 
Poly(hydroxybutyrate)s Biodegradable, used as matrix for drug. 
Poly (caprolactone) and 
copolymers 
Delivery systems, cell microencapsulation. 
Poly(alkylene succinate) 
Properties can be tuned by chemical modification, 
copolymerization and blending. 
Polyanhydrides 
Biodegradable, useful in tissue engineering and for the release 
of bioactive molecules. 
Poly(ortho esters) 
Surface–eroding polymers. Application in sustained drug 
delivery, ophthalmology. 
Poly(cyanoacrylate)s 
Biodegradable, depending on the length of the alkyl chain. Used 
as surgical adhesives, glues, and in drug delivery. 
Poly(acrylonitrile) Dialysis membranes. 




Can be tailored with versatile side–chain functionality. 
Applications in drug delivery. 
Polyamides 
Used for sutures and hemofiltration membranes. Inhibitors of 
DNA transcription. 
Polyurethanes 
Used for prostheses, vascular grafts, catheters tissue adhesives, 
artificial cardiac structures, coatings. 
Polypropylene Membrane plasmapheresis, sutures, external medical devices. 
Polyethylene Used for orthopaedic implants and catheters. 
Poly(methyl 
methacrylate) 
This and its copolymers are used as dental implants, in bone 
replacement and as intraocular lenses. 
Poly(hydroxyethyl 
methacrylate) 




Used for vascular grafts, clips and sutures facial prosthesis, 
coatings. 
Polydimethylsiloxanes 
Used for implants in plastic surgery, orthopedics, blood bags, 
pacemakers, drug delivery devices, membrane oxygenators. 
Poly(N-vinyl 
pyrrolidone) 
Hydrogels for controlled release of drugs from metal stents, or 
in blood substitutes. 
Polysulfone Heart valves, penile prostheses. 
Poly(vinyl chloride) Used for tubing, blood bags. 
Polystyrene Used as substrates for cell cultures. 
Poly(ethylene oxide) 
Different polymer derivatives and copolymers used in a variety 
of biomedical applications. 
Poly (ethylene glycol) 
Several applications as spacer, in bioconjugations, coatings, 
excipient in many pharmaceutical products. 
Polylysine Applied in gene delivery, formation of conjugate vectors. 
Poly(ethylenimine) Applied in gene delivery, formation of conjugate vectors. 
Poly(amidoimine) Vectors of nucleotide transfer and gene delivery. 
 




Polycaprolactone (PCL) is an aliphatic polyester composed of hexanoate repeat units.  
PCL is a hydrophobic,  semi-crystalline polymer having a glass transition temperature 
(Tg) of −60◦ C and melting point ranging between 59 and 64°C, dictated by the 
crystalline nature of PCL which enables easy formability at relatively low temperatures. 
Its crystallinity tends to decrease with increasing molecular weight ; the number average 
molecular weight of PCL samples may generally vary from 3,000 to 80,000 g/mol and 
can be  graded according to the molecular weight. The good solubility of PCL, its low 
melting point (59-64°C) and exceptional blend-compatibility has stimulated extensive 
research into its potential application in the biomedical field [Labet 2009 ]. 
The monomer ε-CL can be produced by a  number of microorganisms that  oxidise 
cyclohexanol into adipic acid [Thomas 2002]. In this process, both ε-CL and 6-
hydroxyhexanoic acid are intermediary products. Industrially, ε-CL is produced from the 
oxidation of cyclohexanone by peracetic acid [Rocca 2003]. 
Two main pathways to produce PCL have been described in the literature: the 
polycondensation of a hydroxycarboxylic acid: 6-hydroxyhexanoic acid, and the ring-
opening polymerisation (ROP) of a lactone: ε-caprolactone (ε-CL) [Labet 2009]. The 
ROP of lactones is an attractive method to synthesize aliphatic polyesters such as PCL 
because it enables living polymerizations to be conducted and therefore provides a route 
to tightly control the polymers’ physical properties and polydispersity indices. The 
thermodynamic driving force for the polymerization is the relief of ring strain, which 
enables the entropy, unfavourable in all polymerizations, to be overcome [Williams 
2007]. A mechanism for ROP using lipases has been proposed by several authors : first, 
the lipase reacts with the monomer to form a lipase-activated CL complex, then the 
alcohol reacts with the complex (Figure 5). 
 
 
Figure 5 : Mechanism of the eROP 
Modelling studies on the eROP of ε-CL have revealed that polymerisation, degradation 
and enzyme deactivation all occur simultaneously [Sivalingham 2004]. There are various 
mechanisms which affect the polymerisation of PCL and these are  anionic, cationic, co-
ordination and radical. Each method affects the resulting molecular weight, molecular 
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weight distribution, end group composition and chemical structure of the copolymers 
[Okada 2002].  
PCL has uses in different fields such as scaffolds in tissue engineering [Hutmacher 
2001], in long-term drug delivery systems [Sinha 2004] in microelectronics, as 
adhesives, and in packaging. Its wide applicability and interesting properties (controlled 
degradability, miscibility with other polymers, biocompatibility and potential to be made 
from monomers derived from renewable sources) makes PCL a very useful polymer if its 
properties can be controlled and it can be made inexpensively [Labet 2009]. 
PCL is suitable for controlled drug delivery due to a high permeability to many drugs 
excellent biocompatibility and its ability to be fully excreted from the body once 
bioresorbed. However, the rather high crystallinity of PCL decreases its compatibility 
with soft tissues and lowers its biodegradability. These drawbacks may obstruct its 
application in drug-controlled release systems. This problem might be overcome by 
blending PCL with various polymersor preferably by copolymerization of e-caprolactone 
with other monomers as demonstrated for PCL-based block copolymers. 
Mainly two synthetic pathways are available for the preparation of block copolymers 
comprising a PCL block. Each block can be prepared separately and connected by 
coupling of functional end groups, by the so-called ‘‘click’’ chemistry [Binder 2008]. An 
alternative consists in preparing the first sequence of the copolymer with a chain end 
functionality suitable to initiate the polymerization of the second monomer. 
Up to now, a variety of well-defined copolymers comprising PCL blocks have been 
synthesized by a combination of controlled/‘‘living’’ polymerizatio methods, such as 
anionic or coordinated anionic for the PCL synthesis [Jacquier 1996], atom transfer 
radical polymerization (ATRP) [Nasser-Eddine 2005], nitroxide-mediated 
polymerization (NMP) [Yoshida 1998], and ROP-Aldol-GTP for the synthesis of the 
second block [Zhou 2004].‘‘Click’’ reactions, have been applied in polymer synthesis 
because of their quantitative yields, mild reaction conditions, and tolerance with a wide 
range of functional groups. 
 
1.1.2.2 Polymethacrylamide 
Polymethacrylamide  and poly(amido-amine)s are a unique family of synthetic 
functional polymers that have been widely developed for use both as biomedical 
materials and polymer therapeutics [Ferruti 2002]. 
Poly[N-(2-hydroxypropyl)methacrylamide] [p(HPMA)] is a hydrophilic, biocompatible 
polymers that has been widely used in biomedical field. Water soluble HPMA 
copolymers have developed into a group of mostly frequently studied hydrophilic 
polymers utilizable for synthesis of polymer drug conjugates in order to reduce non 
specific toxicity, and increase the therapeutic index of low molecular weight anticancer 
drugs, to deliver tumor-specific of antisense oligonucleotides to their target mRNAs 
[Ulbrich 2010]. 
The first example of HPMA copolymer conjugate was represented by HPMA 
copolymer–drug (N-(4-aminobenzensulfonyl)-N′-butylurea) conjugate in the 1977. At 
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the same time studies in the modification of proteins were initiated – HPMA copolymer–
insulin and HPMA copolymer–chymotrypsin conjugates [Kopeček 2010]. 
Methacryloilglycilglicine (MAGG), is an anionic methacrylamide monomer that has 
been widely used as a co-monomer for the delivery of anticancer drugs, as a spacer in 
HPMA copolymer and as polymer drug-conjugate [Journo-Gershfeld G. 2012 , Ulbrich 
K., 2010]. 
Bioeliminable co-polymers based on poly(methacryloylglycylglycine-OHx-co-
hydroxypropylmethacrylamidey) (p(MAGG-OH-co-HPMA) were successfully converted 
into nanoparticles and loaded  with human serum albumin as model protein drug 
[Chiellini 2007]. 
 
1.1.3 Polymeric Drug Delivery Systems 
The most common problems and challenges concerning bioactive molecules are their 
absorption, biodistribution, metabolism and excretion, named ADME profile. Excipients, 
an essential part of the drug formulation have been traditionally used in order to 
ameliorate the ADME profile of the bioactive substance. During the last decade, 
excipients – named as drug delivery system-  have evolved to the extent that they 
represent a very important component of the drug compound playing a key role in the 
final formulation almost as important as the bioactive ingredient a role that has begun to 
take new dimension with the arrival of nanotechnology. Drug delivery is one of the 
scientific fields that benefits  to a large extent from this new technology breakthrough by 
the formation of  Drug Delivery Nanosystems. The new nano-scale drug carriers offer 
the possibility of  increasing the therapeutic index of drug molecules by increasing their 
effectiveness, diminishing their toxicity against physiological tissues and achieving 
controlled and sustained therapeutic levels of the drug for prolonged time. Controlled 
release systems can be effective if the release of the drug can be modulated by the 
biomaterials (natural or synthetic) from which the system has been produced. 
Polymer DDS can be used to transport a large number of different types of therapeutic 
agents (including small-molecule drugs and biopharmaceuticals) to the site of action 
precisely and enable controlled release of payload over a prolonged period of time. The 
polymers DDS can be designed and formulated in different forms, such as polymer-drug 
conjugates [Fante 2013], polymeric micelles [Breitenkamp 2013; Gong 2012], 
nanoparticles [Chiellini 2008; Parven 2012], polymer-modified liposomes [Watarai 
2013; Park 2013], multi-component polyplexes (complexes of polymers and genes or 
proteins) [Shim 2012; Palivan 2012], and polymersomes [Lee 2012 ; Zhao 2014], where 
drug payloads can be covalently bound, complexed or encapsulated. 
Polymeric DDS technologies may improve the therapeutic index of drugs by enhancing 
their efficacy and/or increasing their tolerability in the body. For example, polymeric 
NPs can improve the bioavailability of water-insoluble drugs, carry large payloads, 
protect the therapeutic agents from physiological barriers, as well as enable the 
development of novel classes of bioactive macromolecules (e.g., DNA and siRNA). 
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Additionally, the incorporation of imaging contrast agents within nanoparticles can allow 
us to visualize the site of drug delivery or monitor the in vivo efficacy of the therapeutic 
agent [ Wagner 2006; Cai 2007] . Thus far, over two-dozen polymeric DDS products 
have been approved by the US Food and Drug Administration (FDA) and European 
Medicine Evaluation Agency (EMEA) for clinical use, and many are under clinic and 
preclinic development [ Zhang 2007; Davis 2008 ].  
In recent years both natural and synthetic polymers have been investigated as carriers for 
controlling drug release. The first generation DDS were based on non degradable 
polymers matrix, although the disadvantage of this systems was that the release kinetics 
was incontrollable and totally dependent of the diffusive behaviour of the drug through 
the polymer matrix. The second generation of DDS, based on natural or synthetic 
biodegradable polymers, allowed the controlled release of the encapsulated drug and the 
possibility to address the active agents to the target site [Hoffman 2008]. 
The majority of these clinically approved, first-generation nanotechnology products are 
comprised of liposomal drugs and polymer–drug conjugates, which are relatively simple 
and generally lack active targeting or controlled drug release components. To develop 
safer and more effective therapeutic nanoparticles, researchers have designed novel 
multifunctional nanoparticle platforms for cell/tissue-specific targeting, sustained or 
triggered drug delivery, co-delivery of synergistic drug combinations, etc. Among these 
functions the spatial and temporal controls in drug delivery is critical for the successful 
development of next-generation nanotechnology products [Shi 2010] 
Controlled release polymer technology, resulting in the temporal control of drug 
exposure, has benefited virtually every branch of medicine over the past 4 decades. 
Many products utilizing this technology are now in clinical use, including Atridox®, 
Lupron Depot®, Gliadel®, Zoladex®, Trelstar® Depot, and Sandostatin® LAR 
[Farokhzad 2006] and more are listen on Table 2. 
 
Table 2: Marketed and Scientifically Explored Nanosystems [Patel 2014] 
 




Interestingly, various polymeric DDS have been described to treat different diseases. For 
representative examples: polymeric micelle formulated paclitaxel (Genexol-PM®) with 
free of Cremophor EL reducing Cremophor EL-related toxicities and increasing 
therapeutic efficacy (Phase II studies, breast and lung cancers), Adagen® which is a 
conjugate of monomethoxypolyethylene glycol (PEG) covalently attached to the 
adenosine deaminase (ADA) enzyme for the treatment of severe combined 
immunodeficiency disease (SCID) associated with a deficiency of ADA) had received 
FDA approval in 1990 (intramuscular injection), and Oncaspar® which is a Pegylated 
formulation of L-asparaginase, the enzyme that depletes the amino acid asparagine. In 
2006, the FAD approved Oncaspar®for the first-line treatment of patients with acute 
lymphoblastic leukemia. Commercialized Neulasta® which is a PEGylated recombinant 
methionyl human granulocyte colony stimulating factor (G-CSF) stimulating the bone 
marrow and promoting the growth of white blood cells, prevents neutropenia. Neulasta® 
is given intravenously once for each cycle of high-dose chemotherapy [Green M.R. 
2006; Harris J.M. 2003, Tardi P.G. 1996]. 
In general, drug release can be regulated by diffusion of the drug molecules through the 
polymer matrix or by differential surface and bulk erosion of the polymer [Wang 2008] . 
Alternatively, drug release can be triggered by specific body (e.g., changes in pH, 
temperature, and enzymatic activities) or manipulated by external events (e.g., electric 
field, magnetic field, and ultrasound) [Svenson 2012] . By further functionalization with 
targeting ligands, controlled release polymeric nanoparticles could deliver therapeutic 
agents in a spatiotemporally regulated fashion, which may be essential to many medical 
applications. 
Spatially controlled drug delivery can be obtained by conjugating drug-encapsulated 
nanoparticles with targeting ligands, which could facilitate the preferential delivery of 
nanotherapeutics to the sites of interest while reducing undesired side effects elsewhere. 
Since the first description of cell-specific targeted liposomes in 1980 [Leserman 1980] , 
targeted nanoparticles have shown some promising clinical and preclinical results in the 
treatment of different diseases. For tumor cell targeting, the presence of targeting ligands 
could enhance cellular uptake and retention of drugs via receptor-mediated endocytosis, 
although tumor accumulation through the enhanced permeability and retention (EPR) 
effect [Maeda 2001] is largely determined by the physicochemical properties of 
nanoparticles and long circulation half-life.  Active nanoparticle targeting is particularly 
essential for the delivery of biomacromolecules (e.g., DNA and siRNA) that require 
intracellular delivery for bioactivity [Farokhzad 2009]. In the case of vascular 
endothelial targeting for oncology or cardiovascular indications, ligand-mediated 
targeting may be critically important as nanoparticle localization is not a function of EPR 
[Dhar 2011; Rothenfluh 2008 ]. In addition, efforts have been made to transport drugs 
across tight epithelial and endothelial barriers with nanotherapeutics (e.g., the blood–
brain barrier) via ligand-mediated transcytosis [Georgieva 2011] . More recently, 
targeted nanoparticles have been employed in solving the complex problems of 
multidrug resistance [Davis 2008]. 




1.1.3.1 Amphiphilic Copolymers as Polymeric Drug Delivery Systems 
 
The use of nano-delivery systems formed through assembly of synthetic amphiphilic 
block copolymers (ABCs) in experimental medicine and pharmaceutical sciences is 
experiencing rapid development. This rapid development is driven by a crucial need in 
improving the performance of existing therapeutic agents, as well as the necessity for the 
development of advanced delivery systems for complex new entities such as genes, 
proteins and other cellular components [Xiong 2011]. 
The utility of amphiphilic copolymers for delivery of therapeutic agents results from 
their unique chemical composition, which is characterized by a hydrophilic block that is 
chemically tethered to a hydrophobic block. In aqueous solution, polymeric micelles are 
formed via the association of ABCs into nanoscopic core/shell structures at or above the 
critical micelle concentration. ABCs consist of at least two regions of distinct chemical 
nature that undergo phase separation as a result of chain association in solvents that 
selectively dissolve one of the blocks. These materials, when intended for use in drug 
delivery, are generally composed of biocompatible, biodegradable hydrophobic polymer 
blocks such as polyesters or poly(amino acids) covalently bonded to a biocompatible 
hydrophilic block such as PEG, poly(N-vinyl-2-pyrrolidone), poly(2-ethyl-2-oxazoline), 
and poly(acrylic acid) [Letchford 2007, Gaucher 2005] .To date, numerous block 
copolymers have been synthesized, not only with a variety of block combinations, but 
also varying hydrophilic and hydrophobic block lengths. The literature abounds with 
studies using amphiphilic block copolymers of different compositions and various 
methods of preparation that produce nanoparticles referred to as micelles, nanospheres, 
core-shell nanoparticles, micelle-like nanoparticles, crew cut micelles, nanocapsules and 
polymersomes. 
In addition to the benefit of being able to custom synthesize these copolymers for their 
intended use, some amphiphilic copolymers have been shown to modulate the activity of 
the efflux pump, P-glycoprotein [Zastre 2002]. These materials may prove to be useful in 
the delivery of drugs across membranes expressing this protein such as the intestinal 
epithelia, drug resistant tumours and the blood–brain barrier [Letchford 2007]. 
Micelles typically have diameters ranging from 10 to 100 nm and are characterized by a 
core-shell architecture in which the inner core is composed of the hydrophobic regions of 
the amphiphiles creating a cargo space for the solubilization of lipophilic drugs. These 
conformations sterically suppress opsonization by blood components, thus resisting 
phagocytosis by macrophages and decreasing clearance by the reticuloendothelial system 
(RES), resulting in prolonged circulation times [Kataoka K. 2001; Tirrel 2010]. 
 




Figure 7: Micellization model for an amphiphilic diblock copolymer. 
Amphiphilic molecules orientate themselves so that the hydrophobic blocks are removed 
from the aqueous environment in order to achieve a state of minimum free energy. As 
the concentration of amphiphile in solution is increased, the free energy of the system 
begins to rise due to unfavourable interactions between water molecules and the 
hydrophobic region of the amphiphile resulting in structuring of the surrounding water 
and a subsequent decrease in entropy. At a specific and narrow concentration range of 
amphiphile in solution, termed the critical micelle concentration (CMC), several 
amphiphiles will self-assemble into colloidal-sized particles termed micelles. If the 
amphiphile concentration in solution remains above the CMC, micelles are 
thermodynamically stabilized against disassembly. Upon dilution below the CMC, 
micelles will disassemble with the rate of disassembly being largely dependent on the 
structure of the amphiphiles and interactions between the chains [Rösler 2012 ].  
A polymer approach to vesicle formation can broaden the range of the properties 
achievable due to plethora of possibilities to generate such amphiphiles by controlling 
the polymer’s molecular weight, polydispersity and relative hydrophilic to hydrophobic 
block ratio. The use of such amphiphilic block copolymers for generation of polymer 
vesicles, referred to as “polymersomes”, has now become an attractive strategy to create 
stable and biocompatible structures for drug delivery applications. Polymersomes are 
hollow, lamellar and spherical structures whose dimensions and morphologies can be 
controlled by varying chemical constitution and size of copolymer, preparation methods, 
solution properties such as initial copolymer concentration, pH, temperature, solvent 
type, [Jain 2011]. The representative structures of copolymers used, types of 
encapsulants, model structure of polymersomes, and types of stimuli conditions 
responsible for degradation of polymersomes are demonstrated in Figure 8.  
Polymersomes are one of the most interesting and versatile architectures among various 
self assembled systems for drug delivery. The stability and ability to load both 
hydrophilic and hydrophobic molecules make them excellent candidates to use as drug 
delivery systems. 




Figure 8 : A systematic demonstration of various types of amphiphilic block copolymers 
which can self assemble into polymersomes for encapsulation and controlled release of 
bioactive moieties in passive way or in response to stimuli. [ Jain J.P. 2011 ] 
Concluding, the most important feature that makes amphiphilic block copolymers 
attractive for drug delivery applications is the fact that their chemical composition, total 
molecular weight, and block length ratios can be easily changed, which allows control of 
the size and morphology of the micelles [Rösler 2012]. 
 
1.1.3.2 Living radical Polymerization by Reversible Addition- Fragmentation 
Chain Transfer (RAFT) Process 
RAFT polymerization has emerged as one of the most important methods for living 
radical polymerization providing easy access to a large variety of complex polymer 
architectures such as block co-polymers and star polymers with excellent control over 
molecular mass, a narrow molecular mass distribution and appropriate functionality for 
conjugation to and targeted delivery of diagnostic and therapeutic agents. It can be 
performed by simply adding a chosen quantity of an appropriate RAFT agent, a 
reversible chain transfers agent (CTA), to a conventional free-radical polymerization 
[Smith 2010].  
RAFT has been used to polymerize a wide range of monomers, such as styrenic, 
(meth)acrylic, (meth)acrylamido,isoprene, vinylic (e.g., vinyl acetate, vinyl pyridine, 
vinyl carbazole, vinyl pyrrolidone), and diallyl monomers, such as 
diallyldimethylammonium chloride. As RAFT polymerization is adaptable to use in both 
organic and aqueous media, charged polymers can be successfully polymerized at room 
or high temperatures [Boyer 2011]. 
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The first step of polymerization is the initiation step, where a radical is created (Scheme 
1) Many different sources of initiation have been reported for a RAFT polymerization, 
such as the thermal autoinitiation of monomers such as styrene, direct photochemical 
stimulation of the CTA by ultraviolet light, γ radiation,and pulsed laser irradiation. The 
thermal decomposition of radical initiators is, however, the most widely adopted method 
of initiation, due to the commercial availability of such compounds. The oligomeric 
radicals produced in the initiation step react with the RAFT agent (1) in a step of 
initialization The radical intermediate (2) can fragment back to the original RAFT agent 
(1) and an oligomeric radical or fragment to yield an oligomeric RAFT agent (3) and a 
reinitiating R radical. Following initialization, polymer chains grow by adding monomer, 
and they rapidly exchange between existing growing radicals (as in the propagation step) 
and the thiocarbonylthio group capped species (4). The rapid interchange in the chain 
transfer step ensures that the concentration of growing radical chains is kept lower than 
that of the stabilized radical intermediates (4), therefore limiting termination reactions. 
 
Scheme 1 : Mechanism of RAFT polymerization 
The key to the RAFT process and subsequently control over molecular weight is the 
thiocarbonylthio moiety of the CTA. Various thiocarbonylthio groups have been 
reported in the literature and can be classified in one of the following categories: 
trithiocarbonates, dithioesters, xanthates , and dithiocarbamates [Moad 2008]. The CTA 
consists of a stabilizing or destabilizing Z group and the previously mentioned R group 
that must efficiently reinitiate the polymerization [York 2008]. 
Reports of RAFT polymers for biomedical and pharmaceutical applications have 
increased dramatically over the last few years, likely due to facile synthesis of 
biologically relevant architectures with water solubility under mild conditions [Li 2013; 
Giulia Ciampi PhD Thesis 
27 
 
Boyer 2009] . The RAFT techniques offer unprecedented opportunities for size selection 
since polymers with predetermined molecular weights can be easily synthesized. 
Furthermore, it is possible to generate complicated molecular architectures, such as 
block, star and comb copolymers [Barner 2004]. Selecting monomers with appropriate 
biocompatibility and CTAs with reactive functionality also has allowed facile 
bioconjugation to drugs, peptides, proteins, targeting moieties, fluorescent dyes [Stenzel 
2008; Duong 2013,Boyer 2011; Harvison 2011]. 
 
1.1.3.3 Micro-Nanoparticles for Biomedical and Pharmaceutical Applications  
 
Nanoparticle delivery to the skin is being increasingly used to facilitate local therapies. 
The nanoparticle definition designated by the National Nanotechnology Initiative has 
been adopted by the American National Standards Institute as particles with all 
dimensions between 1 nm and 100 nm.  
There are several advantages to using nanoparticles for therapeutics delivery. The use of 
materials on the nanoscale level provides unprecedented freedom to modify some of the 
most fundamental properties of therapeutic carriers, such as solubility, diffusivity, 
biodistribution, release characteristics and immunogenicity. Precise nanoparticle 
engineering has yielded longer circulation half-lives, superior bioavailability and lower 
toxicity [Gronemberg 2006; Brannon 2012 ]. As therapeutic delivery systems, 
nanoparticles allow targeted delivery and controlled release. For diagnostic applications, 
nanoparticles allow detection on the molecular scale: they help identify abnormalities 
such as fragments of viruses, precancerous cells, and disease markers that cannot be 
detected with traditional diagnostics. Nanoparticle-based imaging contrast agents have 
also been shown to improve the sensitivity and specificity of magnetic resonance 
imaging [Zhang 2008]. 
Over the last several decades, numerous nanoparticle platforms have been studied for 
their use in therapeutic applications. These nanoparticle platforms include liposomes, 
polymertherapeutic conjugates, polymeric micelles, dendrimers, nanoshells and nucleic 
acid-based nanoparticles. 
Liposomes have been used widely as pharmaceutical carriers in the past decade, with 11 
formulations approved for clinical use and many more in clinical development. Some of 
the commonly used therapeutics include liposomal amphotericin, liposomal doxorubicin 
and liposomal daunorubicin [Wang 2008].  
Doxil (Table 1) was the first liposomal drug formulation approved by the Food and Drug 
Administration, USA (FDA) for the treatment of AIDS associated with Kaposi’s 
sarcoma in 1995 [Northfelt 1998]. By encapsulating doxorubicin (a widely used 
anticancer chemotherapeutic drug) into stealth liposome carriers comprised of 
hydrogenated soy phosphatidylcholine, cholesterol, and PEGylated 
phosphoethanolamine, Doxil has dramatically prolonged doxorubicin circulation half-life 
and enhanced drug deposition in the tumor tissue [Kaminskas 2012]. Liposomes are 
spherical vesicles that contain a bilayered membrane structure composed of natural or 
synthetic amphiphilic lipid molecules [Torchilin  2013] . Their biocompatible and 
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biodegradable composition, as well as their unique ability to encapsulate both 
hydrophilic and hydrophobic therapeutic agents, make liposomes excellent therapeutic 
carriers. Liposomes can also be coated with biocompatible and antibiofouling polymers, 
such as polyethylene glycol (PEG), to prolong their circulation half-life. Another 
nanoparticle drug delivery platform, polymer-drug conjugates, has been studied 
extensively [Fante 2013] . Small molecule therapeutic agents and proteins usually have 
two unfavourable properties: short circulation half-life, leading to the need for frequent 
administration, and non-site-specific targeting, resulting in undesired systemic side 
effects. The conjugation of drugs to polymeric nanocarriers can reduce these undesirable 
adverse effects. Polymer-drug conjugates not only prolong the in vivo circulation time 
from several minutes to several hours but also reduce cellular uptake along the endocytic 
route. This characteristic enhances the passive delivery of drugs to tissues with leaky 
blood vessels, such as tumors and atherosclerotic plaques [Tanaka 2004; Deguchi 2006]. 
PEG was the first polymer-drug conjugates introduced into clinical use in the early 
1990s, enhances plasma stability and drug solubility while reducing drug 
immunogenicity [Davis 2002]. Today, there are six examples of PEGylated drugs in 
clinical practice (Table 3). For example, Adagen (PEG–adenosine deaminase) is used to 
treat immunodeficiency disease; Macugen (PEG–anti-vascular endothelial growth factor 
aptamer) is used to treat agerelated macular degeneration; Pegasys (PEG-α-interferon 2a) 
is used to treat hepatitis B and hepatitis C; and Oncaspar (PEG–L-asparaginase) is used 
to treat acute lymphoblastic leukemia. Besides PEG, other linear polymers such as 
polyglutamic acid, polysaccharide, and poly(allylamine hydrochloride) have also been 
harnessed as polymeric drug delivery carriers. 
In addition to PEG, other linear polymers such as poly(glutamic acid), poly [N -(2-
hydroxypropyl) methacrylamide p(HPMA), polysaccharide and poly(allylamine 
hydrochloride), have been harnessed as polymeric drug delivery carriers. The polymers 
in the polymer-drug conjugates can be used for conjugation to a targeting ligand, thus in 
turn creating biologically targeted therapeutics.  
Another example is Abraxane, a 130-nm albumin-bound paclitaxel drug, that was 
approved by the FDA in 2005 as a second-line treatment for patients with breast cancer. 
Abraxane concentrates in the tumor partly through the passive enhanced permeability 
and retention effect and partly through the transendothelial transport mechanisms via the 
albumin-binding protein gp60. Clinical studies have shown that Abraxane almost 
doubles the therapeutic response rate and also increases time to disease progression and 
overall survival in patients with breast cancer. 
Besides liposomes and polymeric conjugates, the most common nanoparticle platforms 
today include polymeric nanoparticles, micelles, nanoshells, dendrimers, engineered 
viral nanoparticles, albumin-based nanoparticles, polysaccharide-based nanoparticles, 
metallic nanoparticles, and ceramic nanoparticles. These nanoparticles have shown 
therapeutic potential for almost every branch of medicine such as oncology, cardiology, 
immunology, neurology, endocrinology, ophthalmology, pulmonary, orthopedics, and 
dentistry (Table 4). [Farokhzad 2006; Peer 2007; Kamali 2012] 
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Dendrimers are well defined, regularly branched macromolecules that are 2.5 – 10 nm in 
size. They are synthesized from either synthetic or natural building blocks such as amino 
acids, sugars and nucleotides. The core of a dendrimer is denoted generation zero and 
each additional level of branching adds another generation (first, second, third etc). 
Dendrimers’ characteristics as carriers of therapeutics include nanoscale spherical 
architecture, narrow polydispersity, multifunctional surface chemistry and large surface 
area. Many dendrimer families have been reported [Svenson 2012]. Among the families, 
the polyamidoamine (PAMAM) have been reported for biomedical applications. The 
specific molecular structure of dendrimers enables them to carry various drugs through 
their multivalent surfaces by covalent conjugation or electrostatic adsorption. 
Alternatively, dendrimers can be loaded with drugs, by using the cavities in their cores 
through hydrophobic interaction, hydrogen bonding or chemical linkage. Their surface 
can be engineered to provide precise spacing of surface molecules and to conjugate 
targeting molecules. 
Polymer nanoparticles have been extensively investigated as therapeutic carriers [Gupta 
2013; Svenson 2012].Polymeric nanoparticles have been formulated to encapsulate 
either hydrophilic or hydrophobic small drug molecules, as well as macromolecules such 
as proteins and nucleic acids [Kateb 2010] . The release of encapsulated drugs occurs at 
a controlled rate in a time or environment dependent manner. Furthermore, the rate of 
drug release can be controlled by modification of the polymer side chain, development of 
novel polymers or synthesis of copolymers [Mignani 2013]. In general, these 
biodegradable polymer systems can provide drug levels at an optimum range over a 
longer period of time than other drug delivery methods, thus increasing the efficacy of 
the drug and maximizing patient compliance, while enhancing the ability to use highly 
toxic, poorly soluble or relatively unstable drugs. Several nanoparticle based treatments 
have already been approved by FDA, such as Estrasorb (micellar nanoparticles) for 
topical menopause therapy and Abraxane (albumin-bounded paclitaxel nanoparticles) for 
breast cancer treatment. 
Metallic nanoshells are characterized by a dielectric core coated with a thin metallic shell 
to improve their biocompatibility and optical absorption [Brito-Silva 2013]. These 
particles possess a highly tunable plasmon resonance mediated by the size of the core 
and the thickness of the shell, which in turn determines their absorbing and scattering 
properties over a broad range of the spectrum from the near-ultraviolet to the mid-
infrared. Gold nanoshells have been developed for in vivo photothermal therapy using 
near infrared light [Tong 2013]. Similarly, thermally sensitive polymeric hydrogels and 
optically active nanoshells have been developed for the purpose of photothermally 
modulated drug delivery. Nanoshell particles with a magnetic core (carbonyl iron) and a 
biodegradable poly(butylcyanoacrylate) (PBCA) shell have also been developed for 
controlled release of 5-fluorouracil [Arias 2006] . 
 





Table 3: Clinically approved nanoparticle-based therapeutics. ADA, adenosine 
deaminase; GCSF, granulocyte colony-stimulating factor; HGF, hepatocyte growth 
factor; HIV, human immunodeficiency virus; i.m., intramuscular; i.r., intravitreous; 
IRIV, immunopotentiating reconstituted influenza virosome; i.t., intrathecal; i.v., 
intravenous; PEG, polyethyleneglycol; s.c., subcutaneous; VEGF, vascular endothelial 
growth factor [Zhang 2007]. 
 





Table 4: Nanoparticle-based therapeutics in preclinical development; HER2, human 
epidermal growth factor receptor 2; HIV, human immunodeficiency virus; PAMAM, 
polyamidoamine; PEG, polyethylene glycol; PVA, polyvinyl alcohol. 
 
1.1.3.4 Techniques for Micro-Nanoparticles Preparation  
 
Methods for the preparation of nanoparticles are an important part of the drug delivery 
challenge: they allow to make polymer nanoparticles with suitable properties to ensure 
proper drug delivery and targeting. Thanks to progress in polymer chemistry and in 
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polymer colloid physico-chemistry, it is now possible to prepare polymer nanoparticles 
with a wide range of properties under controlled conditions. 
Several techniques for the preparation of drug-loaded NP systems has been developed. 
The choice of a particular technique depends on polymer and the drug features and the 
process should guarantee the drug stability and biological activity of the incorporated 
agent. Moreover a particular attention should be devoted to the removing of any residual 
organic solvents or excipients, if used, that will have toxicological implications for 
pharmaceutical applications [Chiellini 2008]. 
The Emulsion/Solvent Evaporation method  is the most common , the preparation of 
nanocarriers follows the general protocol of dissolving the polymer in a water 
immiscible, volatile organic solvent which is then emulsified with an aqueous phase to 
stabilize the system. The organic solvent is then evaporated inducing the formation of 
polymer particles from the organic phase droplets. This method has revealed good 
encapsulation efficiency for hydrophobic drugs but poor for  hydrophilic agents, 
therefore oil-in-water emulsion (o/w) and the double (water-in-oil)-in-water, (w/o/w) 
emulsion techniques have been developed [Sanchez 2012]. In the single emulsion 
method, the drug and the polymer are dissolved in an organic solvent and the resulting 
solution is added into an aqueous solution to make an o/w emulsion with the aid of 
amphiphilic macromolecules such as surfactant. The solvent in the emulsion is removed 
by evaporation, resulting in formation of compact NPs. In the double emulsion 
technique, a primary emulsion is prepared by dispersing the aqueous phase into an 
organic solvent containing a dissolved polymer. This is then re-emulsified, under 
vigorous stirring, in an outer aqueous phase containing a stabilizer, thus forming a w/o/w 
emulsion. The w/o/w emulsion system has been used widely for the development of 
protein delivery systems [Meng 2004].  
The Nanoprecipitation technique is based on the interfacial deposition of a polymer, 
dissolved in a semi-polar solvent (i.e., ethanol, acetone, hexane, methylene chloride or 
dioxane), into an aqueous, non-solvent solution, under moderate stirring. In this method, 
the NPs are obtained as a colloidal suspension that forms when the semi-polar solvent 
phase is added slowly to the aqueous phase. The advantage of this method is that it does 
not require sonication or very high temperatures conditions that might damage the active 
agents. This technique is mostly suitable for compounds having a hydrophobic nature, 
but displays very limited solubility in water. In order to overcome this barrier, 
modifications of this technique are under investigation to improve the versatility of the 
nanoprecipitation, particularly with respect to the encapsulation of hydrophilic drugs 
[Bilati 2005].  
The Co-Precipitation method is an original and straightforward procedure developed  
recently. It is particularly advantageous for the loading of protein drugs. In this case, the 
polymer is dissolved in a water/miscible organic solvent and added dropwise to an 
aqueous solution containing the selected protein and appropriate stabilizers. During the 
co-precipitation process, the polymeric material gives rise to micro-phase separation 
because of its low water solubility and the concurrent interaction with protein molecules 
leads to NPs formation. The most important advantage of this methodology is the avoid 
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of use of chlorinated solvents, preventing  the denaturation of the entrapped protein 
molecule that typically occurs with other techniques [Chiellini 2007].  
The Dialysis method is a simple and effective preparation method for small and narrow 
size distributed NPs. In this method, polymer is dissolved in an organic solvent and 
placed inside a dialysis tube with proper molecular weight cut-off. Dialysis is performed 
against a non-solvent miscible with the former miscible solvent. The displacement of the 
solvent inside the membrane is followed by the progressive aggregation of polymer due 
to a loss of solubility leading to the formation of an homogeneous suspensions of NPs. 
The solvent used in the preparation of the polymer solution affects the morphology and 
particle size distribution of the NPs [Vauthier 2009].  
Self Assembling. In this method NPs can be obtained by interaction between charged 
polymers and oppositely charged molecules. Such association depends on many factors 
including coulombic interactions, hydrophobicity of the polymer-molecule pair, and the 
conformational features of the polymer. Typically, self assembled complexes are formed 
by polyions with opposite charges, some examples are the Polyelectrolite Complexs 
(PECs). [Rao 2011; Hartig 2007] Another class of micro/nanocolloids named 
polymersomes are formulated by self assembling of amphiphilic block copolymer in 
water [Jain 2011].  
The Phase separation  method involves the phase separation of a polymer solution by 
adding an organic non-solvent. Drugs are first dissolved in a polymer solution and 
successively an organic non-solvent is added to this solution (e.g. silicon oil, vegetable 
oil, light liquid paraffin) under continuous stirring, by which the polymer solvent is 
gradually extracted and soft coacervate of droplets containing the drug are generated. 
The main disadvantage of this technique is the high possibility of forming large 
aggregates because sticky coacervate droplets can adhere to each other before complete 
phase separation occurs [Koshla 2012].  
The spray-drying technique transforms liquids into dried particles under a continuous 
process; the polymer is dissolved in volatile solvents and the drug is dispersed or 
dissolved in the polymer solution. Solutions or dispersion are sprayed against a stream of 
cold air (-60°C) using a two-fluid pneumatic nozzle with heating facilities. The frozen 
droplets formed  are dried during the following atmospheric freeze-drying in the cold 
desiccated air stream by sublimation. It is one treatment which suits with heat-sensitive 
molecules like proteins preserving them from significant degradation [Vauthier 2009]. 
 
1.2 Nanomedicine in Dermatology  
 
Nanomedicine, which is the medical application of nanotechnology and related 
researches, can be simply defined as the monitoring, repair, construction and control of 
human biological systems at the molecular level, using engineered nanodevices and 
nanostructures [Duncan R. 2011]. 
Nanodermatology represents one of the leading beneficiaries of nanotechnology 
consisting of an emerging technology introduced into dermatology for both diagnostic 
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and therapeutic purposes. Nanotechnology applications have been realized in sunscreens, 
emollients, topical medications, and diagnostic imaging for the maintenance of skin 
health, as well as for the diagnosis and management of skin diseases [Saraceno 2013]. 
During the last twenty years, the pharmaceutical industry began to adopt nanotools to 
implement high throughput screening of drug repositories, to identify drug targets and 
biomarkers for both preclinical and clinical studies, to develop of diagnostic and imaging 
agents, and finally to carry out new nanotechnologies such as nanoformulations and 
nanocarriers as drug delivery approaches. Futuristic scenario for personalized medicine 
includes the development of nanoparticles that simultaneously monitor and treat disease 
called the theranostic approach. 
The entrapment of active moiety in nanocarriers, which is an increasingly implemented 
strategy in skin targeting and topical delivery, may provide a base for a new generation 
of skin delivery of bioactive compounds. Such systems may enable sustained release, 
resulting in an extended activity or enhanced uptake and the possible reduction in 
adverse effects. One way of optimizing topical drug delivery to the skin is to employ 
particulate carriers such as liposomes, nano- and microemulsions, lipid nanoparticles and 
polymeric nanoparticles. The nanocarriers in particular have received attention owing to 
their ability to improve penetration across the stratum corneum and targeting properties. 
 
1.2.1 The Skin Structure and Function  
Skin is the largest sensory organ of the human body with multiple functions: it is an 
important barrier for mechanical disturbances and radiations, microbiological and 
chemical attacks, it plays a key role for the thermoregulation of the body and prevents 
water loss. Moreover it’s important for the synthesis of vitamin D, the protection 
of vitamin B folates and play an important role into the immune response. 
Among the multiple, complex functions of mammalian skin, one of its major roles is to 
prevent invasion of the organism by acting as a defensive barrier to threats from the 
external environment. On the other hand, the skin can be used as a port of entry for 
therapeutic substances such as drugs and vaccines if the mechanisms that confer the 
barrier properties are understood and exploited. 
The skin consists of three main layers: the outermost epidermis layer, which is about 50-
150 μm thick, inner dermis layer about 250 μm thick and subcutaneous fat tissue. No 
blood vessels are present in the epidermis,therefore, nutrients have to diffuse across the 
dermal-epidermal junction to maintain its vitality.  It consists of five layers, which, from 
the outside to the inside are the stratum corneum (SC) , stratum lucidum, stratum 
granulosum (granular layer), stratum spinosum (spinous layer) and stratum 
germinativum (basal layer). Viable epidermis consists of the epidermis without the 
stratum corneum (shown in Figure 9 ).  
 





Figure 9: Diagram of human skin. 
 
The outermost part (15-20 μm) of the epidermis, named stratum corneum, is responsible 
for the barrier function of the skin. It consists of corneocytes (brick) that are embedded 
in a lamellar structure formed by intercellular lipids (mortar) that are rigid, desmosome-
linked epithelial cells. The unique arrangement of this layer represents the basic skin 
permeation resistance that reduces the passage of molecules, especially of those that are 
larger than 500 Da. Keratinocytes, melanocytes (melanin production), Merkel cells 
(sensory perception) and Langerhans cells (immunological function) all might play an 
important role in the functioning of the viable epidermis. Keratinocytes differentiate and 
move upward from the basal layer to the outermost layer through a process termed 
keratinization , on reaching the SC, cells become anucleated and flattened and are 
eventually sloughed off. Along with the above cellular components, appendages 
including the pilosebaceous units (hair follicles and associated sebaceous glands), 
apocrine and eccrine sweat glands are also present. Stratum disjunctum, the outer layers 
of SC , is mainly subjected for desquamation. The flattened, anuclear, proteinrich 
corneocytes of the SC are densely packed within the extracellular lipid matrix which is 
arranged in bilayers often referred to as a ‘bricks and mortar’ arrangement. Depending 
on anatomical site and age, the SC is completely renewed to maintain its optimum 
protective properties.  
Transport of substances across the SC occurs mainly by passive diffusion and based on 
the dual-compartment bricks and mortar structure of the SC, interrupted by appendages, 
is considered to occur via three possible routes (Figure 10).  





Figure 10 : Transport routes across the skin. 
 
These are the intercellular route across the lipids, transcellular route ( across 
thecornecytes, and the transappendigeal route (via hair follicles and associated 
sebacueous gland and sweat ducts) resulting in topical delivery (into skin strata) and 
transdermal delivery (to subcutaneous tissues and into the systemic circulation). Passive 
and active permeation enhancement methods have been widely applied to increase the 
cutaneous penetration [Prow 2011]. 
Lipophilicity and physicochemical properties such as molecular weight or volume, 
solubility and hydrogen bonding ability govern the diffusion rates. Lipid channels, which 
have been estimated to be 19 nm, are expected to physically restrict the free movement 
of particles suggesting that the SC could also present an additional barrier that is not 
present for small molecules [Van Der Merwe 2006]. A large number of protein 
transporters are present in skin, which may play a supportive role in the active transport 
of drugs or other particles. Epithelial layers and follicles consist of several important 
elements as tight junction proteins whose localization and expression have been shown 
to be altered in the diseases characterized by a compromised skin barrier, such as 
psoriasis [Prow 2011]. 
 
1.2.2 Dermatological Diseases  
Today, skin diseases and skin troubles are emerging aspects and afflict millions of 
people every day. Skin-related diseases encompass a vast array of situations ranging in 
severity from benign to life threatening. 
Despite the great progress in dermatological treatments, many skin-associated problems 
are related especially to infectious skin disease and remain difficult to treat. Indeed, these 
problems depend on the type of pathogens involved, the integrity of skin layers and their 
structures and, moreover, the underlying medical condition of the patient 
[Sigmundsdottir 2010]. There are various infectious diseases related to skin and hair 
follicles that might be due to bacterial, fungal and viral infection (Figure 11 ). Chronic 
inflammatory skin diseases such as psoriasis, atopic dermatitis and allergic contact 
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dermatitis are the combined result of infiltration of inflammatory T cells with increased 
production of cytokines in the lesions. Skin diseases caused by inflammatory conditions 





Figure 11 : Schematic representation of various skin disorders and their origin. 
 
The major challenges in treatment of these skin diseases include poor efficiency of drug 
delivery into the disease site and risks of increased toxicity associated with approaches 
used to improve the drug delivery efficiency. Intensive research suggests that the 
effective treatment of skin disorders need a timely identification, estimation and 
management of the disease and adoptability of efficient treatment. To date, the topical 
treatment of skin diseases appears the most favorable choice. Yet the SC counteracts the 
penetration of bioactives into viable skin, and only a few percent of the applied drug is 
absorbed. Marketed topical preparations are associated with side effects relating drug 
absorption to systemic circulation and will thus affect more than just the skin. To achieve 
the localized effect, an easy and non-invasive option such as topical therapy is most 
desirable and ideal for this purpose. The recent innovations mainly focused on exploring 
the novel carriers such as vesicles, lipidic particles and particulate carriers. These nano-
sized particles are of particular interest for topical treatment of skin diseases to increase 
skin penetration of drugs and to reduce side effects. [Prow 2011] 
Despite the achievements in the passive and active skin penetration enhancement 
methods, many skin disease patients are still waiting for treatment based on safer and 
more efficient cutaneous delivery of therapeutics across the SC barrier. 




1.2.2.1 Psoriasis  
 
Psoriasis is an immune-mediated inflammatory skin disease, characterised by scaly, red 
and well demarcated skin plaques, resulting from keratinocyte hyperproliferation and 
altered differentiation, the presence of an inflammatory cell infiltrate and 
neovascularisation. Psoriasis affects 2–4% of the population worldwide and patients 
experience physical and mental symptoms as well as a decreased quality of life. Disease 
aetiopathogenesis is caused by the complex interaction of genetic, environmental and 
immunological factors, all of which contribute to a wide disease spectrum. [Perera GK. 
2012] 
Clinical and experimental evidence points to a central role for the immune system in 
disease pathogenesis. In the initiation phase, activated plamacytoid dendritic cells (pDC) 
contribute to the activation of dermal DC, which in turn activate skin-resident and newly 
recruited helper and cytotoxic T cells that dominate in disease maintenance. Despite 
being considered a T helper (Th) type 1-mediated disease for many years, a pivotal role 
for Th17 cells in psoriasis has recently been revealed. Th1, Th17 and also interleukin 
(IL)-22-producing CD4 T ‘Th22’ cells infiltrate psoriasis plaques, and contribute to the 
disease by cytokine production [Villanova  2013; Zhang 2013].  
Clinically and histologically, psoriatic lesions have an unmistakable morphology with 
distinctive signs of altered epidermal differentiation—massive scaling as a consequence 
of a thickened, irregular stratum corneum with parakeratosis and epidermal thickening 
with acanthosis, papillomatosis, and absence of the granular layer ( Figure 12). 
 
 
Figure 12: (a) acanthosis; (i) dermal inflammation 
 
Thickening of the epidermis is due to a strongly increased keratinocyte proliferation, 
which is comparable with or even more pronounced than in other inflammatory skin 
diseases such as atopic dermatitis. Numerous works have demonstrated the altered 
differentiation of keratinocytes responsible of the clinical appearance of psoriatic lesions: 
several markers of late keratinocyte differentiation including filaggrin, loricrin, caspase 
14, and, in areas of parakeratosis, DNase1L2, are down-regulated, whereas markers of 
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early differentiation such involucrin and small proline-rich proteins are upregulated 
and/or are expressed prematurely (involucrin) and extend over several epidermal layers 
[Tschachler 2007].  
Keratin, a main component of intermediate filaments of KCs, has been found to be 
aberrantly expressed in psoriasis. In normal skin, basal cells express two keratins, K5 
and K14, whereas suprabasal cells express differentiation-related keratins K1 and K10. 
In psoriasis, the changes in keratin expression include a reduction in K1 and K10 and the 
induction of hyperproliferation-associated keratins K6, K16 and K17. Among 
abnormally expressed keratins, K17 is exceptional because it is not normally expressed 
in healthy epidermis but is highly expressed in psoriatic lesions [Fu 2012]. 
In psoriatic lesions, many antimicrobial peptides are highly expressed, and especially the 
associations between psoriasis and cathelicidin, b-defensins or S100 proteins have been 
well studied. Among them, a cathelicidin peptide, LL-37, has been highlighted as a 
modulator of psoriasis development in recent years  
Most of them have not only antimicrobial activities but also immune-modulatory 
functions [ Morizane 2012]. 
Biophysical investigations have confirmed that these alterations of keratinocyte 
differentiation lead to a measurable impairment of the skin barrier function: increased 
transepidermal water loss and reduced hydration of lesional SC have been reported and 
appear to correlate with disease severity. In contrast to lesional skin, virtually no major 
abnormalities of nonlesional skin from patients with psoriasis have been reported with 
regard to expression of markers of keratinocyte differentiation and functional parameters 
of the skin barrier. Therefore, disturbed keratinocyte differentiation in psoriasis has been 
seen by most authors as a consequence of the inflammatory process, that is, the cytokine-
rich microenvironment within the lesions, rather than as a primary event that precedes 
the inflammatory process. Indeed, exposure of keratinocyte to cytokines such as tumor 
necrosis factor (TNF), interferon γ, and interleukin 1 in vitro induces several changes 
that are also observed in psoriasis. In this context, it is of note that artificial disturbance 
of the epidermal barrier by tape stripping of nonlesional skin in patients with psoriasis, 
although inducing a Koebner phenomenon (ie, the emergence of a psoriatic lesion in the 
altered skin area) in some patients, fails to do so in others, arguing against a role of 
barrier breaks as universal trigger of disease activity [Tschachler 2007]. The barrier 
impairment due to disturbed keratinocyte differentiation in lesional skin, however, be it 
primary or secondary to the inflammation, might play an important role in sustaining the 
disease process and contribute to the chronicity of the disease. Support of this 
assumption comes from clinical reports on the therapeutic efficacy of occlusion of 
psoriatic plaques by inert wraps resulting in the resolution of the altered differentiation 
of keratinocytes and the inflammation.  
In conclusion, although altered epidermal differentiation constitutes a hallmark of 
psoriasis, it is confined to lesional skin, and so far, no disturbance, functional or 
structural, that would allow us to predict the occurrence of psoriasis has been identified 
in noninvolved skin.  
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It has been vastly demonstrated over the past decades that keratinocytes are a rich source 
for various cytokines, which act locally in the skin and are able to exert systemic effects, 
suggesting the idea of the epidermis as a secretory organ. Various inflammatory 
cytokines and growth factors have been shown to be strongly induced in keratinocytes in 
psoriatic lesions. Three types of cytokines elaborated by keratinocytes are of particular 
interest in this context: growth factors for keratinocytes and endothelial cells and 
neutrophil attracting chemokines. Several growth factors are able to induce keratinocyte 
proliferation and have been found to be highly expressed in lesional psoriatic epidermis. 
Some of these, transforming growth factor α and ,have been shown to induce epidermal 
proliferation and reproduce some aspects of the psoriatic phenotype when expressed in 
epidermal keratinocytes in transgenic animals [Vassar 1991, Flisiak 2002].Very likely, 
these overexpressed keratinocyte-derived factors may act as autocrine stimulators of 
keratinocyte proliferation in situ in psoriatic lesions. The typical erythema of psoriatic 
lesions is due to the increased, dilated, and tortuous capillaries that extend between the 
epidermal columns protruding into the dermis.  
Strongly increased production of vascular endothelial growth factor (VEGF) by 
keratinocytes has been found in psoriasis. Furthermore, overexpression of VEGF in the 
epidermis of mice triggered subepidermal angiogenesis and increased leukocyte 
adhesion to these vessels, and later in life, these animals develop hyperkeratotic skin 
lesions with a resemblance to psoriasis. Although immune cells are also able to secrete 
VEGF, the findings of VEGF overexpression in psoriatic epidermis together with the 
data reported from the transgenic animals strongly suggest that VEGF derived from 
epidermal keratinocytes might be a central paracrine growth factor contributing to the 
pathology seen in psoriasis [Canavese 2010]. 
Besides the monocytic/lymphocytic infiltrate, the presence of neutrophils, predominantly 
in the upper epidermis and in the SC , is another histologic hallmark of the psoriatic 
lesion that are highly probable attracted by keratinocyte-derived chemokines. These 
keratinocyte-derived chemokines comprise interleukin 8 (CXCL8), Gro-α (CXCL1), 
CCL20, and S100A8/A9 [Nickoloff 2007].  
The contributions of genetic components as predisposing factors for psoriasis are well 
established by linkage analyses and twin studies. Psoriasis heritability is thought to be up 
to 90%. Genome wide linkage studies have identified at least 9 loci referred to as 
psoriasis susceptibility loci (PSORS) with strong evidence for association with psoriasis 
development (PSORS1-9) [Roberson 2010]. 
No natural animal models for psoriasis are available. In contrast, in the past decades, 
many different mouse models that reproduce one or several phenotypic features of 
human psoriasis have been reported and have been reviewed recently. They largely fall 
into 2 groups: (i) xenograft models in which uninvolved or involved skin of patients with 
psoriasis is transplanted on immune-deficient mouse strains and (ii) genetically 
engineered mice that either overexpress individual genes or in which individual genes 
are inactivated [Gudjonsson 2007]. 
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1.2.2.2  Disease Management and Therapeutic Target in Psoriasis  
Management of psoriasis comprises a large repertoire of topical, systemic treatments and 
photo(chemo)therapy. More recently, biological therapies have provided additional 
opportunities to the systemic treatment of psoriasis. Nonetheless, topical therapy remains 
the mainstay in the management of psoriasis; with multiple agents being available, a 
challenge remains to define patients eligibility for a topical treatment or systemic 
treatment. Likewise, severity assessment and improving compliance are important 
approaches to improve care for patients with psoriasis, as is the evaluation of efficacy 
and safety characteristics of individual topical therapies. Once the efficacy and safety 
characteristics are defined, it is possible to define a therapeutic ladder. 
Figure 13 illustrates these approaches and the associated side effects, and the general 
concept applies for the treatment of other dermatological conditions as well. The 
application of systemic treatment and phototherapy is limited to treating severe psoriasis 
patients only, and this is due to the toxicity and carcinogenicity of these approaches. 
Topical treatment approaches are safer, and the drugs are targeted to the basal layer of 
epidermis where psoriasis originates. A number of topically applied formulations are 
available for psoriasis patients upon prescription: anti-inflammatory agents such as 
corticosteroids are the most frequently applied; examples of other agents are anthralin, 
synthetic vitamin D3, and vitamin A. Over the counter formulations containing salicylic 
acid and coal tar are also available [Van de Kerkhof 2004]. The most common side 
effects of topical treatments are skin irritation, thinning of the skin, and dilated blood 
vessels. Controlled drug encapsulation and release systems that not only decrease the 
side effects of the applied agents but also enhance drug permeation into deeper epidermis 
layers would be ideal for psoriasis treatment. 







Figure 13: Standard of care for psoriasis categorized as systemic approach, 
phototherapy, and topical approach. 
 
At present there is no definitive cure, although in recent years biological therapy 
targeting specific inflammatory pathways has proved to be highly effective. Despite this 
success, long-term safety data are still being established, biological agents are expensive, 
and 20–30% of patients still fail to respond [Gudjonsson 2012]. 
 
1.2.2.3 Treatment of Psoriasis by Methotrexate  
Methotrexate (MTX) (C20H22N8O5) is an antimetabolite analog of folic acid (4-amino-
10-methylfolic acid) derived by N10 methylation of its precursor amethopterin (Figure 
14 ). MTX competitively inhibits dihydrofolate reductase, an enzyme that catalyzes the 
reduction of dihydrofolic acid (FH2) to tetrahydrofolic acid (FH4). Aminopterin was used 
empirically for the first time in 1951 to treat psoriasis and rheumatoid arthritis. The first 
published reference to its use specifically in the treatment of psoriasis was in 1958 
[Edmunson 1958].  
 





Figure 14 : Chemical structure of MTX 
 
MTX has a triple anti-inflammatory, antiproliferative and immunosuppressant action. It 
interferes with the metabolic pathway of folic acid, competitively inhibiting the enzyme 
dihydrofolate reductase and consequently the activation of folinic acid. This inhibition 
blocks the synthesis of deoxythymidylic acid, which is required for DNA synthesis. 
MTX binds strongly to the enzyme. However, as the bond is reversible, a large number 
of drug molecules must be in contact with the enzyme to maintain inhibition. Otherwise, 
the bond breaks and the enzyme regains its activity; it is precisely this constraint that 
determines how MTX must be prescribed and administered. MTX also partially, and 
with less sensitivity, inhibits the formation of the purine ring of inosinic acid, the 
precursor of all DNA and RNA purine nucleotides. High concentrations of MTX can 
even directly inhibit protein synthesis. It seems clear that at high doses the chief effect of 
MTX is its antifolate effect but the mechanism of action at low doses is still poorly 
understood. It has been suggested that the effects of low-dose MTX may be due more to 
the formation of intracellular polyglutamates (polyglutamation) and the increased 
formation of adenosine, a potent endogenous anti-inflammatory mediator  [Warren 
2008]. Some authors have suggested that the chief mechanism of action of low-dose 
MTX in psoriasis and other inflammatory diseases may result from the induction of 
apoptosis in activated lymphocytes or from the inhibition of these cells’ activation and 
expression of certain adhesion molecules [Johnston 2005]. 
Concerning the Pharmacokinetics of MTX, at doses under 30 mg/m
2
, MTX is entirely 
absorbed in the gastrointestinal tract by active transport. At higher doses, absorption is 
incomplete because of transport saturation. Once absorbed, the drug is partially 
inactivated in the intestinal tract and the liver, which means that its bioavailability is low. 
It is distributed throughout the body but penetrates pleural and cerebrospinal fluid slowly 
and with difficulty such that the peak concentrations are 30 times lower at these sites 
than in plasma. The drug is eliminated practically unchanged (90%) in urine by both 
filtration and active secretion. MTX clearance is therefore reduced when elimination 
depends on creatinine clearance. The bioavailability achieved with oral and intravenous 
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routes is comparable but highly variable (25%-70%). Peak levels in serum are achieved 1 
to 2 hours after oral administration and 30 to 60 minutes after intramuscular injection. 
MTX is sold in 2.5-mg tablets for oral use and in preloaded syringes containing 7.5, 10, 
15, 20, or 25 mg for parenteral administration (subcutaneous or intramuscular). Also 
available are 50-mg vials for intramuscular injection. A low weekly dose is the MTX 
regimen that has been used since the drug was first prescribed for the treatment of 
psoriasis. The weekly dose of 7.5 to 30 mg is administered on a single day or divided 
into 3 doses and administered at 12-h intervals over 2 consecutive days.  
The common adverse effects of MTX are nausea, vomiting, anemia, neutropenia, 
pulmonary fibrosis, diarrhea, dermatitis, bone marrow depression, mucositis, bruising, 
hepatitis, and so on. MTX shows dose- and duration-dependent teratogenicity [Khan 
2012]. 
Traditionally, MTX has been prescribed as single-drug therapy in psoriasis and used 
particularly in patients with accompanying arthritis. Psoriasis is a chronic disease 
therefore new treatment strategies with the aim of achieving an acceptable level of 
efficacy with the lowest doses and least risk possible will still be valid strategies, 
especially in the case of MTX since the most common form of toxicity of this drug is 
related to the cumulative dose. In patients with psoriasis, tailoring therapy to take into 
account all constraints related to the course of the disease and the patient’s lifestyle is the 
key to maximizing efficacy.  
MTX was the first systemic treatment for psoriasis. After more than 50 years of 
experience, oral MTX continues to be safe, effective, cheap, and easy to use. It can 
therefore be considered the standard systemic therapy, especially for long-term 
antipsoriatic treatment with a classic systemic drug in carefully selected and monitored 
patients. 
 
1.2.3 Topical and Transdermal Drug Delivery  
Whilst the skin has historically been used for the topical delivery of compounds, it is 
only since the 1970s with the advent of transdermal patches that it has widely been used 
as a route for systemic delivery. The permeation barrier properties of human skin elicit 
challenging but exciting delivery avenues for drugs and other compounds into the skin 
strata (topical delivery) and/or to the systemic exposure (transdermal delivery). 
Currently, there are more than 30 transdermal products in the US market; formulations of 
a number of low-molecular-weight drugs and macromolecules have been developed and 
some are currently under clinical trial [Paudel KS 2010]. 
Despite the significant permeability barrier of the SC , drug delivery via the skin is a 
very attractive option and is widely employed for both local and systemic therapy 
[Prausnitz 2008]. Topical treatment of cutaneous disorders obviously targets the site of 
disease, thereby minimizing adverse side effects elsewhere within the body. Delivery of 
systemic therapies via the skin avoids degradation of the medication within the 
gastrointestinal tract and first-pass metabolism by the liver, both of which are associated 
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with oral administration of drugs, in addition to evading the pain and safety issues 
associated with injections. Transdermal delivery of drugs, especially via long-acting 
patches, enables infrequent dosing and maintenance of steady state drug levels [Zhang 
2013]. 
Many dermatologic medications can be applied topically to the skin because the required 
dosage is often exceedingly small and therefore they can be effective even in the setting 
of highly inefficient absorption. In addition, a number of skin disorders are associated 
with compromised barrier function, which leads to enhanced drug uptake in sites of 
involvement. In contrast, systemic drug delivery via the skin typically requires 
administration of larger doses through normal skin. As a result, only ~20 drugs have 
been FDA-approved for transdermal administration. The drugs contained within these 
patches share several characteristics: they are low molecular weight (< 400 Da), 
lipophilic (octanol-water partition coefficient up to 10000), and relatively low dose 
(typically < 10 mg per day) [Bucks 2008]. 
Significant efforts have been expended on the development of new approaches to 
enhance and optimize the cutaneous delivery of drugs, and they can be categorized into 
passive and active penetration enhancement methods (Figure 15). 
 
 
Figure 15 : An overview of passive and active skin penetration enhancement methods 
 
Topically applied therapies are promising for the treatment of skin diseases such as 
psoriasis, contact dermatitis, and skin cancers, because the drugs are delivered directly 
into skin strata. 




1.2.3.1 Polymeric Nanoparticles Based Topical Delivery Systems  
Nanosized drug carriers have attracted much attention in the past decade as options in 
formulations for topical therapy and nanoparticles (including nanospheres, solid lipid 
nanoparticles, micelles, and micellar-like nanoparticles), liposomes, and nanoemulsions 
are among the most studied systems. Inorganic and metal nanoparticles such as quantum 
dots and gold nanoparticles are widely used for diagnosis. Among these nanosized 
carriers, polymeric nanoparticles with readily tunable chemical and physical features can 
effectively protect unstable drugs from degradation/denaturation, decrease the side 
effects of toxic drugs by producing controlled release, and enhance the cutaneous 
penetration of the drugs across the skin barrier by increasing the concentration gradient. 
The potential sites for targeting nanoparticles include the surface of the skin, furrows, 
and hair follicles (Figure 16). Topical nanoparticle drug delivery takes place in three 
major sites: stratum corneum (SC) surface (panel a), furrows (dermatoglyphs) (panel b), 
and openings of hair follicles (infundibulum) (c). The nanoparticles are shown in green 




Figure 16: Sites in skin for nanoparticle delivery. 
 
The tendency of natural polymers as chitosan, alginate and gelatine, for example, to form 
hydrogels makes them ideal carriers for oligonucleotides, peptides, proteins, and water-
soluble drugs. For example, pilocarpine hydrochloride-loaded gelatin nanoparticles were 
reported for topical ophthalmic use; oxybenzone loaded gelatin microspheres, although 
not in the nanosized range, were used for sunscreen applications. Table 2 shows a 
summary of topical delivery systems based on natural polymeric nanoparticles. 




Table 5: Topical delivery systems based on natural polymeric nanoparticles 
 
 
Among various natural polymeric nanoparticles, chitosan-based nanoparticles have been 
most frequently applied for topical skin delivery. The antioxidant, anti-inflammatory, 
and antimicrobial properties of chitosan make it a suitable vehicle for delivering 
therapeutics to treat dermatological disorders. Moreover, at physiological pH, the 
primary amine groups of CS are protonated, and therefore CS is positively charged. The 
positive charge can be used to form nanoparticles in solution via cross-linking with 
polyanions, to efficiently encapsulate negative charged drugs via electrostatic 
interaction, and to promote cellular internalization of drug-containing CS nanoparticles.  
Kim et al.  encapsulated retinol, a vitamin A derivative in chitosan nanoparticles [Kim 
2006]. The encapsulation of retinol in chitosan nanoparticles minimized the irritation and 
toxicity of retinol, and the retinol loaded chitosan nanoparticles can be potentially used 
for acne and anti-wrinkle treatment. Nanoparticle fabrication based on the cross-linking 
between chitosan and polyanions such as tripolyphosphate (TPP) was developed. 
Hasanovic et al. demonstrated that the encapsulation of aciclovir into chitosan–TPP 
nanoparticles resulted in significantly increased drug stability, decreased 
photodegradation, and enhanced drug penetration through porcine skin [Hasanovic 
2009]. 
There is enough evidence that the size of the applied nanoparticles plays a key role in the 
penetration depth and the selective targeting of certain compartments within the hair 
follicle. Preliminary experiments of Rolland et al., 1993, showed that the use of 5 μm 
adapalene-loaded PLGA particles resulted in the increased permeation of adapalene and 
a better therapeutic effect. Similar observations were made by Shim et al., 2004, with 
minoxidil-loaded P(CL) 40–130 nm nanoparticles. 
Three different therapeutic strategies taking advantage of the selective follicular 
penetration of topically applied nanoparticles have currently emerged: firstly, the use of 
the follicular infundibulum as a reservoir for the sustained release of therapeutic 
substances encapsulated in nanoparticles; secondly, the use of hair follicles as a shunt 
taking advantage of the ability of certain types of particles to accumulate within hair 
follicle infundibula and release rapidly the loaded drug; thirdly, the use of skin barrier 
disruption methods or penetration enhancers to favor particle translocation to the viable 
skin and their interaction with important cell populations. [Papakostas 2011] 
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Lademann et al., 2007, showed that a nanoparticle formulation of a fluorescent dye 
penetrated deeper than a particle-free formulation of the same dye only when the 
formulations were applied with a massage. Without massage, similar hair follicle 
penetrations were detected for both formulations. These results were explained with a 
‘‘geared pump mechanism’’: the movement of the hairshaft would work as a ratchet 
pump pushing micro and nanoparticles deeper into the hair follicle canal.  
The accumulation of nanoparticles within the hair follicle canal can take advantage of 
their depot function allowing a sustained drug release over a period of time. Thus, a 
constant drug level in tissue could be achieved opening the way for topical delivery of 
active compounds to specific targets within the hair follicle. Vogt et al. , 2006, 
demonstrated, with experiments on excised human skin pre-treated with cyanoacrylate 
skin surface stripping, that 40-nm polysytirene NPs were able to translocate through the 
barrier of the follicular infundibulum to the viable epithelium of the hair follicle and to 
get internalized by LCs, whereas 750- or 1500-nm particles were not. This was the first 
hint of nanoparticle translocation through the skin barrier and raised toxicological 
concerns, but also opened new perspectives for the field of transcutaneous vaccination as 
LCs are potent antigen-presenting cells (APC). 
Batheia et al projected a nanogel system based on  PLGA-chitosan bilayered 
nanoparticles with oleic acid into a gel matrix to successfully deliver a wide range of 
therapeutic agents. Nanogels are nano-sized networks of physically or chemically cross-
linked polymeric particles. They may be useful for offering a uniform dispersion of the 
nano-carriers in the matrix and augment the contact time, which results in enhanced skin 
penetration of the bioactives [Batheia 2011]. This recent study investigated the skin-
permeating nanogel system containing surface-modified polymeric bilayered 
nanoparticles along with a gelling agent entrapping two anti-inflammatory drugs, 
spantide II and ketoprofen. The findings support that nanogel has significant impact on 
the percutaneous delivery of drugs to the deeper skin layers and may be useful for the 
treatment of various skin inflammatory disorders. Abdel-Mottaleb et al., 2011, reported a 
comparative study between lipid nanocapsules (LNCs), solid lipid nanoparticles (SLNs), 
nanostructured lipid carriers (NLCs) and polymeric nanoparticles for dermal delivery. 
They concluded that polymeric carriers showed fourfold greater accumulation in the skin 
compared with that of the LNCs and twice the accumulation of SLNs and NLCs. These 
findings support that the LNCs can be considered as a potential carrier with respect to 
SLNs and NLCs for the transdermal drug delivery while polymeric nanoparticles are 
more appropriate for localized drug delivery to the skin. 
The wide spectrum of dermatological applications for nanoparticle-based formulations 
could revolutionize the therapeutic and diagnostic strategies of modern dermatology, 
offering solutions to old challenges but also opening new perspectives for the treatment 
and prevention of chronic diseases such as psoriasis, infections and cancer.  
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1.3 Tissue Engineering for Cartilage Repair  
 
Tissue loss or organ failure caused by injury or damage is one of the most serious and 
costly problems in human health care. Tissue engineering, proposed by Langer et al. in 
the early 1990’s, is an emerging strategy of regenerative biomedicine that holds promise 
for the restoration of defect tissues and organs. The concept of tissue engineering is 
defined as “the application of the principles and methods of engineering and the life 
sciences towards the fundamental understanding of structure-function relationships in 
normal and pathological mammalian tissues and the development of biological 
substitutes that restore, maintain or improve tissue function” [Langer 1993]. In order to 
accomplish these goals by tissue engineering, three essential components are required, 
that is, cells for the generation of new tissues, scaffolds for supporting the cell growth 
and the regeneration of new tissues, and bioactive factors capable of stimulating 
biological signals in vivo for cell proliferation, differentiation and tissue growth. Among 
these, the scaffolds play an important role in the success of tissue regeneration since they 
serve as temporary temples to mimic the extracellular matrix for cell growth and interim 
mechanical stability for tissue regeneration and integration. 
When the field of tissue engineering emerged it was predicted that tissue engineering of 
articular cartilage would be one of the first success stories. Research in the past 20 years 
on articular cartilage has provided a deeper understanding on the behaviour of this 
apparently relative simply but actually complex tissue and has led to the current research 
area of injectable hydrogels for articular cartilage tissue engineering. A multitude of 
injectable gels for the repair of articular cartilage defects has been investigated and it is 
culminated in the design of several injectable hydrogels that are currently in phase 2 
clinical trials. 
 
1.3.1 Composition and Structure of Articular Cartilage  
In synovial joints like the hip, knee, elbow and shoulder hyaline cartilage covers the 
articulating surface of the bones. Articular cartilage is a connective tissue composed by a 
unique type of cell, the chondrocyte, embedded within a dense ECM consisting of 80% 
water, a collagen type II network, and proteoglycans. Although cartilage appears to be a 
simple aneural, avascular, connective tissue, there are many levels of complexity in its 
composition and structure. Both cells and matrix distribute within successive cartilage 
layers identified as superficial, transitional, radial (deep zone), and calcified zones 
[Cancedda 2003]. Cartilage tissue demonstrates significant differences in cell phenotype, 
composition, and matrix organization along the depth of the tissue, reflecting different 
biomechanical and functional requirements of different zones [Keeney 2011, Bhosale 
2008 ]. 
Hyaline cartilage is characterized by its high content on proteoglycan aggrecan, which 
exists in the form of proteoglycan aggregates in association with hyaluronan (HA) and 
link protein (LP). These aggregates are responsible for the turgid nature of cartilage, 
Giulia Ciampi PhD Thesis 
50 
 
providing the osmotic properties necessary to resist compressive loads [Roughley 2006]. 
The most basic functions of cartilage include providing near frictionless surface between 
load bearing in the joints to allow for pain-free motion, shock-absorbance, and load 
distribution. Cartilage tissue is not able to repair itself because it is an aneural, avascular 
and alymphatic tissue. The avascularity of articular cartilage has led to the assertion that 
the tissue is immunoprivileged, whereby the body’s immune system is limited in its 
ability to detect and reject implanted tissue [Santo 2012].  
The main role of fibrillar collagen is to provide resistance to shear stresses and 
compressions forces, while the hydrated proteoglycan rich matrix acts as a shock 
absorber. Chondrocytes are cells present in the cartilage that produce ECM and  their 
interaction with the ECM is critical for both development and maintenance of the tissue. 
The immediate microenvironment of the chondrocytes is the chondron which main 
function is to insulate and physically separate the chondrocytes from direct interaction 
with the bulk of the load bearing matrix. 
In articular cartilage there are 4 different zones can be distinguished which have different 
functions and compositions and where chondrocytes have different size, shape and 
metabolic activity: the superficial zone, where the collagen fibrils, a major component of 
cartilage are oriented horizontally and are thereby resisting the shear forces resulting 
from the movement of the joint. In the transitional and radial zone the fibrils are oriented 
randomly and with a high concentration of aggrecan present create a structure that is 
perfectly suited for shock absorption. In the calcified cartilage zone the fibrils are 
oriented perpendicular to the bone surface. This orientation is important in the resistance 
against compression forces. The fibrils are attached to the subchondral bone tissue in 
order to relay any meaning forces to the underlying bone. 
Other important components of articular cartilage are the proteoglycans. Two major 
classes of proteoglycans are found in articular cartilage,  large proteoglycans called 
aggracans and small proteoglycans including decorin, biglycan and fibromodulin. 
Proteoglycans are comb like molecules composed of glucosaminoglycans (e.g. 
chondroitin sulphate and keratin sulphate) linked to a core protein. With hyaluronic acid 
they form large complexes, the aggrecan aggregates with high molecular weights. Upon 
articulation a compressive force is applied to the cartilage and a small amount of fluid is 
released. After articulation the balance is restored [Seror 2011]. 
Numerous  growth factors (GFs) work in concert to regulate development and 
homeostasis of articular cartilage throughout life, in particular bioactive factors from the 
TGF-b superfamily,  Fibroblast growth factor (FGF) family, and IGF-I [Fortier 2011]. 
 
1.3.2 Strategies for Cartilage Repair  
Articular cartilages defects can be due to the trauma or diseases and they cause many 
disambling symptoms such as pain and limited articulation of the joint. A classification 
of cartilage defect has been defined and it ranges from grade 0 to grade 5 giving a 
macroscopic description of articular cartilage defects [Mainil-Varlet 2003]. Briefly, 
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grade 0 corresponds to normal healthy cartilage;  grade 1 is given when the cartilage 
remains intact but shows increased swelling due to the degradation of proteoglycans, 
which are changes at the macromolecular level. Because the patient is generally not 
aware of the damage progressive deterioration leads to further degeneration of the tissue 
to grade 2 or even grade 3.These defects are accompanied with an increased proliferation 
of the chondrocytes and an increased synthesis of matrix molecules, but the newly 
formed matrix does not fill the defect and soon cell activity end proliferation cease. The 
defect becomes permanent, which alters the mechanical function of the joint, thereby 
increasing the risk of further cartilage degeneration surrounding the defect. A grade 4 
defect is an injury that passes through the subchondral bone and reaches the bone 
marrow. This triggers the formation of a blood clot that fills the defect site. After the 
formation of a dense fibrin network, blood vessels invade the fibrin network and scar 
tissue is formed. This tissue has inferior mechanical properties with less proteoglycans 
and collagen type II as present in healthy articular cartilage. After 1 year, this repair 
tissue often shows sign of deterioration such as, fibrillation, fragmentation and 
irregularities, which promotes degeneration of the surrounding healthy cartilage. 
Typically, chondrocytes respond to injury caused by mechanical insult, joint instability, 
and inflammatory cytokines through matrix activation, cell proliferation, apoptosis, and 
matrix destruction [Martin 2004].The activation of chondrocytes can result in 
modulation of gene expression, resulting in different patterns of protein synthesis, 
fibroblast dedifferentiation, hypertrophy, or regeneration of mature cartilage. The lack of 
vascular supply in cartilage limits early repair responses upon injury,  consequently, 
injury to cartilage usually heals through a scar tissue formation mainly composed of 
fibrocartilage with inferior mechanical properties and a gradually degrading nature. 
Moreover, cartilage has a low cell:matrix ratio and chondrocytes have a relatively low 
metabolic activity limiting the tissue remodelling activity [Bedi 2010]. 
Current clinical treatments for articular cartilage repair include: abrasion,  microfracture, 
mosaicplasty and autologous chondrocytes transplantation (ACT) [Redman 2005]. 
Especially ACT introduced in 1994 can be regarded a breakthrough since it is based on 
cartilage regeneration using the patient’s own cartilage cells. The main limitation of this 
method is the low number of cells obtained through  the biopsy, the rather difficult 
surgical procedure and the high costs. A major problem is that fibrocatilage that forms is 
mechanically inferior to hyaline cartilage. 
New strategies to generate articular cartilage have emerged from the rapidily developing 
field of tissue engineering. For the fabrication of new cartilage tissue three different 
approaches are generally chosen: guided tissue regeneration using engineered matrices, 
injections of cells or cells seeded with matrices. In the most frequently used approach 
cells are seeded on a scaffold and grown in vitro and the resulting tissue engineered 
material is implantated in the appropriate location. For cartilage engineering a great deal 
of progress has been made using solid scaffolds, that must be biocompatible whereas the 
construct should be mechanically stable and permeable to allow cell seeding and 
migration. Ideally the material is biodegradable and primarily serves as a temporary 
construct which is in time replaced by newly synthesized ECM. A wide variety of 
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materials have been explored to construct scaffolds that suffice the above mentioned 
requisites such as synthetic polymers, including biodegradable and bioresorbable 
polymers already used for clinically established products (PLGA and PCL), polymers 
under current clinical investigation, such as polyhydroxyalkanoates (PHAs), 
polyurethanes (PURs), polyphosphazenes, and natural polymers such as collagen, fibrin 
and hyaluronic acid (HA) have been proposed [Puppi 2010]. Despite the large progress 
made several limitation have been encountered, it is often difficult to achieve a 
homogenous distribution of cells within 3-dimensional construct. Additionally, bulky 
scaffolds necessitate invasive implantation procedures which are costrly and have a 
higher risk of infections than minimally invasive procedures. 
 
1.3.3  Hydrogels for Tissue Engineering  
The ideal design criteria for tissue-engineered articular cartilage require 
biocompatibility, ease of handling, mechanical properties approaching native tissue, and 
ease of implantation. Since articular cartilage has hydrogel-like properties, an attractive 
scaffold for the native tissue is the hydrogel. Thus, hydrogels have become a focal 
approach for cell and morphogen delivery for articular cartilage tissue engineering and 
regeneration [Kloxin 2010]. 
Hydrogels are hydrophilic polymer networks that can retain large amount of water. Well 
known examples in everyday use are contact lens and cosmetic like hair gels. Their 
hydrophilic nature resembles that of soft tissues and potential applications are their use 
as tissue engineering scaffolds or as drug delivery vehicles. Moreover, due to their high 
water content hydrogels don’t evoke serious immune reactions and show good 
cytocompatibility. 
Hydrogels of alginate, agarose, chitosan, and collagen are natural biomaterials. In 
addition, there are a plethora of synthetic materials where molecular weight, chemistry, 
and composition can be varied for optimal biological properties. Through novel 
approaches for structural modifications, the mechanical properties of hydrogels can also 
be tuned to modulate and direct cellular activity [Reddi 2011]. 
Hydrogels can be classified either by type of polymer, synthetic or natural, or by the 
method of crossilinking, physical or chemical. Natural polymer, like  polysaccharides 
and proteins have inherent macromolecular properties similar to the natural extracellular 
matrix and can induce specific cell-material interactions. Synthetic materials have the 
advantage that mechanical properties can be tailored and a much broader range of 
materials with specific properties can be prepared. However, cell-material interactions 
and biocompatibility may be an issue and have to be taken into account in the design of 
these materials. Physically crosslinked hydrogels maintain a network structure by the 
formation of non-covalent crosslinks through e.g. hydrophobic or ionic interactions. 
Especially physically crosslinked gels that exhibit a reversible sol-gel transition 
depending on temperature contributed to a large extend to the development of these 
materials for biomedical and pharmaceutical applications. Examples of these material are 
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amphiphilic block copolymer of aliphatic polyesters and poly (ethylene glycol). 
Depending on type of polymer and hydrophilic to hydrophobic weight ratio a transition 
from the sol to the gel phase or gel to sol phase takes place when the temperature is 
elevated and this means that locally n the body a gel can be formed by injection of a 
polymer solution that will gel by an increase in temperature. Chemical crosslinking 
involves the formation of covalent bonds between polymer chains. 
The success of tissue engineering depends on biomimetic hydrogel scaffolds that possess 
controlled structures and on-demand properties to modulate specific cellular behaviors. 
The development of suitable synthetic methods encompassing chemistry and molecular 
biology open a new way for the design of biomimetic hydrogels mimicking basic 
processes of living systems. In general, biomimetic hydrogels can be categorized into 
bioactive, bioresponsive, and biofunctional hydrogels. Bioactive hydrogels can instruct 
cell behaviors and promote tissue regeneration. A well-know bioactive ligand is cell-
adhesive peptides, e.g., Arg-Gly-Asp (RGD). It was revealed that RGD-modified PEG 
diacrylate hydrogels could induce enhanced cell attachment and mineralized matrix 
deposition of osteoblasts as compared to RGD-free hydrogels [Burdick 2002]. Natural 
proteins such as collagen and its analogs may also serve as bioactive ligands due to 
inherent nature of biological recognition. 
Bioresponsive hydrogels can response to biological components, such as enzymes, 
receptors and antibodies. After the hydrogels undergo a macroscopic transition (gelation, 
enzymatic degradation and swelling/shrinkage), this in turn directly leads to microscopic 
response of living cells (cell migration, differentiation, cell division and matrix 
production). For example, Lutolf et al. developed cell-responsive hydrogels that can 
degrade in response to local protease activity such as matrix metalloproteinase (MMP) at 
the cell surface. The hydrogel systems were made from vinyl sulfone-functionalized 
multiarmed PEG and the bis-cysteine peptide crosslinker which contained the sequence 
sensitive to matrix metalloproteinases [Lutolf 2003] By mimicking the MMP mediated 
invasion of the natural provisional matrix, the hydrogels were shown to assist tissue re 
generation.  
Depending on intended application, biofunctional hydrogel should provide sufficient 
mechanical strength so as to protect seeded cells and developing neotissue as well as to 
withstand the physiologic load. However, most of hydrogels reported so far are not 
qualified especially for bone or cartilage tissue regeneration due to the lack of a high 
mechanical strength. Thus, robust hydrogels have been developed with on-demand 
mechanical properties. Two types of robust hydrogel systems can be classified. First, 
hydrogels can be fabricated by double crosslinking methods: by this approach, the 
hydrogels have increased crosslinking density improving the mechanical properties 
without comprising other properties such as permeability and biocompatibility. For 
example, Feijen and coworkers reported on the in situ hydrogels crosslinked by 
combining stereocomplexation and photopolymerization [Hiemstra 2007]. Second, 
robust hydrogels can consist of two interpenetrated polymeric networks. The hydrogels 
with double networks contain a subset of interpenetrating networks formed by two 
hydrophilic networks, one highly crosslinked, the other loosely crosslinked. The double 
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network structure can be obtained by pre- and postcrosslinking through exploiting the 
disparity of their reaction times. For example, a double network composed of two 
mechanically weak hydrophilic networks based on N,N-dimethylacrylamide and glycidyl 
methacrylated hyaluronan, provides a hydrogel with outstanding mechanical properties 
[Weng 2008]. 
 
1.3.3.1  In Situ Forming Biomimetic Hydrogels for Tissue Regeneration  
The formation of the gel at the site of injection ensures a proper shape filling of a defect 
or may be used to induce a local release when a drug is incorporated. The use of polymer 
precursor solutions also allows for easy incorporation of cells and biologically active 
compounds before injection. 
As a base for the design and production the of a 3D microenvironment inside the human 
body, injectable hydrogels need to satisfy several requirements: (a) they should be made 
of biocompatible materials and should degrade into biocompatible products; (b) their 
viscosity should be sufficiently low before gelation, allowing a homogeneous dispersion 
with drugs/cells; (c) mild gelation conditions and proper gelation rates after in vitro or in 
vivo injection should exist to avoid toxicity, overheating caused by severe reactions, and 
rapid extravasation in the surrounding tissues, and also to effectively encapsulate cells/ 
drugs; (d) they should show enough stability and tenacity for holding cells/drugs and 
avoiding initial burst effects, supporting the internal/external loads (like neighbouring 
soft tissue invasion and movements) and maintaining a relatively stable environment for 
cell activity, matching the tissue strength; (e) they should present an adequate percentage 
of porosity, pore size and pore interconnectivity to allow space for cell activity and free 
exchange of oxygen and nutrients; (f) they should be biodegradable to create space for 
cell growth and rearrangement, and for the newly formed tissues (Figure 17 ) [Li 2012]. 







Figure 17: Schematic illustration of injectable biodegradable hydrogels for biomedical 
applications. 
 
Articular cartilage can be damaged due to trauma and diseases like osteoarthritis are 
frequently the cause of disambling symptoms such as pain and limited articulation of the 
affected joint. 
Nowadays, treatments for articular cartilage repair include: microfracture mosaicplasty, 
autologous chondrocytes transplantation and osteochondral allograft transplantation. 
Although these techniques do relieve pain and improve joint function, the repaired tissue 
often lacks the structure of native cartilage and shows signs of deterioration after 1 year. 
Recent studies conducted towards in-situ chemically crosslinked hydrogels as scaffold 
for articular cartilage repair offer a promising alternative. As mentioned above they can 
fill irregularly shaped defects and allow homogenous cell distribution (Figure 18). 
 
 
Figure18: Principle of minimally invasive procedure for an in-situ forming injectable 
hydrogel 




They also introduce the possibility of implantation by arthroscopic techniques thus 
removing the necessity for open procedure which are costly and have a higher risk of 
infections. 
A polymeric hydrogel based on the hydrophilic copolymer poly(propylene fumarate-co-
ethylene glycol) was developed [Fisher 2004]. Solutions of this polymer are in liquid 
state at temperatures below 25°C and in a gel at temperatures above 35°C. This 
thermoreversible hydrogel scaffold would appear to be useful for articular cartilage, as 
one can encapsulate chondrocytes with optimal growth factors and/or morphogens such 
as BMPs. Bovine articular chondrocytes were used in this hydrogel, and they exhibited 
optimal proteoglycan and collagen II synthesis. The addition of BMP-7 to chondrocytes 
in the hydrogel stimulated cell proliferation but not biosynthesis of proteoglycans. 
Although thermoreversible hydrogels are a potential delivery system, much additional 
work is needed. 
Microspheres/nanospheres have been widely used as tools for controlled drug delivery 
due to their small dimensions and the corresponding high surface area, high drug loading 
efficiency, high reactivity toward surrounding tissues, and high diffusibility and mobility 
[Wang 2011]. Moreover, their size allows them to respond quickly to environmental 
stimulus.  When included in a scaffold, they can also act as reinforcement phase, 
providing higher mechanical strength and protecting the drug from in vivo degradation. 
Moreover, the incorporation of preformed delivery systems allows the combination of 
carriers with different release rates, entrapping different drugs, thus showing the 
potential for tailoring the availability of multiple signaling molecules at different pre-
programmed rates [Niu 2009; Perets 2003].Some of the advantages of entrapping 
preformed microparticulate delivery systems in TE constructs include the extra 
protection of the entrapped drugs to the physical and chemical adversities inherent to 
scaffold processing techniques and the fact that it avoids a new scaffold design for 
optimization of processing parameters. Delivery from scaffolds loaded with particulate 
carriers allows to retain the bioactive factor for an extended time, overcoming the 
disadvantages of the direct immobilization of GF in scaffolds that have poor control over 
release rates due to an open pore structure and exposure of the drug to the medium [Silva 
2009; Wang 2011]. 
When molded into 3D constructs, the drug delivery capacity of the carriers is coupled 
with the structural support provided by the scaffold. Although in these cases the release 
is mostly controlled by the properties of the carriers, the entrapment within the 
hydrogel/scaffold also influences the delivery profile [Santo 2012]. 
 
1.3.3.2 Strategies to Design in Situ Forming Hydrogel 
Several methods can be applied for in situ formation of hydrogels. These methods can be 
classified by the nature of network formation: by physical or chemical crosslinking. In 
physically crosslinked hydrogels the crosslinks are formed by e.g. hydrophobic 
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interaction, ionic interactions between polycations and polyanions, hydrogen bonds, 
supramolecular self-assembly or inclusion complexes. Especially, temperature dependent 
gelation induced by hydrophobic interactions in amphiphilic block copolymers has been 
extensively studied. Depending on the composition, concentration and architecture of the 
block copolymer, the phase transition from a solution to a gel can take place by 
increasing or decreasing the temperature [Ruel-Gariepy 2004]. The advantages of 
physical crosslinking are good biocompatibility and less toxicity since toxic crosslinking 
reagent or initiators are not used during crosslinking. However, physically-crosslinked 
hydrogels can  be unstable and mechanically weak. The changes in the environment such 
as pH, temperature and ionic strength may lead to the disruption of the gel network.  
Pluronics [block copolymers of poly(ethylene oxide) and poly(propylene oxide)] and 
poly (N-isopropylacrilamide) (PNIPAAM) are well known materials that provide 
thermo-sensitive hydrogels [Jung 2010; Park 2008; Cohn 2005]. They have been 
combined with chitosan, hyaluronic acid or gelatin and studied as a potential materials 
for cartilage tissue regeneration [Park 2008; Chen 2009] As an example, a 
thermosensitive chitosan/pluronic hydrogel was synthesised by grafting pluronics onto 
chitosan using EDC-NHS chemistry [Park 2009]. 
Chitosan mixed with glycerol-phospate disodium salt affords thermo-reversible 
hydrogels [Chenite 2001]. The system remains liquid at room temperature, but quickly 
gels at body temperature. β-Glycerol phosphate disodium salt (GP) showed an 
osteogenic effect when added to cultures of human bone marrow stromal cells. The 
CTS/GP gel was shown to be capable of delivering an osteogenic mixture of β-
Transforming Growth Factor (β-TGF) family members and of encapsulating 
chondrocytes in vitro for normal cartilage regeneration over 3 weeks [Chenite 2000]. A 
thermosensitive CTS/GP blend developed by BioSyntech Inc. (Laval, Quebec, Canada) 
is currently in clinical trials for cartilage repair [Ruel-Gariepy 2004]. 
In situ-forming chemically crosslinked hydrogels can be prepared from soluble 
precursors having complementary relative groups that are introduced in the polymer 
chains by conjugation or end group functionalization. Alternatively, conjugated groups 
may be used to form covalent bonds between adjacent polymer chains by the action of 
e.g. radical initiators or enzymes. As for any biomedical applications, it is desirable that 
chemical reactions take place with minimal unwanted side reactions to nearby tissue. 
Unlike preformed scaffolds, crosslinking agents and non-crosslinked material remain in 
an injectable gel, so all reactant must be non cytotoxic at the concentrations they are 
employed. 
A method used for the covalently crosslink hydrophilic polymer conjugates onto 
hydrogels is the Michael type addition between thiols and acrylated or vinyl sulfones 
[Hiemstra 2007]. 
In-situ hydrogels formation using enzymes have emerged recently. Enzymes are known 
to exhibit a high degree of substrate specificity, which potentially avoids side reactions 
during crosslinking. Another advantage of the enzymatic crosslinking is bound to the 
mild gelation conditions (e.g. physiological conditions), favourable for tissue 
regeneration. An example is the radical coupling of phenols by the enzyme horseradish 
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peroxidase (HRP) in the presence of hydrogen peroxide (H2O2). The disadvantage of this 
approach is the use of hydrogen peroxide. It is reported that high concentration of 
hydrogen peroxide (>0.2 mM) may induce cell apoptosis [Asada 1999]. Therefore, it is 
important to control the amount of hydrogen peroxide that has to be used in a cell-
favourable range. The principle has been described by Kaplan et al for the formation of 
hydrogels from poly(aspartic acid) conjugated with tyramine, tyrosine or aminophenol 
groups [Sofia 2002]. Kurisawa et al  and Jin et al used the HRP catalyzed crosslinking of 
hyaluronic acid tyramine conjugates and dextran tyramine conjugates, respectively, to 
produce in-situ forming hydrogels [Kurisawa 2005; Jin 2007].  
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I. AIM OF THE WORK 
The present PhD work is part of a long–standing research activity regarding the design 
and synthesis of polymeric materials for biomedical and pharmaceutical applications that 
has been carried out by chemists, biologists, pharmaceutical technologists, engineers and 
computer scientists constituting the research group active at the Laboratory of Polymeric 
Materials for Biomedical and Environmental Applications (BIOLab) of the Department 
of Chemistry and Industrial Chemistry of the University of Pisa. 
In the last years the impact of polymeric biomaterials in the field of medicine has 
brought new impulse to the development of multifunctional drug delivery systems and 
supports for tissue engineering. The new technological solutions entail integrated 
collaborations by various scientific areas, material science, chemistry, biology, medicine 
and this synergy has been giving a great contribution to human health care. 
For many years, fundamental and applied investigations have focused on the 
development of pharmaceutical formulates allowing for maximization of the therapeutic 
efficacy and minimization of the adverse effects of the drugs of interest. 
The research project constituting the body of the present thesis involves 
multidisciplinary skills. The focal point consists on the synthesis of novel polymeric 
biomaterials and realization of biocompatible polymeric nanoparticles and hydrogel 
designed for the controlled release of active principles. New dosage forms designed for 
controlled and targeted delivery of bioactive agents represent at present the best 
approach for maximization of the therapeutic efficacy, minimization of the adverse 
effects of drugs and administration of labile molecule otherwise degraded under 
conventional route. 
The PhD research activity is focused on the following three main topics aimed at: (I) 
Synthesis and characterization of a novel amphiphilic copolymer with hydrophobic 
poly(ε-caprolactone) (PCL) branches and a hydrophilic poly(methacryloylglycylglycine) 
(p(MAGG)) chain; (II) Preparation and characterization of nanoparticles formulation 
based on chitosan (CS) and poly-γ-glutamic acid (γ-PGA) as vehicles for the topical 
sustained delivery of Methotrexate (MTX); (III) Development of injectable hydrogels 
based on chitosan (CS) and hyaluronic acid (HA) loaded with nanoparticles based on 
poly[(R)-3-hydroxybutyrate-co-(R)-3-hydroxyhexanoate] (PHBHHx) for the sustained 
controlled delivery of dexamethasone (DEXA). 
 
The first research activity will be devoted to the design and synthesis of a novel 
amphiphilic copolymer with hydrophobic PCL branches and hydrophilic p(MAGG) 
chains. Block copolymer micelles represent an important drug delivery system that has 
generated much interest in many areas (eg. parenteral, oral, topical, ophthalmic) because 
of their unique structure and properties. The most important feature that makes 
amphiphilic block copolymers attractive for drug delivery applications is the fact that 
their chemical composition, total molecular weight, and block length ratios can be easily 
changed to control the size and morphology of the micelles. To date there is no evidence 
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in the literature regarding the synthesis of this copolymer. The synthesis of the new 
amphiphilic block copolymer based on PCL and p(MAGG) will be investigated using 
two different synthetic routes: the first using the combination of Ring Opening 
Polymerization (ROP) of ε-caprolactone and xanthate-mediated Reversible Addition-
Fragmentation Transfer (RAFT) polymerization; the second by combination of ROP and 
free radical polymerization. In the perspective of a practical application in the 
pharmaceutical field, the block copolymer micelles will be submitted to in vitro 
biological evaluation in order to investigate the cytocompatibility of the prepared 
nanosystems. 
 
In the second research activity polymeric nanoparticles (NPs) formulation, as carriers for 
the topical sustained delivery of the antipsoriatic drug MTX, will be investigated. 
For such purpose, one of the main objective is represented by the design and set up of 
polyelectrolyte complexes NPs based on polymers of natural origin, namely chitosan and 
poly(γ-glutamic acid), and produced by a polyelectrolyte self assembly method. 
The use of natural polymers for the preparation of nanoparticles has attracted appreciable 
attention due to their biocompatibility, biodegradability, and hydrophilic behaviour, 
which are favourable characteristics in various biomedical applications. Nanosystems as 
polymeric nanoparticles can proficiently control the release of a therapeutic moiety to the 
affected region at the skin site with localized effect by creating skin reservoirs and their 
narrow size distribution may allow an efficient site-specific skin targeting favouring 
greater drug retention. MTX belong to an antifolate class of anti-neoplastic agent used 
for the treatment of psoriasis. Regarding the potential severe toxicity associated with 
systemic administration of MTX, a topical formulation might be of greater utility for the 
treatment of hyperproliferative skin disorders such as psoriasis. Various studies suggest 
that CS and γ-PGA based polyelectrolyte complexes (PECs) are promising for topical or 
transdermal drug delivery. The parameters for the obtainment of NPs based on CS and γ-
PGA loaded with MTX will be investigated and optimized. Moreover drug encapsulation 
efficiency and release kinetic will be evaluated. 
 
The third research activity will be carried out at Laboratory of Drug targeting and Drug 
Delivery System of the West China School of Pharmacy, Sichuan University (Chengdu, 
China), the activity will be part of the project funded by the European Community 
entitled “Hyaluronan-based in ectable material for tissue engineering” (Hyan i scaffold). 
The research activity will be aimed at the preparation of injectable hydrogels for the 
sustained drug delivery in cartilage tissue engineering. Two biocompatible and 
biodegradable natural polymers, CS and HA, will be employed to prepare the 
thermosensitive hydrogel. Thermogels are a class of biomaterials capable of existing as 
injectable solutions at room temperature that transition to colloidal gels in situ as they 
warm to body temperature. These systems are ideal for sustained and localized drug 
delivery, they can be used as three-dimensional (3D) scaffolds for cell culture (e.g. stem 
cells, adipose stem cells, chondrocytes) to be employed in injectable tissue engineering. 
They provide minimally invasive drug delivery, the drug can be easily dispersed and 
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injected into the patient where upon gelation, the thermogel will maintain drug delivery 
at the injection site. The formation of the gel at the site of injection ensures a proper 
shape filling of a defect and it may be used to induce a local release when a drug is 
incorporated. 
The injectable hydrogel will be characterized in terms of morphology by SEM and it will 
be loaded with PHBHHx nanoparticles encapsulated with DEXA, a potent synthetic 
corticosteroid which is used clinically as an anti-inflammatory and immunosuppressive 
agent with the ability to promote the differentiation of chondrocytes. 
Processing conditions for the obtainment of PHBHHx NPs with high encapsulation 
efficacy of the drug will be optimized and the prepared NPs will be characterized in term 
of size, Z-potential, morphology and drug loading. Moreover, PHBHHx NPs will be 
successfully loaded into the CS-HA thermogel and the DEXA kinetics release  study will 
be performed. 
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III. LIST OF ABBREVIATION 
 
AHP = Ammonium Phosphate Dibasic 
AIBN = Azoisobutyronitrile 
ATCC = American Type Culture Collection 
BSA = Bovine Serum Albumin 
CMC = Critic Micelle Concentration 
CS = Chitosan 
DCM = Dichloromethane 
DDS = Drug Delivery Systems 
DEXA = Dexamethasone 
DMEM = Dulbecco’s Modified Eagles Medium 
DMSO = Dimethyl sulfoxide 
E.E. = Encapsulation Efficiency 
FDA = Food and Drug Administration 
FT-IR = Fourier Transformed Infrared 
GPC = Gel Permeation Chromatography 
HA = Hyaluronic Acid 
HEMA = 2-hydroxyethyl methacrylate 
HPMA= Hydroxypropylmethacrylamide 
HSA = Human Serum Albumin 
MAGG = Methacryloylglycylglycine 
MeOH = Methanol 
MTX = Methotrexate 
Mw = Molecular Weight 
N% = Number percent 
NMR = Nuclear Magnetic Resonance 
NPs = Nanoparticles 
O/W = Oil in water emulsion 
PBS = Phosphate Buffered Saline 
PC= Phosphatidilcoline 
PCL = poly (ε-caprolactone) 
PECs = Polyelectrolyte Complexes 
PHAs = Polyhydroxyalkanoates 
PHB = Poly-3-hydroxybutyrate 
PHBHHx = Poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) 
PHBV = Poly (3-hydroxybutyrate-co-3-hydroxyvalerate) 
PI = Polydispersity Index 
PLA = Poly (lactic acid) 
PLGA = Poly (Lactic-co-Glycolic Acid) 
pMAGG = Poly (Methacryloylglycilglycine) 
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POL188 = Poloxamer 188 
PVA = Polyvinyl alcohol 
RAFT = Reversible Addition Fragmentation Transfer 
RES = Reticulo-endothelial System 
ROP = Ring Opening Polymerization 
SD = Standard Deviation 
SEM = Scanning Electron Microscopy 
TEM = Transmission Electron Microscopy 
TGA = Thermal Gravimetric Analysis 
V% = Volume percent 
W/O = Water-in-oil emulsion 
W/O/W = Water-in-oil-in-water emulsion 
Z-Pot = Zeta Potential 
γ-PGA = Poly-γ-glutamic acid  
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2 Chapter II : Synthesis and Characterization of 





With topical dosage forms, great attention has been devoted to new formulations that can 
ensure adequate localization of the drug within the skin to enhance the local effect or 
increase the penetration through the stratum corneum and viable epidermis for a local or 
systemic effect. Block copolymer micelles represent an important drug delivery system 
that has generated much interest in many areas (e.g, parenteral, oral, topical, ophthalmic, 
rectal delivery) because of their unique structure and properties [Gupta 2012; Tyrrel 
2010]. Block copolymer micelles are generally formed by the self-assembly of either 
amphiphilic or oppositely charged copolymers in aqueous medium. The hydrophilic and 
hydrophobic blocks form the corona and the core of the micelles, respectively. A variety 
of drugs with diverse characteristics, including genes and proteins, can be incorporated 
into the core by engineering the structure of the core-forming segment of the block 
copolymer so that one can expect sufficiently strong interaction with drug molecules 
[Shim 2004; Yang 2013]. The presence of a non-ionic water-soluble shell as well as the 
scale (10–100 nm) of polymeric micelles are expected to restrict their uptake by the 
mononuclear phagocyte system and allow for passive targeting of cancerous or inflamed 
tissues through the enhanced permeation and retention effect. Research in the field has 
been increasingly focused on achieving enhanced stability of the micellar assembly, 
prolonged circulation times and controlled release of the drug for optimal targeting. 
Compared to surfactant micelles, polymeric micelles are generally more stable, because 
of their intrinsic and lowered critical micellar concentration (CMC), and have a slower 
rate of dissociation, allowing retention of loaded drugs for a longer period of time and, 
eventually, achieving higher accumulation of a drug at the target site. Moreover 
functionalization of the outer surface of the polymeric micelle to modify its 
physicochemical and biological properties is reviewed from the standpoint of designing 
micellar carrier systems for receptor-mediated drug delivery. This can be accomplished 
in a regulated fashion by constructing micelles from a variety of end-functionalized 
block copolymers. [Kataoka  2012; Rösler  2012; Gaucher 2006]. 
To date, numerous block copolymers have been synthesized, not only with a variety of 
block combinations, but also varying hydrophilic and hydrophobic block lengths. The 
literature is abound with studies using amphiphilic block copolymers of different 
compositions and various methods of preparation that produce nanoparticles referred to 
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as micelles, nanospheres, core-shell nanoparticles, micelle-like nanoparticles, 
nanocapsules and polymersomes.  
The aim of utilizing the polymeric micelles in drug delivery are to improve the solubility 
of water insoluble drugs, to stabilize and protect drugs which are sensitive to the 
surrounding environment, to reduce the nonspecific uptake by the reticuloendothelial 
system, to prolong the circulation time in the blood, and to achieve targeted delivery.  
In this study, we have investigated the possibility of designing and synthesizing a novel 
amphiphilic copolymer with hydrophobic poly(ε-caprolactone) (PCL) branches and a 
hydrophilic poly(methacryloylglycylglycine) (p(MAGG)) chain. To date there is no 
evidence in literature about the synthesis of this copolymer. The hydrophobic part is 
composed of linear PCL, an important member of the aliphatic polyester family and of 
interest for biomedical applications owing to its good biocompatibility and low 
immunogenicity. For drug release applications, the advantages of PCL include its high 
permeability to drugs, and less acidic degradation products as compared to polylactide 
and polyglycolide. However, the rather high crystallinity of PCL decreases its 
compatibility with soft tissues and lowers its biodegradability. These drawbacks may 
obstruct its application in drug-controlled release systems; this problem might be 
overcome by copolymerization of  ε-caprolactone with other monomers. The hydrophilic 
part of this copolymer is composed by poly(methacryloyglycylglycine) (p(MAGG)), 
based on MAGG, an anionic monomer that has been widely used as a co-monomer for 
the delivery of anticancer drugs, as a spacer in HPMA copolymer and as polymer drug-
conjugate [Journo-Gershfeld 2012 ; Ulbrich 2010]. The p(MAGG) was selected because 
of the easy modification of its functional groups, that makes it an attractive polymer for 
targeted drug delivery. 
The synthesis of the new amphiphilic block copolymer based on PCL and p(MAGG) 
was investigated using two different synthetic routes: the first using the combination of 
Ring Opening Polymerization (ROP) of ε-caprolactone and xanthate-mediated 
Reversible Addition-Fragmentation Transfer (RAFT) polymerization; the second by 
combination of ROP and free radical polymerization. 
   
2.2 Materials 
The products were used as received unless otherwise specified. 
2-Bromopropionyl bromide, potassium ethyl xanthogenate, Lipase acrylic resin from 
Candida antartica (Novozym 435), glycil glicine, 2-hydroxyethyl methacrylate (HEMA) 
and tin(II) 2-ethyl-hexanoate (Sn(Oct)2) were purchased from Sigma-Aldrich.  
Methacryloyl chloride was purchased from Fluka Analytical. Triethylamine was 
purchased from Baker J.T. Poly(methacryloilglycilglycine) (p(MAGG)100) was supplied 
by Polymer Laboratories Ltd. (UK). Ɛ-Caprolactone (Ɛ-CL) was purchased from Aldrich 
and dried over calcium hydride for 48 hours at room temperature and then distilled under 
reduce pressure before the use. Azoisobutyronitrile (AIBN) was purchased from Fluka 
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Analytical and was recrystallized from methanol before use. Benzyl alcohol was 
obtained from Fluka Analytical and it was distilled from calcium hydride under reduce 
pressure before use. 
Dyalisis membranes [(Specta/Por, float-A-Lyzer, diameter 10 mm, Mw cut-off  3500 Da, 
cellulose ester (CE)] were obtained from Spectrum Laboratories Inc. Dulbecco’s 
Modified Eagle’s Medium (DMEM), Bovine Calf Serum (BCS), Penicillin/Streptomycin 
(P/S) solutions were purchased from Gibco. Complete Dulbecco’s Modified Eagle’s 
Medium (Complete DMEM) was prepared by adding penicillin (100 U/mL), 
streptomycin (100μg/ mL), glutamine (4 mM) and 10% calf serum to DMEM. The 
Balb/3T3 Clone A31 (ATCC CCL163) mouse embryo fibroblast cell line was purchased 
from ATCC (American Tissue Culture Collection) and propagated following the 
instructions provided by the supplier. The cell proliferation reagent WST-1 was 
purchased from Roche Molecular Biochemicals and stored at -20°C in the dark. 
All solvents used were commercially available. 
 
2.3 Methods 
Synthesis of methacryloylglycylglycine (MAGG) 
Glycyl-glycine dimer (GG) (10 g, 0.076 mol) was added to a solution of 3 g (0.076 mol) 
of sodium hydroxide in 15 mL of water. After complete dissolution, the solution was 
cooled at 0°C and 7.3 mL (0.076 mol) of methacryloyl chloride and a solution of 3 g 
(0.076 mol) of sodium hydroxide in 15 mL of water were added dropwise 
simultaneously. The reaction mixture was stirred at room temperature for two hours then 
acidified with concentrated hydrochloric acid to pH = 2. The crystal that precipitated 
from solution was collected by filtration and recrystallized from 1:1 (v/v) water/ethanol 
solution. The crystalline white powder upon drying in vacuum amounted to 7 g (yield 
50%). 
1
H NMR (DMSO-d6, 200 MHz, at 20 °C)(Figure 1a): 1.8 ppm (s, 3Ha), 3.8 ppm (m, 2Hd 
+ 2He) 5.3ppm (s, 1Hb), 5.7 ppm (s, 1Hc,), 8.2 ppm (m, 1Hf + 1Hg). 
FT–IR (KBr): ν = 3380-3100 (ν OH, NH), 1740 (ν C=O carboxylic), 1647.4 (ν C=O 
amide I band), 1605.9 (ν C=C), 1540.4 (δ N-H and ν C-N amide II band), 1431 (ν C-O 
and O-H carboxylic) and 1337.9 (δ CH3). 
 
Synthesis of monohydroxy-terminated Poly(ε-caprolactone) (PCL-OH) 
Under dry nitrogen atmosphere, 0,175 mL of dry benzyl alcohol (1,7 x 10
-3
 mol) and 10 
ml of dry CL (10,6 g, 0,09 mol) were charged to a dry Schlenk tube equipped with a 
magnetic bar. After that, 220 mg Novozym ( 2% respect to the benzyl alcohol) was 
added to the reaction mixture and the tube was immersed in a thermostated oil bath at 50 
°C for 48 h. After cooling at room temperature, the reaction mixture was diluted with 
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dichloromethane then was filtered to remove the catalyst and precipitated from methanol 
twice (1/10 solvent-non solvent ratio). The precipitated polymer was collected by 
filtration and the solid was dried under vacuum at room temperature. Yield was 70%. 
1
H–NMR: (CDCl3, 200 MHz, at 20°C)(Figure 2) = 1.4-1.6 ppm (m, 2Hd), 1.6 -2.0 ppm 




, Mn (GPC) = 12726 g mol
-1
, Mw /Mn= 1,44 
 
Synthesis of 2- bromopropionyl-terminated PCL (PCL-Br) 
In a dried and nitrogen purged round bottom flask 6,5 g [ 5,40 x 10
-4
 mol, calculated on 
the basis of molecular weight (12000) obtained from 
1
H–NMR ] of PCL-OH were 
dissolved in 39 ml of dry THF with 0,189 ml of triethylamine (13,5 x 10
-4
 mol). The 
reaction mixture was cooled to 0°C and 0,113 ml (10,8 x 10
-4
 mol) of 2-bromopropionyl 
bromide were added dropwise. The obtained mixture was stirred for 72 h at room 
temperature. The precipitated by-products (i.e. Et3N,HBr), were removed by filtration 
and the filtrate was evaporated to dryness. The product was dissolved in THF and 
precipitated in deionized water (1/10 solvent-non solvent ratio). The precipitated 
polymer was collected by filtration and the solid was dried under vacuum at room 
temperature, then was redissolved in THF, precipitated from hexane  (1/10 solvent-non 
solvent ratio)and dried under vacuum at room temperature. The yield was 85%. 
1
H–NMR: (CDCl3, 200 MHz, at 20 °C) (Figure 3) : 1.3-1.5 ppm (m, 2Hd), 1.5-1.8 ppm 
(m, 4Hc), 1.82 ppm (d, 3Hg), 2.2-2.5 ppm (m, 2Hb), 4.0-4.2 ppm (t, 2He), 4.2-4.4 ppm (t, 
2Hf), 5.1ppm  (s, 2Ha), 7.2-7.3 ppm (m, 5HAr). 
Mn(NMR)=11870 g mol
-1
 , Mn (GPC) = 12806 g mol
-1
, Mw /Mn= 1,45 
 
Synthesis of xanthate-terminated PCL (PCL-X) 
 
In a dried and nitrogen purged round bottom flask 5 g of PCL-Br (4,20 x 10
-4 
mol, 
calculated on the basis of molecular weight (11870) obtained from 
1
H–NMR) and 0,267 
g of potassium O-ethyl xanthate (1,57 x 10
-3
 mol) were dissolved in 39 ml of dried 
acetone. The reaction mixture was stirred at room temperature for 48 h under nitrogen. 
The obtained PCL was precipitated in methanol twice, recovered by filtration and dried 
under vacuum at room temperature. The yield was 90 %. 
1
H–NMR: (CDCl3, 200 MHz, at 20°C)(Figure 4): 1.3-1.6 ppm (m, 2Hd); 1.6-2.0 ppm 
(m, 4Hc+ 3Hg+3Hi); 2.3-2.5 ppm (m, 2Hb); 4.0-4.4 ppm (t, 2He), 4.4-4.5 ppm (q, 2Hf), 
4.6-4.8 ppm (q, 2Hh), 5.18-5.22 ppm (s, 2Ha), 7.2-7.3 ppm (m, 5HAr). 
FT–IR (KBr): 2945(νas CH2 ), 2865 (νs CH2),1725 (ν C=O) 
Mn (NMR)= 12600 g mol
-1
 , Mn (GPC) = 13114 g mol
-1
, Mw /Mn= 1,39 
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Synthesis of the block copolymer PCL-b-p(MAGG) 
In a dried schlenk tube 0,834 g of MAGG ( 4,17 x 10
-3
 mol) and 0,0017 g of AIBN were 
dissolved in 2,8 ml of anhydrous DMSO and mixed with1 g of PCL-X ( 8,33 x 10
-5 
mol) 
in 6 ml of dry DMSO ( PCL-X/AIBN mol ratio= 1/0,2 , PCL-X/MAGG mol ratio = 
1:50)  
After three freeze–pump thaw cycles the mixture was left and gently stirred for 24 h at 
60 °C under nitrogen atmosphere. After cooling at room temperature, the crude product 
was purified by membrane dialysis against 1000 mL of water in a 10 mL cellulose ester 
membrane at room temperature. The pure polymer was frozen-dry to yield 60%.  
1
H–NMR: (DMSO, 200 MHz, at 50°C)(Figure 5): 0.8-1.2 ppm (s, 3Hi), 1.2-1.4 ppm (m, 
2Hd), 1.4-2 ppm (m, 2Hh + 4Hc + 3Hg + 3Hq), 2.2-2.4 ppm (m, 2Hb), 3.6-3.9 ppm (m, 
2Hm + 2Ho), 3.9-4.3 ppm (t, 2He ), 4.3-4.5 ppm (q, 2Hf), 4.5-4.6 ppm (q, 2Hh), 5.1 ppm 
(s, 2Ha), 7.3-7.4 ppm (m, 5HAr), 8.0-8.2 ppm (m, 1Hl + 1Hn). 
FT-IR (KBr) : 2940 (νas CH2 ), 2868 (νs CH2), 1725(ν C=O), 1647(ν C=O amide I band), 
1542(δ N-H and ν C-N amide II band) 




Synthesis of the methacrylate-terminated PCL (PCL-HEMA) 
A solution of Sn(Oct)2 in hexane (12 µL; 0.5% w/w respect to ε-CL) was added in a 
dried round bottome flsk, under nitrogen atmosphere. Hexane was then removed under 
vacuum in order to dry Sn(Oct)2. Then 3 mL (0,027 mol) of ε-CL and 0.752 µL (0,0062 
mol) of HEMA were added and mixed to homogeneity. The reaction mixture was left 
stirring at 110 °C for 4 h. At the end, the mixture was cooled to room temperature, 
dissolved in CHCl3 and then precipitated twice in methanol (1/10 solvent-non solvent 
ratio). The product was freeze drying under vacuum providing a white solid. The yield 
was 70%. 
1
H NMR (200 MHz, CdCl3)(Figure 12): 1.4 ppm (m, 2Hh ), 1.8 ppm (m, 2Hg + 2Hi), 2.0 
ppm (s, 3Hc), 2.5 ppm (m,  2Hf), 3.7 ppm (t, 2Hm), 4.2 ppm (m, 2Hl), 4.6 ppm (t, 2Hd 
+2He), 5.6 ppm (s, 1Hb), 6.2 ppm (s, 1Ha). 








Synthesis of the graft copolymer PCL-g-p(MAGG) 
In a dried schlenk tube 0,500 g of MAGG ( 2,5 x 10
-3
 mol) and 36 g of AIBN (3% w/w) 
were dissolved in 2,2 ml of anhydrous DMSO and mixed with 0,624 g of PCL-HEMA ( 
2,7 x 10
-4 
mol) in 2,2 ml of dry DMSO. After three freeze–pump thaw cycles the mixture 
was left and gently stirred for 18 h at 50 °C under vacuum. After cooling at room 
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temperature, the crude product was purified by precipitation in water and recovered by 
filtration. The polymer was frozen-dry to yield 30%. 
1
H–NMR: (DMSO, 200 MHz, at 50°C) (Figure 13): 0.8-1.2 ppm (m, 3Hp +3Hd), 1.2-1.4 
ppm (m, 2Hg), 1.4-2.0 ppm (m, 2Hh + 2Hf + 1Ha + 2Hl), 2.2-2.4 ppm (m, 2He), 3.6-3.9 
ppm (m, 2Hm + 2Hn), 3.9-4.4 ppm (m, 2Hi + 4Hc), 8.0-8.2 ppm (m, 1H + 1H). 
FT-IR (KBr) : 2946 (νas CH2 ), 2863 (νs CH2), 1725(ν C=O), 1644(ν C=O amide I band), 
1535(δ N-H and ν C-N amide II band) 
 
Characterization of Monomers and Polymers 
Spectroscopic characterizations 
Fourier Transformed Infrared (FT-IR) spectra were recorded as KBr pellets (1/100 mg) 
or as solution in KBr pellets, in the range of 4000-400 cm
-1
 by using a Jasco FT-IR 410 
spectrophotometer with a resolution of 4 cm
-
1. Each spectrum was recorded after 16 
scans. 
Nuclear Magnetic Resonance (NMR) spectra were recorded on 5–10% (w/v) solutions, 
in deuterated solvents, at 20°C or 50°C by using a Varian Gemini 200 spectrometer and 
tetramethylsilane (TMS) as internal standard. 
1
H–NMR spectra were recorded at 200 
MHz, using the following spectral conditions: 3 KHz spectral width, 30° impulse, 2s 
acquisition time, 1–16 transients.  Chemical shifts (δ) are reported in ppm and refer to 
tetramethylsilane as standard. Peak multiplicity is denoted by the following: s = singlet, 
d = doublet, , t = triplet, q = quartet, m = multiplet. 
 
Thermal characterization 
Thermal Gravimetric Analysis (TGA) measurements were carried out on 10–12 mg 
samples in the 25–700°C temperature range in a nitrogen atmosphere at 10 °C/min 
heated with a Thermogravimetric Analyzer TGA Q500. 
Polymers molecular weight 
Gel Permeation Chromatography (GPC) analysis was carried out at 25°C with a Jasco 
PU 1580 liquid chromatograph equipped with a Jasco 830 RI refraction index detector 
and Perkin Elmer LC–75 UV–vis detector, using two PL Mixed D styrene–divinyl 
benzene columns. Chloroform was used as eluent at a flow rate set at 1.0 mL/min. 
Molecular weight calibration was performed with monodispersed polystyrene samples.  
Polymeric micelles characterization 
Dimensional analyses 
Polymeric micelles size analyses were carried out by using a Coulter Beckman LS230 
Laser Diffraction Particle Size Analyzer, equipped with small volume module plus. 
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Samples were added into the cell until a 30-50% obscuration of the PIDS detector was 
reached. 
Fluorescence measurements 
In order to determine the critical micelle concentration (CMC) of PCL-b-p(MAGG) 
copolymer,  
fluorescence measurements were carried out using pyrene as previously described [ 
Wilhelm M. 1991]. The fluorence excitation spectra, λem =390 nm of pyrene was 
measured at varying polymer concentrations using Victor 1420 Multilabel Counter 
fluorescence spectrometer at 25 °C. The concentration of PCL-b-p(MAGG) micelles and 
pyrene used were within the ranges 1,4 x 10
-3 





Biological investigations  
 
Cell line 
Cytotoxicity evaluations of PCL-b-p(MAGG) and relative micelles were carried out 
using the 3T3/BALB-C Clone A31 cell line. Cells were grown in DMEM containing 
10% Bovine Calf Serum BCS, 4 mM glutamine and 100 U/ml:100 μg/ml 
penicillin:streptomycin (complete DMEM). 
Subculturing 
A 25-ml flask containing exponentially growing 3T3 cells was observed under an 
inverted microscope for cell confluence. The complete DMEM media was then removed, 
and cells were rinsed for a few minutes with PBS. The buffer solution was removed, and 
cells were incubated with 0.5 ml of trypsin/EDTA solution at 37 C in 5% CO2 incubator 
for 5 min or until the monolayer started to detach from the flask. Cells were suspended in 
an appropriate volume of DMEM at a split ratio of 1:6 or 1:10 in a 75 ml flask. 
Absorbance measurements on microplates 
Microplate absorbance measurements were performed by means of Benchmark Bio–Rad 
Microplate Reader. All data were processed by using Microplate Manager III (Biorad) 
and Igor Pro (Wavemetrics). 
CO2 incubator 
Cell cultures were performed in a Hera Cell (Heraeus Instruments S.p.A.) CO2 Incubator 
in 5% CO2 enriched atmosphere.  
Laminar flow cabinet 
Experiments that required sterile conditions were performed under a Hera Safe HS12 
Bioclass II (Heraeus Instruments S.p.A.) laminar flow cabinet. 
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Optical Microscopy (OM)  
Optical microscopy observations were performed by Nikon Eclipse TE 2000 inverted 
microscope equipped with epifluorescence lamp and Nikon D Eclipse C1 confocal 
system. 
WST-1 cell proliferation assay 
Quantitative proliferation of cells exposed to polymeric micelles was evaluated by WST-
1 cell proliferation assay. A subconfluent monolayer of 3T3 fibroblast was trypsinized 
using a 0.25% trypsin, 1mM EDTA solution, centrifuged at 200 × g for 5 min, re-
suspended in growth medium and counted. Appropriate dilution was made in order to 
obtain 2 ×10
3
 cells per 100 μl of medium, the final volume present in each well of a 96 
well plate. Cells were incubated at 37 C, 5% CO2 for 24 h until 60–70% confluence was 
reached. The medium from each well was then removed and replaced with medium 
containing a different concentration (100–50 μg/ml) of polymeric materials. Control 
cells were incubated with fresh growth medium and wells containing only growth 
medium were used as blanks. After 24 h of incubation with medium containing the 
polymeric sample, cells were incubated with WST-1 reagent diluted 1:10 (as indicated 
by the manufacturer) for 4 h at 37°C, 5% CO2. Plates were then analyzed with a Biorad 
Microplate Reader. 
 
2.4 Results and Discussions 
Amphiphilic copolymers  
2.4.1 Synthesis and Characterization of the Block Copolymer PCL-b-p(MAGG) 
The new copolymer PCL-b-p(MAGG) based on hydrophilic p(MAGG) and hydrophobic 
PCL segments was successfully prepared via the combination of ring opening 
polymerization (ROP) and xanthate-mediated reversible addition-fragmentation chain 
transfer (RAFT) polymerization. The synthesis of the desired copolymer needs the 
preliminary preparation of the monomer MAGG and of the macro chain transfer agent 
xanthate-terminated PCL (PCL-X). 
 
2.4.1.1 Preparation and characterization of MAGG 
 
Methacryloylglyicylglycine is an N-methacrylamide obtained by amidation reaction 
between methacryloyl chloride and glycilglycine, according to Scheme 1 [Drobník 
1976].  




Scheme 1: Synthesis of the monomer MAGG. 
The reaction was performed in a basic aqueous media with NaOH and the product was 
obtained pure after recrystallization from a solution of ethanol and water (50/50 v/v) 
with yield of 50 %. The formation of the product was confirmed by spectroscopic 













Figure 1: Spectroscopic characterizations of MAGG: 
1
H- NMR spectrum (a), FT-IR 
spectrum (b). 
2.4.1.2 Preparation and characterization of  xanthate-terminated PCL 
The synthesis of xanthate-terminated PCL was performed according to Scheme 2.  
In the first step (Scheme 2a), hydroxyl-terminated PCL was synthesised by ring-opening 
polymerization (ROP) of ε-caprolactone by using enzymatic catalyst.  
Enzymatic catalysts represent an attractive alternative to conventional catalyst in 
polymerization processes because of their high stereo-, regio-, and chemoselectivities, 
their ability to operate under mild conditions, recyclability, and biocompatibility. Among 
the different types of enzyme, lipases represent a suitable catalyst system for the ring-
opening polymerization of lactones combining reasonable control of the molecular 
weight and chain end functionality [Hans 2006; Lars van der 2006; Kobayashi 2001]. 
The reaction was conducted in bulk at 50 °C for 48 h using benzyl alcohol as initiator 
and Lipase B from Candida antarctica, immobilized on macroporous acrylic resins 









Scheme 2: Synthesis of xanthated-terminated PCL. 
The polymer was obtained with good yield (60%). The 
1
H-NMR spectra of the polymer 
was consistent with its expected structural feature (Figure 2). In the spectra, in fact, the 
characteristic peaks correspond to PCL were observed together with the benzyl protons 
peak at around 5.2 ppm. 
1
H NMR end group analysis was also used for the calculation of the number average 
molecular weights (Mn). By comparing the ratio of the average peak intensity of 
backbone methylene peak at ~ 4.1 ppm to that of the benzyl protons of the polymer 
chain-end at ~ 5.2 ppm the Mn (NMR) of PCL-OH was estimated to be 12000 Da. The 
result was in agreement with the value of Mn obtained by GPC analysis [Mn (GPC) 
=12726 Da and polydispersity index (PDI) = 1.44]. 







H-NMR spectrum of PCL-OH 
 
The PCL-OH polymer was further reacted with 2-bromopropionyl bromide in the 
presence of triethylamine to prepare 2-bromopropionyl terminated PCL (PCL-Br), 
(Scheme 2b).  
The successful incorporation of the 2-bromopropyionyl group on PLC was confirmed 
from the appearance in the 
1
H-NMR spectrum of the resulted polymer of methine “f” and 
methyl “g” protons of the 2-bromopropionyl end group at around 4.2 and 1.8 ppm, 
respectively (Figure 3). The partial overlapping of these peaks with the signal of PCL 
backbone not allows the determination of –OH end-group conversion (%) into its 
corresponding 2-bromopropionyl end-group. 
The observed Mn (NMR) of this polymer calculated by dividing average peak area of 
methylene protons “e”, “b” and “d” of the PCL backbone chain by the peak area of “a” 
was  11870 g mol
-1
. The corresponding observed Mn and PDI by GPC analysis were 
12806 Da and 1.45, respectively. 
GPC analysis showed the presence of a monomodal system and the value of Mn was 
perfectly in agreement with the result obtained for the PCL-OH thus suggesting that the 
adopted experimental conditions did not induce polymer degradation. 
 
 







H-NMR spectrum of PCL-Br 
 
PCL-Br polymer was then reacted with potassium-O-ethyl xanthate to convert the bromo 
end-group into their corresponding xanthate (PCL-X) by nucleophilic substitution 
reaction (Scheme 2c). Figure 4 shows the typical 
1
H-NMR spectrum of the resultant 
PCL-X polymer obtained. The conversion of bromo end-group was confirmed by the 
appearance of the new characteristic peak attributed to the methylene proton “h” of the 
xanthate end group at 4.6 ppm. The calculated conversion of Br-end group into its 
corresponding xanthate end-group determined by calculating the ratio of the peak area of 
methine protons “f” of the proprionyl group to that of the methylene protons “h” of the 
xanthate end-group  was  found to be 90 %.. This result confirmed the quantitative 
conversion of –Br end-group into the corresponding xanthate end-group. 
The observed Mn (NMR) of this polymer calculated by dividing the peak area of  “e”, 
“b” and “d” of the PCL backbone chain by the peak area of “a” was 12600 Da. Unimodal 
GPC cromatograph was observed with Mn (GPC) =13114 Da and PDI 1.39. The result 
suggested that no polymer degradation was occurred during functionalization reaction. 
 
 






H-NMR spectrum of PCL-X 
 
2.4.1.3 Preparation and characterization of Amphiphilic PCL and p(MAGG) 
Block Copolymer 
 
The desired block copolymer was obtained by RAFT polymerization.  RAFT 
polymerization has emerged as one of the most important methods for living radical 
polymerization providing easy access to a large variety of complex polymer architectures 
such as block co-polymers and star polymers with excellent control over molecular mass, 
a narrow molecular mass distribution and appropriate functionality for conjugation to 
and targeted delivery of diagnostic and therapeutic agents. It can be performed by simply 
adding a chosen quantity of an appropriate RAFT agent, a reversible chain transfers 
reagent, to a conventional free-radical polymerization [Smith A.E. 2010]. 
The PCL-X was used as macro-chain transfer agent for the xanthate mediated RAFT 
polymerization of MAGG in DMSO using PCL-X/AIBN = 1/0,2 (mol/mol) and  PCL-









Scheme 3: RAFT polymerization of MAGG with the macro-chain transfer PCL-X 
 
The purification of copolymer was carried out by two in sequence precipitations of the 
crude product from concentrated solutions of DMSO in ethyl acetate and in water 
respectively and by membrane dialysis against 1000 mL of water in a 10 mL cellulose 
ester membrane at room temperature. The second step of purification significantly 
decreased the yield in the final isolated polymeric materials, but the purification of 
polymeric materials from residual low molecular weight matrix appeared of paramount 
importance in view of biomedical applications. 
The formation of the copolymer PCL-b-p(MAGG) was confirmed by 
1
H-NMR, FT-IR 
and TGA analyses. 
1
HNMR spectrum showed  in addition to the  characteristic peaks of the PCL block,, the 
presence of the methane proton “i” at 0.8-1.2 , the amide  protons “l”, “n” at 8.0-8.2 and 
the methylene protons “m” and “o” of the p(MAGG) units (Figure 5). Moreover the 1H-
NMR spectrum showed the total elimination of monomer double bond indications. The 
molar fraction of p(MAGG) in the copolymer was calculated by comparing the ratio of 
the average peak intensity of the methylene protons at 1.4 ppm of the PCL chain and the 
methylene protons of p(MAGG) at 3.8 ppm and resulted of about 0,12. The result 
indicated that the copolymer was composed by a longer hydrophobic PCL block 
compared to the hydrophilic pMAGG block.  
The Mn (NMR) of the block copolymer  was calculated by comparing the peak are of the 
pMAGG proton “m” with the peak are of the PCL block proton ‘d’ and considering the 
repetitions of the block PCL-X obtained by the analysis of 
1
HNMR of PCL-X macro-
chain transfer. The Mn of the block copolymer resulted of 17159 Da. 
Given the poor solubility of the block copolymer, the determination of its molecular 
weight by GPC analysis was not possible. 
 







H-NMR spectrum of PCL-b-p(MAGG) 
 
The recorded FT IR spectra of the copolymer (Figure 6 ) presented the characteristic 
peaks at 1650 cm
-1
 assigned to the C=O stretching vibration of amide I and at 1470 cm
-1
 
related to N-H bending vibration of amide II that indicate the presence of the p(MAGG) 
block. The comparison of the FT IR spectrum with that of a p(MAGG)100 homopolymer 
supplied by Polymer Laboratories Ltd. (UK) provided further evidence to the presence of 
the p(MAGG) block within the structure of the synthesized copolymer. The peaks found 
at 1727 cm
-1
 and at 1470 cm
-1 
 were attributed respectively to the stretching and bending 
vibrations of the C=O group of the PCL block. 
 
 
Figure 6: FT-IR spectra of PCL-b-p(MAGG), PCL-X and p(MAGG) 
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2.4.1.4 Thermal characterization of PCL-b-p(MAGG) copolymer 
The thermal stability of the synthesized copolymer in the 25-700 °C temperature range 
was investigated by thermal-gravimetric analysis under non-oxidative conditions 
(nitrogen blanket) (Figure 7). TGA analysis evidenced that the copolymer was thermally 
stable up to 200 °C. Above this temperature the copolymer underwent extensive 
degradation (98-99% weight loss) by means of two decomposition steps. The 




Figure 7: TGA traces of PCL-b-p(MAGG), PCL-X and p(MAGG)100 
 
2.4.1.5 Preparation and characterization of PCL-b-p(MAGG) micelles 
Amphiphatic block copolymers such as PCL-b-p(MAGG) would display self-assembly 
behaviour in aqueous media leading to micellar systems. The formation of micelles was 
investigated by fluorescence spectroscopy by using pyrene as probe since the intensities 
of the various vibrational bands of pyrene showed a strong dependence on solvent 
environment. 
Figure 8 shows the plot of the ratio of intensities of the excitation spectra of pyrene at 
355 nm vs the log of the block copolymer concentration (mg/mL) in water. A major 
change in the slope indicated the onset of micellization. The CMC value was taken from 
the interception point of two straight lines and resulted to be 0,038 mg/ml. 




Figure 8: Semilogarithmic plot of the fluorescence excitation intensity of pyrene (6 x 10-
7 M) vs the concentration of PCL-b-p(MAGG) block copolymer in water. 
When an amphiphilic block copolymer is dissolved in an aqueous media, micelles are 
formed in a wide range of size from ten to hundred nanometer. As a general rule, 
amphiphilic copolymers containing PCL blocks longer than the nearby hydrophilic 
blocks were reported to form larger micelle particles [Xintao S. 2004]. The size of the 
micelles formed by PCL-b-p(MAGG) in aqueous solution was determined by dynamic 
light scattering by fixing the copolymer concentration at 0,2 mg/ml. The recorded size 
distribution reported in Figure 9 evidenced that micelles dispersions were constituted by 
monodispersed nanosystems having an average diameter of 124 ± 20 nm.  
 
 
Figure 9: Diameter distribution of PCL-b-p(MAGG) micelles 
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2.4.1.6 In Vitro Biological Evaluation of the new copolymer 
The evaluation of polymer biocompatibility represents a fundamental step for ensuring 
the safety of using the investigated material in biomedical applications. The 
biocompatibility of PCL-b-p(MAGG) in the form of micelles was quantitatively assessed 
by using a cell proliferation assay (WST-1 assay). The assay is based on the cleavage of 
the tetrazolium salt WST-1 to formazan by cellular mitochondrial dehydrogenases. This 
process is largely dependent on the glycolitic production of NAD(P)H in viable cells, 
therefore the amount of formazan dye formed directly correlates to the number of 
metabolically active cells in the culture. In vitro experiments were carried out on balb 
3T3 mouse embryo fibroblasts clone A31 cell line, by following the procedures of ISO 
10993 – Part 5: “Test for cytotoxicity – in vitro methods”. Cytotoxicity, defined as the 
“in vitro evaluation of toxicological risks using cell culture”, is a rapid, standardized, 
sensitive and inexpensive way to assess the in vitro biocompatibility of materials to be 
used in biomedical applications [Chiellini F. 2006].  
The PCL-b-p(MAGG) copolymer was dispersed in micellar form in Dulbecco's 
Modified Eagles Medium at three different concentrations above its CMC (50μg/ml, 75 
μg/ml and 100 μg/ml). Cells were incubated for 24 h in a 96-well tissue culture plate 
containing each the polymeric dispersion and then incubated with the WST-1 reagent for 
4 h. The obtained results, reported in Figure 10 evidenced a high level of 
cytocompatibility for the investigated micelles displaying values comparable with those 




Figure 10: WST-1 cell viability assay. 
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2.4.2 Preparation and characterization of the copolymer 
Poly[(polycaprolactonyl)methacrylate-co-glycylglycinemethacrylamide] PCL-
co-p(MAGG) 
2.4.2.1 Preparation and characterization of PCL macromonomer 
The preparation of the copolymer containing both PCL and p(MAGG) as pendant chains 
was carried out by radical polymerization of methacryloyl(glycylglycine) with a PCL 
based macromonomer containing a methacryloyl group in terminal position. The 
macromonomer PCL-HEMA, was synthesized by Ring Opening Polymerization (ROP) 
of ε-caprolactone onto 2-hydroxyethyl methacrylate (HEMA) used as initiator according 




Scheme 4: Synthesis of the Poly (ε-caprolactone)-graft-poly (Methacryloylglycylglycine) 
copolymer by combined ROP and free radical polymerization methods: a) Synthesis of 
PCL-HEMA by ROP, b)Copolymerization of PCL-HEMA and p(MAGG). 
 
The course of the polymerization was followed by FT-IR analysis by monitoring the 
disappearance of the peaks at 890 cm
-1
 and 693 cm
-1
 characteristics of the monomer. The 
successful preparation of the PCL-HEMA macromonomer was confirmed by FT IR and 
1
HNMR analysis. The FT IR spectrum of the product revealed the presence of prominent 
peaks at 1725 cm
-1
 and 1190 cm
-1 
ascribed respectively to the carbonyl stretching 
vibration and C-O stretching vibration of the ester group of PCL. The absence of the 
peaks at 890 cm
-1
 and 693 cm
-1
 revealed the complete removal of unreacted monomer 
from the product (Figure 11).  
 





Figure 11: FT-IR spectrum of PCL-HEMA 
 
1
H-NMR analysis strongly supported the successful preparation of the PCL-HEMA 
macromonomer and provided important data for the calculation of its number average 
molecular weight (Mn). The presence of HEMA in the macromonomer was evidenced 
by the peaks found at 5.6 and 6.2 ppm ascribed to the alkenyl protons of methacrylate. 
The covalent linkage between the HEMA initiator and PCL chain was confirmed by the 
peak found at 4.4 ppm typical of methylenic protons close to carboxyl ester groups 
(Figure 12). The peaks found in the spectrum at 4.2 ppm, 2.4 ppm and 1.7-1.3 ppm were 
relevant to the protons of the PCL chain. The Mn of PCL-HEMA was estimated by 
calculating the mean value of the degree of polymerization (DP) of the macromonomer 
from the relevant 
1
HNMR spectrum. DP was obtained by dividing the area of the peak of 
CH2 of the PCL chain at 4.2 ppm to that of the alkenyl protons of the initiator found at 
5.6 ppm. The product between the obtained DP and the molecular weight of the 
repeating unit of the PCL chain provided a fair estimation of the actual Mn value of the 
macromonomer that resulted to be about 2700 Da.  
 







H-NMR spectrum of PCL-HEMA 
 
2.4.2.2    Preparation and characterization of 
Poly[(polycaprolactonyl)methacrylate-co-glycylglycinemethacrylamide] PCL-
co-p(MAGG) 
The copolymer PCL-co-p(MAGG) was prepared through free radical polymerization of 
MAGG with PCL-HEMA in DMSO by using 2,2’azo-isobutyronitrile (AIBN) as 
initiator (Scheme 4b). The product was extensively purified by precipitating it 
sequentially in water and in chloroform to remove respectively the p(MAGG) 
homopolymer and the unreacted PCL-HEMA. Two different PCL-co-p(MAGG) 
copolymers were prepared having MAGG/PCL-HEMA molar ratio respectively 80/20 
and 70/30. Notwithstanding the chemical composition of the prepared materials the PCL-
co-p(MAGG) copolymers were partially soluble in most organic solvent and unsoluble 
in DMSO.  
The copolymer PCL-co -p(MAGG) was characterized spectroscopically by 
1
H-NMR and 
FT-IR analysis and thermally by TGA analysis.  
1
HNMR spectrum showed the characteristics peaks of both the PCL and the p(MAGG) 
blocks. The peaks found at 4.2 ppm and 2.4 ppm were ascribed respectively to the 
methylene protons “c”, “h” and “d” of PCL (Figure 13). The peaks found at 8.0-8.2 ppm 
and 3.8 ppm revealed the presence of the p(MAGG) comonomer since they were 
assigned respectively to the amide protons “o” and “p “and the methylene protons “m” 
and “n” of the polyamide (Figure 13).  
 






H-NMR spectrum of PCL-g-p(MAGG) copolymer 
 
The FT IR spectrum of the product (Figure 14) displayed the characteristic peaks of the 
p(MAGG) block at 1650 cm
-1
 assigned to the C=O stretching vibration of amide I and at 
1470 cm
-1
 relevant to N-H bending vibration of amide II and the characteristic 
absorption peaks of PCL such as the stretching and bending vibrations of the C=O group 
respectively at 1727 cm
-1






Figure 14: Overlay of the FT-IR spectra of PCL-HEMA (black line), PCL-co-p(MAGG) 
(red line), p(MAGG)100 (blu line) 
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2.4.2.3 Thermal characterization of PCL-co-p(MAGG) copolymer 
The thermal stability of the graft copolymer in the 25-700 °C temperature range was 
investigated by TGA analysis (Figure 15). The thermal degradation profile of PCL-co-
p(MAGG) copolymer  was similar to that displayed by the block copolymer PCL-b-
pMAGG showing a thermal stability up to 200 °C. Above this temperature the 
copolymer underwent extensive degradation (90% weight loss) in two decomposition 
steps. The first derivative of the thermogravimetric curve of the PCL-co-p(MAGG) 
copolymer showed the peak of degradation of the pMAGG comonomer while the peak 




Figure 15: TGA traces of PCL-g-p(MAGG), PCL-HEMA and p(MAGG)100 
 
2.5 Conclusions 
This work has been devoted to the investigation and preparation of novel biodegradable 
and biocompatible amphiphilic copolymers based on PCL and p(MAGG) , the block 
copolymer-PCL-b-p(MAGG) and the random copolymer PCL-co-p(MAGG), using two 
different synthetic routes.  
Giulia Ciampi PhD Thesis 
109 
 
The amphiphilic block copolymer PCL-b-p(MAGG) was prepared by Reversible 
Addition-Fragmentation Transfer (RAFT) polymerization of MAGG onto a 
polycaprolactone based xantate initiator. The successful preparation of the copolymer 
was confirmed by 
1
H-NMR, FT-IR and TGA analyses. As expected PCL-b-p(MAGG) 
self-assembled into micelles in water and the CMC of the copolymer was determined. In 
vitro citotoxicity tests performed on copolymer micelles showed an excellent 
compatibility, thus highlighting their potential in biomedical applications. 
The amphiphilic random copolymer PCL-co-p(MAGG) was synthesized by free radical 
polymerization of MAGG with a PCL containing a methacryloyl group in the terminal 
position (PCL-HEMA). The copolymer PCL-g-p(MAGG) was characterized 
spectroscopically by 
1
H-NMR and FT-IR analysis and thermally by TGA analysis. The 
poor yield and solvent solubility of the random PCL-co-p(MAGG) copolymer prompted 
us to consider the block copolymer PCL-b-p(MAGG) as the best candidate for being 
employed in biomedical applications. Indeed it was obtained in good yields and 
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3 Chapter III : Chitosan and Poly( γ-glutamic acid) based 




Drugs can be delivered to and through the skin for the treatment of skin diseases and 
systemic diseases, respectively. These include various types of dosage forms and 
delivery systems such as powders, solutions, sprays, suspensions, emulsions, ointments, 
creams, pastes, gels, and patches. For dermatological applications, formulations are 
targeted to different layers of the skin to protect (e.g., sunscreens), enhance the 
appearance (e.g., cosmetics), or therapeutically treat (e.g., pharmaceuticals) skin 
pathologies [Paudel 2010]. 
Polymeric carriers have shown merits of controlled and sustained release via 
modification of polymer composition and reducing irritation associated with direct 
contact of drug to the skin. There is an increasing need for the development of new 
carrier system that could effectively improve skin penetration and reduce the undesirable 
effects associated with drugs. It is obvious that skin is a widely explored route, which 
can be reached directly for drug administration; however, it does not automatically mean 
that the drugs are getting to the right site of action.  
Nanosystems as polymeric nanoparticles can proficiently control the release of a 
therapeutic moiety to the affected region at the skin site with localized effect by creating 
skin reservoirs and their narrow size distribution may allow efficient site-specific 
targeting favouring greater drug retention. 
Various biocompatible and biodegradable polymers such as chitosan, poly α-esters 
[poly(L-lactide), poly(lactide-co-glycolide), polycaprolactone], polyalkylcyanoacrylates 
and polyamidoamines have been utilized in the formulation of NPs for topical or 
transdermal drug delivery [Venuganti 2009; Pawar 2010]. 
Chronic inflammatory skin diseases, such as psoriasis, require new strategies for the 
delivery of antipsoriatic drugs such as Methotrexate (MTX). Topically applied therapies 
are promising for the treatment of psoriasis because the drugs are delivered directly into 
skin strata thereby minimizing adverse side effects elsewhere within the body. MTX is 
an anti-neoplastic agent acting as folate antagonist and frequently prescribed for the 
treatment of severe psoriasis. The systemic use of this drug causes numerous side effects, 
the most important being the hepatic toxicity. Delivery of systemic therapies via the skin 
avoids degradation of the medication within the gastrointestinal tract and first-pass 
metabolism by the liver, both of which are associated with oral administration of drugs, 
in addition to evading the pain and safety issues associated with injections. 
Topical delivery of MTX would be beneficial to reduce its side effects, but a 
disappointing result has been reported which was mainly due to insufficient 
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percutaneous absorption of MTX [Radan 2004]. A major problem is that the drug is 
water soluble and it is mostly in its ionized form at physiological pH, so the capacity for 
passive diffusion is limited. 
Chitosan (CS) is a cationic polysaccharide with many interesting biopharmaceuticals 
properties and has been widely explored as a penetration enhancer in topical 
formulations [Senygit 2010]. CS is a linear cationic heteropolymer of D-glucosamine 
and N-acetyl-d-glucosamine linked by beta-(1–4) glycosidic bonds, obtained by the 
partial deacetylation of naturally derived chitin. It is hydrophilic and soluble in acidic 
water solution thanks to the protonation of the amine groups, and is degraded in vivo by 
enzymatic hydrolysis such as lysozymes, in vitro by cellulase, pectinase, lipase, amylase, 
papain and pectinase [Prashanth 2007]. CS based delivery systems have been described 
for nasal, ocular, oral, parenteral and transdermal drug delivery constructs. CS NPs have 
been used as carriers for growth factors such as epidermal growth factor and fibroblast 
growth factor, which could ultimately be embedded into engineered tissue construct 
[Nitta 2013]. Considering the cationic nature of chitosan and the fixed negative charges 
in the tight junction between epithelial cells and stratum corneum (SC), it has been 
observed that chitosan can enhance the penetration through the skin by decreasing the 
cell membrane potential, leading to reduced skin resistance and consequently enhanced 
permeation. Chitosan-encapsulated drug molecules have demonstrated sustained release 
profiles and enhanced safety profiles, while reducing skin irritation [He 2009]. 
Permeation enhancement effect of chitosan has been reported in the transdermal delivery 
of carvedilol [Sapra 2008]. In particular it has been reported to enhance skin penetration 
by altering the secondary structure of keratin promoting hydration of the SC and 
increasing cell membrane fluidity [Pawar 2010]. There are also many studies showing 
that chitosan accelerates wound healing in many clinical cases. It was reported that 
chitosan granules could enhance regeneration of normal skin in open wounds. It has been 
suggested that chitosan may be used to inhibit fibroplasias in wound healing and to 
promote tissue growth and differentiation in tissue culture [Kumar 2000]. 
Poly-γ-glutamic acid ( γ-PGA) is another promising natural polymer for the skin drug 
delivery.  γ-PGA is an anionic peptide produced as capsular substance or as slime by 
members of genus Bacillus. It is known that γ-PGA is water-soluble, biodegradable, 
nontoxic, and relatively nonimmunogenic. 
γ-PGA can be used as a value-added component to enhance the properties of existing or 
novel personal care products as a moisturizer, exfoliant and wrinkle-remover. The 
chemistry of γ-PGA allows it to be homogenously miscible as well as chemically stable 
in a matrix of ingredients typically used in facial creams [Ben-Zur 2007]. Additional 
qualities of γ-PGA include the ability to form a smooth, elastic, self-moisturizing and 
soft film on the skin. γ-PGA inhibits hyaluronidase that degrades hyaluronic acid (which 
is a component of skin connective tissue) and helps to maintain the elasticity of the skin 
[Bajaj 2011]. 
Various studies suggest us that CS and γ-PGA based polyelectrolite complexes (PEC) 
are promising for topical or transdermal drug delivery: Lee et al have developed a 
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nanoparticle system, composed of CS and γ-PGA, prepared by an ionic-gelation method 
for transdermal DNA delivery using a low-pressure gene gun [Lee 2008].  
Lin et al prepared γ-PGA-CS nanoparticles system using ionic-gelation method, 
founding that the nanoparticles with chitosan dominated on the surfaces could effectively 
reduce the transepithelial electrical resistance of Caco-2 cell monolayers and opened the 
tight junctions between Caco-2 cells and allowed transport of the nanoparticles via the 
paracellular pathways. Moreover, the nanoparticles were further used for transdermal 
gene delivery. As compared with chitosan/DNA, chitosan/poly-γ-glutamic acid/DNA 
improved their penetration depth into the mouse skin and enhanced gene expression [Lin 
2005; Lee 2008]. 
The present study was undertaken to prepare a nanoparticles formulation based on CS 




Chitosan (CS) (Mw 70 kDa, 75-85% deacetylaton degree), Methotrexate hydrate (MTX), 
were purchased from Sigma-Aldrich. Poly-γ-glutamic acid (γ-PGA) (Mw 100 kDa) was 
purchased by Natto Bioscience (Osaka, Japan). 
Phosphate Buffer Saline solution (PBS 10X) was prepared by dissolving 2.0 g of KCl, 
2.0 g of KH2PO4•H2O, 80 g of NaCl, and 15.6 g of Na2HPO4•12H2O in 1 liter of distilled 
water. The pH was adjusted to 7.4 with 10 N NaOH. Phosphate Buffer solution (PB) was 
prepared by dissolving 2.0 g of KH2PO4•H2O 15.6 g of Na2HPO4•12H2O in 1 liter of 
distilled water. 
Dyalisis membranes [(Specta/Por, float-A-Lyzer, diameter 10 mm, Mw cut-off  3500 Da, 




Preparation of CS/γ-PGA/MTX nanoparticles 
 
MTX loaded NPs were prepared using a polyelectrolyte self assembly method under 
magnetic stirring at room temperature: an aqueous γ-PGA solution (0,55 mg/ml or 0,25 
mg/ml in deionized water) was added into an aqueous CS solution (1,6 mg /ml in 
deionized water acidificated with HCl, pH 4 ) (γ-PGA-CS) or vice versa (CS- γ-PGA), 
under magnetic stirring at room temperature.  
The reference parameters of the formulations are the weight ratio of the two polymers 
used : Wt ratio CS/γ-PGA: 3.6/1 and Wt ratio CS/γ-PGA: 8/1. 
The polymer ratio 3,6/1 include two formulations where 1 ml of γ-PGA (0,55 mg/ml) 
was added to 1 ml of CS (1,6 mg/ml) or vice versa. 
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The weight  ratio  8/1 indicate that 1 ml of γ-PGA (0,25 mg/ml) was added to 1 ml of CS 
(1,6 mg/ml) or vice versa. 300 µl of MTX (1 mg/ml, pH 8) was alternately added to the 
γ-PGA solution or into the CS solution [(γ-PGA-MTX)-CS or γ-PGA-(CS-MTX)]. 
  
Purification of Nanoparticles 
 
The NPs suspensions were purified by using an ALC PK121R refrigerated centrifuge. 
NPs were centrifugated at 13000 RPM  for 20 min at 4˚C.  
 
Dimensional and Z-potential analyses 
 
Dimensional analyses of NPs were carried out using a Beckman Coulter LS230 Laser 
Diffraction Particle Size Analyzer, equipped with small volume module plus. 
Zeta potential analyses of NPs were performed on Delsa™ Nano C (Beckam Coulter) 
instrument at 25°C. The analyses weer performed directly on the n<Ps suspension 
obtained from the preparation procedure. All the water suspensions are at pH 3.6.  
 
Morphological analyses 
NPs morphology was evaluated by scanning electron microscopy (SEM) (JEOL 
LSM5600LV) and atomic force microscopy (AFM) (Multimode controller Nanoscope 
IV (Veeco Instr.)). 
The samples were prepared from purified and lyophilised NPs. Gold sputtering was 




After freezing at -20°C, nanoparticles were lyophilised in FreeZone 2,5 (LABCONCO) 
lyophilisator, equipped with Welch 8912(USA) vacuum pump. 
 
Encapsulation efficiency and drug loading 
 
The loading content and the encapsulation efficacy of NPs were determined by assaying 
the amounts of free MTX in the supernatants of centrifuged NPs samples. The 
supernatant of not loaded NPs was used for baseline correction. The MTX content was 
estimated using a calibration curve of standard concentrations of MTX in deionized 
water pH 4.1 (range 0,49-28,57 µg/ml; R
2
=1) by UV spectrophotometry. Only CS/ γ-
PGA: 3.6/1 NPs formulations underwent the L% and E% evaluations.  
Loading content (L%) and encapsulation efficacy (EE%) were calculated as follows: 
 
 




L % =  
 
EE % =  
 
 
In vitro MTX release kinetics from CS/γ-PGA/MTX nanoparticles 
 
The in vitro release of MTX from nanoparticles was studied using the dialysis method 
under two experimental conditions. Cellulose ester membrane with molecular weight cut 
off of 3,5-5 kDa were used in both cases. The release was performed in either PBS 0,001 
M pH 7.4 or PB 0,003 M pH 7.4, both at 37°C. At fixed time intervals, the release 
medium was collected and replaced with equal volume of fresh solution. Samples were 
analysed for MTX content by UV absorbance at 303 nm using a calibration curve of 
MTX in PB 0,001 M pH 7.4 (range 0,46-26,66 µg/ml; R
2
=1) .  
The cumulative release percentage (CR%) of MTX at each time point was determined 
using the following equation:  
CR% = (Mt/Mi) x 100  
where Mi and Mt are the initial amount of drug encapsulated in the NPs and the 
amount of drug released at the time t, respectively. 
 
3.4 Results and Discussion 
 
Topical or transdermal drug delivery is challenging because the skin acts as a natural and 
protective barrier. Several methods have been examined to increase the permeation of 
therapeutic molecules into and through the skin. One approach is to use the 
nanoparticulate delivery system. Starting with liposomes and other vesicular systems, 
several other types of nanosized drug carriers have been developed such as solid lipid 
nanoparticles, nanostructured lipid carriers, polymer-based nanoparticles and magnetic 
nanoparticles for dermatological applications. In the present research activity, MTX 
loaded NPs were prepared using a polyelectrolyte self-assembly method based on the 
ion-ion interaction process between the carboxylic groups of linear γ-PGA chains and the 
amino groups of CS linear chains. The preparation of PEC nanoparticles is quite simple 
and can be easily performed under mild conditions without the use of organic precursors, 
catalysts, or reactive agents, alleviating the concern about toxicity or reactions with a 
therapeutic payload [Dash 2011]. Mixing oppositely charged polyelectrolytes in solution 
determine their self assembly or spontaneous association due to the formation of strong, 
but reversible electrostatic links. These direct interactions between the polymeric chains 
lead to the formation of polyelectrolyte complex networks with non-permanent structures 
Total amount of MTX – amount of free MTX 
Dry weight of NPs 
Loaded MTX 
Total MTX employed in the formulation process 
100 
100 
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while avoiding the use of covalent cross-linkers. In general, these polymeric networks 
are well tolerated, biocompatible and are more sensitive to changes in environmental 
conditions. The formation and stability of these polyelectrolyte complexes depend on 
many factors such as the degree of ionization of each of the oppositely charged 
polyelectrolytes, the density of the charges on the polyelectrolytes, the charge 
distribution over the polymeric chains, the concentration of the polyelectrolytes, their 
mixing ratio, the mixing order, the duration of the interaction, the nature of the ionic 
groups, the position of the ionic groups on the polymeric chains, the molecular weight of 
the polyelectrolytes, the polymer chain flexibility as well as the temperature, ionic 
strength and pH of the reaction medium. When polyelectrolytes are mixed in such a ratio 
that there is an excess of one charge (either positive or negative), a non-stoichiometric 
complex is formed that are usually soluble. On the other hand, a stoichiometric 
polyelectrolyte complex contains equal amounts of each opposite charge with a zero net 
charge in the resultant complex. Stoichiometric polyelectrolyte complexes are usually 
insoluble and precipitate out of solution upon formation [Hartig 2007]. 
The selection of CS and γ-PGA as NPs components was based on their good 




Different reaction conditions such as the weight ratio of CS and γ-PGA, the order of 
addition of the two polymer and the presence of MTX into the γ-PGA aqueous phase (γ-
PGA-MTX)-CS or into the CS phase γ-PGA-(CS-MTX) were investigated. When CS 
solution, with or without MTX, was dropped into the γ-PGA solution a precipitation was 
observed, without particle formation. NPs were obtained only when γ-PGA was added 
dropwise to CS solution (Table1).  
 
 
Wt ratio CS/ γ-PGA: 3.6/1 Wt ratio CS/ γ-PGA: 8/1 
Dimension 
(nm±SD) 





γ-PGA-(CS-MTX) 143 ± 31 +55,6 ± 0,70 8,6 ± 0,6 34,2± 0,8 147 ± 20 +53,6 ± 0.5 
(γ-PGA-MTX)-CS 153 ± 27 +51,9± 0,9 4,3± 0,9 21,2± 1,2 82 ± 23 +54,7± 0,8 
 
Table 1: Characterizations of MTX loaded NPs, obtained by the addition of -PGA 
solutions to CS solutions. 
 
Figure 2 shows the macroscopic appearance of γ-PGA-(CS-MTX) with the two different 
weight ratio. 
 





Figure 2 : γ-PGA-(CS-MTX) NPs suspensions. 
 
All the NPs formulations showed positive zeta potential, as expected (Table 1).  
First of all, the NPs were prepared in presence of CS excess and the  preparation 
procedure consisting in the addition of γ-PGA to CS water solution facilitates the 
formation of PECs with CS on the external part of the particles. Additionally, the γ-PGA 
contribution to the measured Z-Pot values is null because its carboxyl moieties are in the 
form of COOH at the pH of the analysis. Conversely, the CS is completely protonated 
and the highly positive Z-Pot values can be totally attributed to the NH3
+
 moieties of the 
polycation. 
DLS analyses showed no difference about NPs size distributions among the different 
formulations and they were all in the range of 140-150 nm except for (γ-PGA-MTX)-CS 
formulation with Wt ratio CS/ γ-PGA: 8/1 that showed NPs with 82 nm of diameter 
(Figure 2 ).  
 





Figure 2: DLS images of MTX loaded NPs size distribution. 
Surface charge and NPs dimension are two important parameters for topical and 
transdermal drug delivery. A positively charged delivery system would strongly interact 
with cells and has shown better permeability of the drug and prolonged pharmacological 
activity [Martin 1999]. The electronic interaction with the tight junction in SC might be 
responsible for the penetration enhancement of biochemical compounds, as a consequent 
the charged properties of these biomaterials are of great significance to the transdermal 
enhancing activity [Taveira 2009].  
Concerning the morphology of the prepared colloidal NPs, SEM images (Figure 3) 
confirms the presence of spherical NPs and AFM micrographs (Figure 4) provide visual 
evidence that prepared nanoPEC include a prominent  NPs population with dimensions 
less than 50 nm. This data is different from that obtained by DLS analysis where 
particles showed a diameter dimension around 100 nm. As a matter of fact, the DLS 
instrument LS230 (Coulter Beckman) has 40 nm as lower diameter cut-off, thus being 
unable to detect nanostructure in that nm scale. Although displaying an heterogeneous 
NPs populations, the AFM results are encorauging because only those agents with size  
around 50 nm are considered effectively able to diffuse through lipidic or aqueous 
channels, accumulating in the SC and in skin appendages (sebaceous glands and hair 
follicles) [Pawar 2010]. 
 




Figure 3 : SEM images of γ-PGA-(CS-MTX) NPs wt ratio 3.6/1  
 
  
 Figure 4 : AFM micrographs of γ-PGA-(CS-MTX) NPs wt ratio 3.6/1 
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Because of the poor yield and the poor lactescence of wt ratio CS/ γ-PGA: 8/1 
formulations, MTX loaded formulations with wt ratio CS/ γ-PGA: 3.6/1 were selected 
for drug loading characterization (Table 1). The best formulation in terms of MTX 
content, L % and EE% was obtained when γ-PGA was dropped into CS solution in the 
presence of MTX, probably due to a first interaction between the MTX and CS, before 
being constricted into the NPs.  
This formulation was then used for the in vitro drug release study of MTX. 
The release profile of the prepared NPs was first determined in PBS 1mM pH 7.4 
medium at 37˚C to reproduce the physiological conditions. The result of the release 




Figure 5: In vitro MTX kinetic release in PBS at 37 °C. 
 
The release of MTX from NPs in PBS showed a progressive and homogeneous release, 
leading to 10 % of cumulative drug release after 5 hours, 33 % at 20 hours, followed by 
the formation of a precipitated in the dialysis tube. The observed precipitate could have 
been promoted by the presence of KCl in the medium, which can be responsible of 
structural changes, affecting theswelling behaviour of the PEC and the ionic interactions 
of CS and γ-PGA [Nagpal 2010]. 
Therefore the drug release was further investigated in PB medium 3 mM (Figure 6). The 
cumulative release profile of MTX from NPs in PB displays the diffusion of about 12% 
of the loaded drug in the first 4h, followed by a sigmoid shape presenting the progressive 
release of MTX up to 18 % after 50 h, 88 % 265 h followed by the slow (almost plateau) 
release of the remaining cargo, which results almost complete at 350 h from the 
beginning of the study. 
 





Figure 6: In vitro MTX kinetic release in PB at 37 °C. 
 
The stability of the MTX released by the NPs system was monitored by the analysis of 
its UV spectrum. No changes of its spectrum were observed, suggesting that degradation 
of the drug did not occur. 
In vitro release of MTX from PLGA microparticles also followed biphasic pattern and 
was faster, the total release was obtained after only 12 hours. [Patel 2010]; same results 
have been observed in PLA, PLA-PEG NPs [De Faria 2005]. The release was slower 
compared to [Nogueira 2013], from MTX loaded CS NPs. The slower release of MTX 
from γ-PGA-(CS-MTX) formulation is probably due to a strong interaction between the 
drug and the PEC, based on hydrophobic, ionic and hydrogen bound interactions 




A formulation method for the preparation of polymeric NPs based on CS and γ-PGA 
loaded with MTX was developed and characterized. NPs showed positive Z-Pot values 
and formulations were constituted mainly by NPs with dimensions less than 50 nm. The 
sustained release of MTX from NPs was completed in 350 h (15 days). From in vitro 
release profile it can be concluded that [γ-PGA-(CS-MTX)] NPs is a good formulation 
for MTX delivery, thanks to the small dimensions and the sustained drug release profile. 
The future developments of the developed nanoPEC would comprise the insertion of the 
particles into a gel vehicle for topical skin administration. Moreover, surface 
modifications of biocompatible NPs may target the drug to the precise sites and assist 
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4 Injectable and Biodegradable Thermogels Based on 
Hyaluronic Acid and Chitosan Loaded with Poly[(R)-3-
hydroxybutyrate-co-(R)-3-hydroxyhexanoate] 
Polymeric Nanoparticles for the Sustained and 




Injectable in situ setting hydrogels have tremendous potential as carrier matrices for a 
wide range of biomedical and pharmaceutical applications such as drug delivery and 
tissue engineering [Moon 2012]. Current approaches in regenerative medicine are 
directed towards using less invasive surgical technique with the objective of  reducing 
tissue morbidity and duration of hospitalization. In situ forming hydrogels that can be 
applied using arthroscopic technique largely contribute to this development. Biopolymer 
systems with in situ gel-forming capability have recently been of increasing importance 
in the development of therapeutic implants and drug delivery systems. 
The purpose of this study was to develop and characterize formulations of nanoparticles 
based on poly[(R)-3-hydroxybutyrate-co-[R]-3-hydroxyhexanoate] (PHBHHx) 
containing dexamethasone (DEXA) to load in an injectable thermogel based on 
hyaluronic acid and chitosan.  
PHBHHx is a newly developed member of the polyhydroxylkanoates (PHAs) family, 
with improved physical and chemical properties compared with other PHAs as 
polyhydroxybutyrate (PHB) and poly(hydroxybutyrate-co-hydroxyvalerate (PHBHV). It 




DEXA is a poor-water soluble synthetic corticosteroid which is used  clinically as an 
anti-inflammatory and immunosuppressive agent. Its use is often restricted by the 
induction of some side effects (hypertension, peptic ulcers, hyperglycemia and 
hydroelectrolytic disorders) mainly when administered by systemic route. 
Steroids have a well-described role in skeletogenesis, and both prostaglandins and 
steroids have been shown to influence chondrogenic differentiation. In particular, the 
synthetic glucocorticoid DEXA, in addition to its anti-inflammatory actions, can activate 
mesenchymal tissue differentiation to chondrocytes in a dose and time-dependent 
manner
 
[Derfoul 2006; Park 2008]. DEXA is widely considered as a reliable factor for 
osteogenic differentiation for human bone marrow mesenchymal stem cells(hBMSCs). It 
has been demonstrated to promote the differentiation of chondrocytes while maintaining 
the integrity of the cartilaginous matrix in isolated primary cell populations as well as in 
mesenchymal stem cells
 
[Martins 2010]. Embryonic chondrocytes cultured with 
Giulia Ciampi PhD Thesis 
125 
 
dexamethasone showed delayed expression of collagen type X [Takano 1985], which is 
associated with osteogenesis during endochondral bone formation
 
[Young 1993; Quarto 
1992]. In the pluripotent mesoblastic murine C1 cell line, dexamethasone played a role 
in upregulation of Sox9, a key chondrogenic transcription factor that interacts with the 
collagen type II promoter
 
[Schulze-Tanzil 2002; Lefebvre 2002]. In human articular 
chondrocytes, concurrent administration of dexamethasone and TGF-b1 reduced cell 
proliferation and induced re-expression of a chondrocytic phenotype [Choi 2008].  
Chitosan has been widely used in biomedical applications due to its biocompatibility, 
non-toxicity, bioactivity, biodegradability, and ease of modification through hydroxyl 
and amine groups. Moreover, the structure of chitosan is very similar to 
glycosaminoglycans (GAGs) discovered in cartilage and meniscus so that it can mimic 
the in vivo environment for cultivating chondrocytes and meniscus cells
 
[Croisier 2013]. 
Hyaluronic acid (HA) is a natural polysaccharide consisting of alternate N-acetyl-D-
glucosamine and D-glucuronic acid linked by (1/3) and (1/4) glycoside bonds. HA is a 
key component of ECM in connective tissues and is particularly abundant in the synovial 
fluid with its high water adsorption and retention capability. This highly viscous and 
viscoelastic fluid is found in joint cavities, and serves as a lubricant and shock absorber 
for the protection of joints and bones. HA is known to influence chondrocytes by 






Figure 1: Chemical structure of PHBHHx 
 
 
Figure 2: Chemical structure of DEXA 
 




Poly[(R)-3-hydroxybutyrate-co-[R]-3-hydroxyhexanoate] (PHBHHx; Mw = 190,000 
Da) containing 14 mol% of R-3-hydroxyhexanoate (HHx) was kindly donated by 
Laboratory of Microbiology, Tsinghua University (Beijing, China). Dexamethasone 
(DEXA), poly(vinyl alcohol) (PVA; Mw =30,000-70,000 Da), chitosan (CS; low 
molecular weight) were purchased from Sigma (St.Louis, USA). Hyaluronic acid sodium 
salt (HA; Mw= 1000 Kda) and ammonium phosphate dibasic (AHP) were purchased 
from Aladdin Reagents (Shanghai). 
Poloxamer 188 (F68) and soybean lecithin containing 99 % phosphatidylcholine (PC) 
were purchased by from BASF SE Chemical Company, Germany. 
All chemical solvents were of analytical grade or better. 
 
4.3 Methods: 
Dimensional and Z-potential analyses 
The mean particle size, size distribution and zeta potential (ZP) of the NPs were 
characterized using dynamic light scattering (DLS) and electrophoretic light scattering 
(ELS) technology, respectively, with a Zetasizer Nano ZS90 instrument (Malvern 
Instruments Ltd., U.K.), using water as a dispersant at  25 °C. The particle size was 
displayed by intensity distribution, and the size distribution was evaluated by 




The morphology of nanoparticles was examinated by Transmission Electronic 
Microscopy (TEM). The samples were stained with 2% (w/v) phosphotungistic acid 
before being placed on copper grids with film for transmission electron microscopy (H-
600; Hitachi, Tokyo, Japan). 
The morphology of the hyaluronic and chitosan based injectable thermogel was 
examinated by Scanning Electron Microscopy (SEM). The sample was lyophilized and 
analysed at SEM (JSM-5900LV, JEOL Ltd. Japan) at an accelerating voltage of 5.0 kV. 
 
Preparation of nanoparticles by emulsification solvent-evaporation process 
 
PHBHHx based NPs were prepared by an emulsification solvent-evaporation process. 
Briefly, the PHBHHx polymer was dissolved in organic solvent to prepare the organic 
phase. The aqueous phase was prepared by dispersing the surfactant in 10 ml of 
deionized water and the resulting suspension was homogenized by sonication for 3 
seconds with 5 seconds of rest (10 times) at a power of 200 W in an ice bath. The 
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resulting mixed phase immediately turned milky with bluish opalescence as a result of 
the formation of nanoparticles. The organic solvents were removed under reduced 
pressure.  
DEXA loaded nanoparticles were prepared by dissolving the drug in methanol and 
adding the solution to the polymer organic phase. Blank nanoparticles were produced in 
the same conditions but without drug into polymer solution.  
 
Purification of nanoparticles 
  
Nanoparticles suspensions were purified at 14000 RPM for 30 minutes at 4 °C by using a 
Beckam Coulter Allegra™ X-22R Centrifuge. The obtained pellet of purified 
nanoparticles were freeze-dried for further analyses. 
 
Encapsulation efficiency and drug loading 
 
Free drug was determined in the supernatant following separation of nanoparticles from 
the aqueous medium by centrifugation of  NPs formulations. The amount of DEXA  
present in supernatant solution was obtained from the absorbance of the solution after 
subctracting the absorbance of blank nanoparticles. The drug content was determined by 
using a calibration curve of the drug in water (5,85 /66,7μg/ml ; r2 = 0,9999). 
The encapsulation efficiency (EE%) was calculated as the percentage of DEXA loaded 
into PHBHHx nanoparticles with respect to total amount of drug employed during the 
preparation process (Equation 1). Drug loading (L%) was calculated as percentage of 









Equation 2:  
 
L(%) =  
 
 
Drug in NPs 
Drug in NPs 
100 
100 
Drug employed in the formulation 
NPs dry weight 
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In vitro drug release study of NPs loaded with DEXA 
 
The in vitro release of DEXA from NPs was studied using the dialysis method. Dialysis 
bags with molecular weight cut off of 7 kDa were used to retain the NPs and allow the 
released DEXA to permeate into release medium (PBS 0,01M, pH 7.4). NPs suspension 
was added to dialysis bag and after tight bundling, the sample-loaded dialysis bag was 
soaked in PBS that was heated to 37 °C in advance, and to ensure sink condition. The 
system was placed on a horizontal shaker at 100 rpm and 37 °C. At fixed time intervals, 
the release medium was collected and replaced with equal volume of fresh PBS. Samples 
were analysed for DEXA content by UV absorbance at 242 nm using a calibration curve 
of DEXA in PBS 0,01 M pH 7.4 .  
 
Preparation of HA and CS solutions 
 
CS powder was dissolved in 0,5 % acetic acid solution until translucent (1,6 % w/v) and 
the solution was kept at 4°C until further use. 
HA solutions were prepared by mixing HA powder in deionized water; a 60 % AHP 
solution was prepared and kept at 4 °C until further use. 
 
Preparation and gelation time of thermogelling HA-AHP-CS suspension 
 
AHP solution was added to 1 ml of HA solution under magnetic stirrer. Successively 1 
ml of CS was added to HA-AHP solution at room temperature with vigorous stirring. 
The viscous suspension was kept at 37 °C. The gelation time of HA-AHP-CS suspension 
at 37 °C was determined by the test tube inverting method
 
[Chung 2002]. Briefly, the 
HA-AHP-CS suspension was added to a glass tube and heated in a water bath (37°C). At 
fixed time intervals, the tube was taken out and inverted. The sample that had not flowed 
for 30s in the inverted tube was considered to form an hydrogel, and the time point was 
recorded as the gelation time. 
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Preparation of HA-AHP-CS gel containing DEXA loaded PHBHHx nanoparticles 
 
DEXA loaded PHBHHx NPs were prepared as described before. 5 mg of DEXA loaded 
PHBHHx NPs have been resuspended in 50 μl of water after centrifugation and the 
suspension was added to chitosan solution and stirred gently. The NPs containing 
chitosan solution was then added to HA-AHP solution and stirred gently. The  resulting 
suspension was kept to 37 °C. 
 
In vitro drug release study of  HA-AHP-CS thermogel loaded with DEXA-NPs  
 
The in vitro release of DEXA from the thermogel was studied using the dialysis method. 
Dialysis bags with molecular weight cut off of 7 kDa were used to retain the NPs-HA-
AHP-CS gel and the release DEXA-loaded NPs, and allow the released DEXA to 
permeate into release medium (PBS 0,01M, pH 7.4). 2 ml of NPs-HA-AHP-CS were 
added to dialysis bag and after tight bundling, the sample-loaded dialysis bag was soaked 
in PBS that was heated to 37 °C in advance, and to ensure sink condition. The system 
was shaken in a horizontal shaker at 100 rpm and 37 °C. At fixed time intervals, the 
release medium was collected and replaced with equal volume of fresh PBS. Samples 
were analysed for DEXA content by UV absorbance at 242 nm using a calibration curve 
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- 0,5 % PVA 
326 ; 
0,147 
- 2,67 -   
GC5 80 
2ml DCM + 
1ml MeOH 
2 0,5 % PVA 
397 ; 
0,196 
-11,1 5,5  0,16  
GC6 40 
2ml DCM + 
1ml MeOH 
1 0,5 % PVA 
337 ; 
0,125 
-2,73 6,9  0,20  
GC7 40 

























2ml DCM + 
1ml MeOH 
- 2 % Pol188 
281 ; 
0,007 
-0,18 - -  
GC10 40 
2ml DCM + 
1ml MeOH 
2 2 % Pol188 
291 ; 
0,237 





2ml DCM + 
1ml MeOH + 
20 mg PC 
- 0,5 % PVA 
261 ; 
0,167 
-2,31 - - - 
GC12 40 
2ml DCM + 
1ml MeOH + 
20 mg PC 
2 0,5 % PVA 
245 ; 
0,144 
-2,42 30 1,38 - 
GC13 40 
2ml DCM + 
1ml MeOH + 
40 mg PC 
- 0,5 % PVA 
>1000 ; 
0,515 
-1,25 - - - 
GC14 40 
2ml DCM + 
1ml MeOH + 
40 mg PC 
2 0,5 % PVA 
>1000 ; 
0,557 
-1,11 38 1,20 - 
GC15 40 
2ml DCM + 
1ml MeOH + 
40 mg PC 
- 2% PVA 
237 ; 
0,220 




2ml DCM + 
1ml MeOH + 
40 mg PC 
2 2% PVA 
420 ; 
0,285 





2ml DCM + 
1ml MeOH + 
40 mg PC 
- 2 % PVA 
453 ; 
0,280 
-11,5 - - 
Surnatant not 
clear  
GC18 80 2ml DCM + - 0,5 % PVA 310 ; -9,41 - - - 
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60 mg PC 
10 0,5 % PVA 
331 ; 
0,191 




2ml DCM + 
1ml MeOH + 
40 mg PC 
15 0,5 % PVA 
262 ; 
0,184 




2ml DCM + 
1ml MeOH + 
40 mg PC 
20 0,5 % PVA 
255 ; 
0,144 








- 0,5 % PVA 
301 ; 
0,132 
-10,5 - - - 
GC30 80 




10 0,5 % PVA 
350 ; 
0,162 
-10,3 82 12,20 -  
GC31 80 




15 0,5 % PVA 
420 ; 
0,210 
-9,8 65% 5,3 - 
 




4.4 Results and Discussions 
4.4.1 DEXA-loaded PHBHHx NPs 
 
In this work PHBHHx polymeric nanoparticles were successfully prepared by an 
emulsification solvent-evaporation process. Different parameters as the organic solvent, 
the amount of polymer, the surfactant and drug amount were changed in order to analyse 
the features of the resulting nanoparticles formulation and to obtain the best formulation 
in terms of encapsulation efficiency and drug release. This technique allowed the 
preparation of polymeric particles with size ranged  from 212 nm to 1000 µm. The 
formulations  prepared with PVA at 0,5 or 2 % (w/v) in the aqueous phase were stable 
with good polydispersity index, on the contrary in the presence of Poloxamer 188 in the 
aqueous phase all formulations were unstable presenting a precipitate just after 
preparation. The zeta potential and size of DEXA-loaded nanoparticles and unloaded 
nanoparticles prepared using PVA at 0,5 or 2 % did not differ significantly, and it ranged 
from -0,29 to -17 mV.  
The low EE% obtained from GC3 to GC10 formulations is probably due to the fact that 
the organic solvents used to dissolve the polymer and the drug can diffuse in the 
continuous phase because of its miscibility in water, which can temporarily increase the 
drug solubility in the continuous phase. 
In order to improve dexamethasone encapsulation, a phospholipid (PC) was incorporated 
in the nanoparticles to favor hydrophobic interactions between DEXA, phospholipids 
and the PHBHHx polymer matrix. In the presence of PC in the polymer-drug solution 
the EE % increased from 10 % to 38 %. By raising the polymer and PC amounts, the 
EE% of the drug did not change significatively. Despite the high hydrophobicity of 
PHBHHx, the amount of polymer has not significantly influenced on this parameters.  
Keeping constant the polymer ,the PC and the surfactant amounts, the effect of  DEXA 
mass was investigated. The DEXA amount was varied between 2 mg to 20 mg; the EE% 
increases as the initial mass of DEXA increases, until it reaches 86% for 20 mg of  
DEXA initial mass. As shown in Table 1, the nanoparticle size was not influenced by the 
initial DEXA weight in the formulation. The importance of initial DEXA amount in the 
formulation was also found from Gomez-Gaete et al
 
(2007) with PLGA nanoparticles 
loaded with DEXA. However their encapsulation efficiency was very low compared to 
this PHBHHx nanoparticles formulations. Moreover these results are better than those 
demonstrated by Fessi et al (1987) for poly(DL lactide) nanocapsules containing 
dexamethasone prepared by interfacial polymer deposition (entrapment efficiency: 40%).
 
 
The unloaded (GC18) and DEXA loaded NPs (GC28) were characterized by monomodal 
distribution of diameters (Figure 5 a,b) with an average diameter size of 310 nm and 255 
nm respectively. The narrow diameter distributions were confirmed by the PI, 0,106 and 
0,144 respectively. The prepared NPs displayed a negative Z-Pot value (Figure 6 a,b) 
around -10 mV. 




    
 
Figures 5: Diameter distribution of PHBHHx based NPs. Unloaded NPs (GC18) (a) and 





Figures 6: Z-potential of PHBHHx based NPs. Unloaded NPs (GC18) (a) and loaded 
with DEXA (GC28) (b). 
 
 
TEM micrographs of blank NPs (GC18) and DEXA loaded NPs (GC28) showed the 
presence of phosphotidilcoline between nanoparticles and even PC micelles (Figures 7, 
8). 
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Figure 8: TEM micrographs of DEXA-loaded nanoparticles (GC28). 
 
The release profiles of DEXA from GC28 formulation (Figure 9) showed a very fast 
drug release, with 90 % of the total drug encapsulated released in the first 24h. The 
kinetic release and TEM images of GC28 suggested the hypothesis that the drug was not 
encapsulated within PHBHHx nanoparticles, but mainly complexed with PC outside the 
nanoparticles or dispersed in PC micelles in the medium. 
 
 
Figure 9: In vitro drug release of GC28 in PBS 0,01 M, pH 7.4. 
 
In order to improve DEXA encapsulation, Poloxamer 188 was added to the organic 
solution in presence of the polymer and drug. The resulting formulation (GC30, Figure 
10) showed good encapsulation efficiency (82%) using less drug amount (10 mg) 
compared to the GC26 formulation. Increasing the drug amount the EE% drastically 




decrease. The unloaded (GC29) and DEXA loaded NPs (GC30) were characterized by 
monomodal distribution of diameters (Figures 11) with an average diameter size of 301 
nm and 350 nm respectively. The narrow diameter distributions were confirmed by the 
PI, below to 0.2 in both NPs formulations. The prepared NPs displayed a negative Z-Pot 
value (Figures 12), around -10 mV. 
TEM micrographs of blank GC29 showed smooth spheric nanoparticles, whereas 










       
         
 
Figures 11: Diameter distribution of PHBHHx based NPs. Unloaded NPs (GC29) (a) 












Figures 12: Z-potential of PHBHHx based NPs. Unloaded NPs (GC29) (a) and loaded 




   
 
Figure 13: TEM micrographs of blank nanoparticles (GC29). 
 
   
 
Figure 14: TEM micrographs of DEXA-loaded nanoparticles (GC30). 
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The release profile of DEXA from GC30 formulation (Figure 15) showed a first day 
burst followed by gradual release. It was found that 20% of the encapsulated 
dexamethasone was released in the first 24 hours and after 7 days we had the 100 % of 





Figure 15:  DEXA release kinetics of GC30 formulation PBS 0,01 M, pH 7.4 
 
4.4.2 HA-AHP-CS thermogel 
Hydrogels are one of most used scaffolds in the field of tissue engineering. They are 
three-dimensional, water-swollen, crosslinked networks of hydrophilic polymers. From 
the clinical point of view, in situ forming hydrogels are highly desirable since they gain 
advantages over preformed hydrogels: enabling minimally invasive surgeries for 
implantation, formation in any desired shape in good alignment with surrounding tissue 
defects, easy encapsulation of bioactive molecules and progenic cells.  
In this preliminary work a thermogelling hydrogel based on two natural, bioactive and 
biocompatible  polymers as hyaluronic acid and chitosan, was developed in order to be 
employed as delivery system of  the potent corticosteroid dexamethasone. The 
combination of chitosan, a cationic and hyaluronic acid as anionic polysaccharides with 
ammonium phosphate salts was chosen to benefit from several synergistic forces 
favorable to gel formation including hydrogen bonding, electrostatic interactions and 
hydrophobic interactions. 
The thermogel was easily prepared by adding CS solution in a HA solution containing 
AHP and the resulting liquid suspension was kept to 37°C to obtain a solid thermogel. 
The effect of CS, AHP and HA concentration on gel formation was investigated (Table 
2).  
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When CS solution is added to HA solution the two polymers formed some precipitates as 
a result of polyelectrolytes complexes formation, but when CS is added to HA-AHP 
solution no aggregates are visible (Figure 16,C). 
Moreover HA-AHP solution doesn’t form a thermogel when kept to 37 °C, the formation 
of the HA-AHP-CS thermogel is probably due to the interaction between the two 
polymers and the salt AHP.  
CS, AHP and HA concentration influenced the gelation time (Table 2) , which showed a 
decreased tendency with increase in HA and AHP concentration. Despite that, high 
concentrations of HA determine a gel solution with high viscosity and not suitable to be 
injected easily.  
After the sol/gel transition, HA-AHP-CS and DEXA NPs/HA-AHP-CS became non-











16 16 - No gelation, precipitation 
16 16 70 13  
16 16 100 6 , high viscosity 
10 16 70 5  
10 16 100 4  
 
Table 2 : Effect of HA, CS and AHP in the resulting HA-AHP-CS suspension 
 on the gelation time 37 °C (n=3). 
 
A HA-AHP-CS suspension containing 10 mg of HA with 100 μl of AHP and 10 mg of 
CS was morphologically characterized by SEM and it was used for the in vitro DEXA 
release studies. 
 
       
 
A B 
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Figures 16: Pictures showing the thermogelation of HA-AHP-CS suspension.(A) HA-
AHP solution, (B) chitosan solution in 0,5% acetic acid,(C) HA-AHP-CS suspension at 
room temperature, (D) thermogelled HA-AHP-CS suspension after incubating at 37°C, 
(E) HA-AHP-CS suspension with DEXA-loaded PHBHHx NPs at room temperature and 
(F) thermogelled DEXA-NPs-HA-AHP-CS suspension after incubating at 37 °C 
 
The morphology of the gel observed using SEM is shown in Figure 17. The thermogel 
exhibits a porous structure with a rough matrix surface. The porous dimensions are 










Figures 17: SEM images of HA-AHP-CS thermogel. 
 
Scaffold architecture and composition are important parameters in cartilage tissue 
engineering. Scaffold physical structure can control cell function by regulating the 
diffusion of nutrients, waste products and cell-cell interactions. Scaffold surface 
chemistry indirectly affects cell adhesion, morphology and subsequent cellular activity 
by controlling adsorption of ions, proteins and other molecules from the culture medium. 
It is then this molecularly populated surface that the cells sense and respond to 
biochemically by means of specific receptors (e.g., integrins) [Zeltinger 2001; Loeser 
1993]. 
For example, hyaluronic matrix based scaffold enables the formation of large amount of 
cartilage like differentiate chondrocytes cells. The hyaluronan web consists of 
hyaluronan, an important macromolecule of the hyaline cartilage where chondrocytes 




The surface’s roughness is thought to additionally promote chondrocyte adhesion and it 
has been shown in previous studies with various materials [Park 2005; Burns 2009].
 
The release profiles of free DEXA, DEXA-loaded PHBHHx NPs, DEXA-loaded HA-
AHP-CS thermogel and HA-AHP-CS thermogel loaded with DEXA encapsulated 
PHBHHx NPs are shown in Figure 18 . 
The introduction of nanoparticles into the HA-AHP-CS suspension didn’t affect the 
gelation time that was also 4 min, the presence of nanoparticles did not interfere with the 
formation of cross links. 
The release of free dexamethasone was very fast and it was completed in 4 hours  
indicating that the dialysis bag had no retaining effect on DEXA release. 
The DEXA-loaded thermogel mediated a burst release of the encapsulated drug over the 
first day followed by more gradual release over the next 10 days. DEXA release showed 
a similar trend compare to the DEXA release from the CS-AHP thermogel studied by 
Foley et al (2013).
  
The drug diffusion is free in solution, but it is impeded when it is incorporated in a gel, 
caused by the interactions between drugs and gel matrix [Ukmar 2011]. In general, the 
processes of drug release from degradable matrices include the diffusion of external 
medium into the matrix system, swelling and degradation of the matrix, drug liberation 
and diffusion into the medium and transport of drug from the local site into the external 
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medium. The latter two processes are significantly limited by the drug-matrix 
interactions. In fact, drug release is a process of desorption against desorption, in which 
the affinity of drug to matrix and release medium plays as a determinant
 
[Lemaire 2003]. 
In the case of DEXA-loaded gel, therefore, the drug-gel matrix interaction may be a rate-
limiting factor. 
DEXA loaded PHBHHx nanoparticles release kinetics was characterized by a first day 
burst followed by gradual release as described before. The longer release of the drug by 
NPs loaded thermogel is probably attributed to the double retaining effect of  NPs-loaded 
HA-AHP-CS thermogel, compared to thermogel loaded with DEXA and DEXA-
encapsulated NPs. In this case drug release is dually impeded by both NPs and gel, the 
drug needs to overcome the barrier of NPs first and then the barrier of gel matrix. Figure 
18 shows that the release-slowing down effect of DEXA is more significant in the NPs 
loaded gel. 
It can be assumed that the high EE of PHBHHx NPs and slow degradability of PHBHHx 




Figure 18: In vitro release of free DEXA, DEXA loaded PHBHHx NPs, DEXA-loaded 
thermogel and NPs loaded gel in PBS (0,01M ; pH 7.4) at 37°C.  
 
4.5 Conclusions 
This study was aimed to the development of an injectable thermogelling drug delivery 
system loaded with PHBHHX based polymeric nanoparticles for the sustained and 
controlled release of dexamethasone.  
Several formulations have been performed by changing different parameter in order to 
obtain the best formulation in terms of EE% and drug release kinetics. 
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PHBHHx NPs were successfully prepared by emulsification solvent-evaporation process 
and were characterized in term of size, Z-Pot and morphology. The best developed NPs 
displayed submicron size (around 300 nm), narrow monomodal diameter distributions 
and negative Z-Pot values. Blank and loaded PHBHHx NPs showed good spherical 
shape by TEM analysis and DEXA loaded NPs displayed an high EE%. The release of 
DEXA encapsulated in PHBHHx NPs was characterized by an initial burst followed by 
sustained release up to 90% in 14 days. The developed NPs were successfully 
incorporated into an injectable thermogel based on hyaluronic acid and chitosan. 
In situ forming injectable hydrogel was prepared and used as a scaffold for drug delivery 
of DEXA and PHBHHx NPs loaded with DEXA. The HA-AHP-CS thermogel showed a 
porous structure and rough surface by SEM analyses. 
The biodegradable and injectable thermosensitive NPs loaded HA-AHP-CS gel showed a 
rapid transition from suspension to gel at 37°C and a long-term release profile in vitro. 
The developed HA-AHP-CS thermogels appear promising as drug or cell delivery 
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5 Chapter V : Overall Conclusive Remarks 
 
The present Research Doctorate Thesis was focused on three fundamental research areas: 
synthesis of novel amphiphilic copolymers,  development of polymeric NPs for topical 
delivery of an antipsoriatic drug and development of injectable hydrogels loaded with 
NPs for the sustained controlled  drug delivery in cartilage tissue engineering. 
Conclusive remarks regarding the experimental results, for each of the topical activities 




5.1 Synthesis and Characterization of Amphiphilic Copolymers based 
on Poly(ε-caprolactone) and Poly(methacryloylglycylglycine) 
 
This work has been devoted to the investigation and preparation of novel biodegradable 
and biocompatible amphiphilic copolymers based on PCL and p(MAGG) polymers. 
Amphiphilic block copolymers represent an important drug delivery system due to their 
ability to self-assembly in micelles in aqueous medium. 
The block copolymer PCL-b-p(MAGG)  and the random copolymer PCL-co-p(MAGG) 
were synthesised using two different synthetic routes. The amphiphilic block copolymer 
PCL-b-p(MAGG) was prepared by Reversible Addition-Fragmentation Transfer (RAFT) 
polymerization of MAGG onto a polycaprolactone based xanthate initiator. The 
successful preparation of the copolymer was confirmed by 
1
H-NMR, FT-IR and TGA 
analyses. As expected PCL-b-p(MAGG) self-assembled into micelles in water and the 
CMC of the copolymer was determined. In vitro citotoxicity tests performed on 
copolymer micelles showed an excellent compatibility, thus highlighting their potential 
in biomedical applications. 
The amphiphilic random copolymer PCL-co-p(MAGG) was synthesized by free radical 
polymerization of MAGG with a PCL containing a methacryloyl group in the terminal 
position (PCL-HEMA). The copolymer PCL-g-p(MAGG) was characterized 
spectroscopically by 
1
H-NMR and FT-IR analysis and thermally by TGA analysis. The 
poor yield and solvent solubility of the random PCL-co-p(MAGG) copolymer prompted 
us to consider the block copolymer PCL-b-p(MAGG) as the best candidate for being 
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5.2 Chitosan and Poly(γ-glutamic acid) based Nanoparticles Loaded 
with Methotrexate 
 
Nanoparticles for the controlled and sustained release of the antipsoriatic drug MTX 
were prepared by self-assembly of natural and biocompatible polymers CS and γ-PGA.  
NPs showed positive Z-Pot values with dimensions below 50 nm. Good levels of drug 
loading and a time-controlled release of the active agent were achieved in 15 days.  
In vitro drug release profiles showed that [γ-PGA-(CS-MTX)] NPs is a good formulation 
for MTX delivery, thanks to the small dimensions and the sustained drug release profile. 
Future developments of the developed nanoPEC would comprise the insertion of the 
particles into a gel vehicle for topical skin administration; moreover, surface 
modifications of biocompatible NPs may target the drug to the precise sites and assist 
their biocompatibility.  
 
5.3 Injectable and Biodegradable Thermogels Based on Hyaluronic 
acid and Chitosan Loaded with Poly[(R)-3-hydroxybutyrate-co-
hydroxyhexanoate] Polymeric Nanoparticles for the Sustained 
Controlled Release of Dexamethasone 
 
This study was aimed at the development of an injectable thermogelling hydrogel to be 
used as a scaffold for drug delivery of DEXA and PHBHHx NPs loaded with DEXA, a 
potent synthetic corticosteroid with ability to stimulate chondrocytes differentiation. 
PHBHHx NPs were successfully prepared by emulsification solvent-evaporation process 
and the formulation parameters were optimised for the loading of DEXA.  
The best developed NPs displayed submicron size (around 300 nm), narrow monomodal 
diameter distributions and negative Z-Pot values. Blank and loaded PHBHHx NPs 
showed good spherical shape by TEM analysis and DEXA loaded NPs displayed high 
levels of drug loading and a time-controlled release of the active agent was achieved. 
The developed NPs were successfully incorporated into an injectable thermogel based on 
hyaluronic acid and chitosan, the HA-AHP-CS thermogel showed a rapid transition from 
suspension to gel at 37°C, porous structure and rough surface by SEM analyses. 
The in vitro release study  that under physiological conditions the developed NPs loaded 
HA-AHP-CS gel release their DEXA content in 14 days.  
Taking into account all these features, the developed NPs loaded thermogel can be 
considered very promising as drug or cell delivery systems for cartilage tissue 
engineering.  






First of all I would like to thank my supervisor Dr. Federica Chiellini for giving me such 
an opportunity and especially for her scientific contribution, for guiding me and 
encouraging me constantly. I am extremely thankful also to Prof. Emo Chiellini for his 
suggestions and support in my research project. 
 
I would like to thank my tutors Dr. Anna Maria Piras and Marcella Ferri, I am grateful 
for their understanding and support during the past three years. 
 
A special thank goes to all the research team of the Laboratory of Bioactive Polymeric 
Materials for Biomedical and Environmental Applications of the University of Pisa, 
Thank you for your support and friendship. 
 
Part of the reported research activities have been performed at Laboratory of Drug 
Delivery and Drug Targeting of West China School of Pharmacy of Sichuan University 
(Chengdu, China) and I would like to thank Prof. Sun and Prof. Zhang and their group 
members, for their assistance and helpful insights in my research. 
 
I am really grateful to my beloved parents, for their caring, understanding and support. 
 
A special thank is due to Chiara, my friend and collegue, who always encouraged me to 
never give up despite life’s adversities. 
 
Thank you all. 
